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I 
Abstract  
 
Arthrogryposis, Renal dysfunction, and Cholestasis (ARC) syndrome is a multisystem 
disorder associated with abnormal localisation of some polarised membrane transporter 
proteins.  Distinct apical and basolateral poles are essential for epithelial function and organ 
development but the molecular pathways determining the biogenesis of polarised membranes 
are not fully characterised.  Mutations in VPS33B, a Sec1-Munc18 protein, account for 75% 
of ARC patients.  Reduced expression of VPS33B at both the RNA and protein level was 
demonstrated in all ARC syndrome patients, even if mutations were not identified in VPS33B.  
A novel protein POLARIN (PLRN) was identified that interacts with VPS33B, and is crucial 
for VPS33B function.  Pathogenic mutations in PLRN occur in ARC patients without VPS33B 
mutations. Decreased Polarin and Vps33b expression in mouse renal collecting duct cells led 
to abnormal localisation of specific apical membrane proteins and to disordered apical 
junction complex formation.  In an in vivo model, knockdown of polarin in zebrafish resulted 
in defects in biliary tract development.  These findings establish that a VPS33B-POLARIN-
Rab11a intracellular trafficking pathway is functionally distinct from another VPS33-related 
pathway (VPS33A/VPS16) and is required for (a) normal epithelial polarisation and apical 
junction complex formation, and (b) normal liver and kidney development and function.  
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CHAPTER 1 - INTRODUCTION 
 
2 
1.1 – ARC Syndrome 
 
Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome (MIM:208085) is a 
severe disorder affecting multiple organ systems with an autosomal recessive mode of 
inheritance [1].  The cardinal features of the syndrome are congenital neurogenic 
arthrogryposis, renal tubular dysfunction and neonatal cholestasis with bile duct hypoplasia 
and low gamma glutamyl transpeptidase (GT) activity.  Platelet dysfunction is also common, 
to the extent that half of the patients that undergo diagnostic biopsy have a life-threatening 
haemorrhage as a result.  Other features include ichthyosis, mild dysmorphic features, absent 
corpus callosum and recurrent infections resulting in severe metabolic acidosis and worsening 
nephrogenic diabetes insipidus [2].  Children born with ARC syndrome are often small at 
birth and fail to thrive.  Death usually occurs during the first year of life despite medical 
intervention.  The affected individuals usually die due to an infection leading to dehydration 
and acidosis [3]. 
 
In 2004, the genetic locus for ARC syndrome was mapped to chromosome 15q26.1 using 
autozygosity mapping on 6 affected consanguineous families.  Nine different germline 
mutations were identified in the VPS33B gene in 14 supposed unrelated families [1].   
Subsequent mutation screening identified further mutations in VPS33B in around 75% of 
ARC syndrome patients [2;4].  Furthermore, several families with no detectable VPS33B 
mutations did not link to the 15q26.1 locus, thus suggesting locus heterogeneity and other 
causative gene(s) for ARC syndrome. 
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1.2 – VPS33B  
  
The VPS33B gene contains 23 coding exons with a transcript length of 2,488 base pairs.  The 
transcript encodes the VPS33B protein comprising of 617 amino acids with a predicted 
unglycosylated weight of 70.6 kDa [5].  In multicellular organisms there are 2 homologues of 
the yeast Vps33 gene and protein, VPS33A and VPS33B.  There is only 31% identity and 
51% similarity between VPS33A and VPS33B, suggesting different functions for the 2 
proteins.  However, both contain a Sec1 like domain that belongs to the Sec1/Munc18 (SM) 
family of proteins.  SM proteins are thought to tightly bind to members of the syntaxin family 
of target SNAREs (Soluble N-ethylmAlemide sensitive REceptors) and may alter interdomain 
interactions and influence vesicle-to-target SNARE complex formation [6].  The predicted 
structure of VPS33B in complex with syntaxin-1 is shown in Figure 1.1.   
 
The function of VPS33B has not been extensively studied in mammals, however, the yeast 
homologue, Vps33, is a Class C vacuole protein sorting protein and is required for vacuole 
biogenesis [7].  Mutations in the genes encoding Class C VPS complex proteins (Vps11, 
Vps16, Vps18, Vps33 or Vps39) all have the same phenotype, and hence the reason why they 
belong to the same group of VPS proteins.  The phenotype comprises of severe intracellular 
acid-base imbalance, amino acid pool deficiency, and temperature sensitive growth failure 
[7].  In Drosophila melanogaster the yeast Vps33 homologue, Car, localises to the endosomal 
compartment.  However, it has been shown that this protein is a homologue of human 
VPS33A and not VPS33B [8].  A hypomorphic allele of Carnation causes the carnation eye 
colour mutant believed to be due to abnormal lysosome delivery and pigment granule 
biogenesis [9;10]. 
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Figure 1.1 – The predicted structure of the VPS33B protein.   
VPS33B is shown in blue, red and orange and in complex with the t-SNARE, Syntaxin-1 
(green).  Red region demonstrates C-terminal region of the protein and the orange shows the 
sequence absent in VPS33A.  [8] 
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1.3 – Pathology of ARC Syndrome 
 
The identification of mutations in VPS33B in ARC syndrome patients, and the protein 
products’ putative function implicates a disorder of vesicular trafficking in the pathogenesis 
of the condition [1].  Indeed, immunostaining of ARC patients’ liver biopsies with antibodies 
against CEA (Carcino Embryonic Antigen), CD13 (alanyl aminopeptidase) and GT, all of 
which should be restricted to the apical or canalicular membrane, revealed mislocalisation to 
the basolateral membrane (Figure 1.2).  These findings were not observed in age-matched 
controls or in patients diagnosed with PFIC (Progressive Familial Inter-hepatic Cholestasis), a 
group of conditions with cholestasis and low GT as a feature.  Immunostaining of kidney 
biopsies with CD26 (dipeptidyl peptidase) also revealed disordered localisation of the apical 
antigen to the basolateral membrane [1;11]. 
 
As mentioned previously, patients with ARC syndrome may have a bleeding tendency leading 
to life–threatening haemorrhage even if clotting studies and platelet counts are normal.  In 
2005 Lo et al. characterised the platelets from ARC patients and observed reduced 
aggregation, abnormal morphology, elevated numbers of -granules and completely absent -
granules [12].  The –granules are a principal storage site for proteins involved in 
haemostasis and wound healing including fibrinogen, von Willebrand factor (vWF), 
thrombospondin and factor V [13].  However, VPS33B is expressed in megakaryocytes and 
not in platelets, suggesting a role in intracellular vesicular trafficking and platelet granule 
biogenesis.  Therefore, VPS33B is essential for the development of platelet -granules but not 
for their subsequent secretion [12]. 
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Figure 1.2 – Immunostaining of ARC patient biopsies.  
A, CEA staining of an ARC patient liver biopsy compared to an age matched control sample.   
Staining is limited to the canalicular (apical) membrane in the control but mislocalised to all 
membranes in the patient.  B, A similar effect is seen in the ARC patient’s kidney biopsy when 
stained with CD26. [1] 
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1.4 – Vesicular Trafficking 
 
VPS33B has a predicted but undefined function in vesicular trafficking pathways.  In 
eukaryotic cells, vesicular trafficking and membrane fusion plays an essential role in 
maintaining physiological integrity and function of distinct intra-cellular organelles [14;15].  
A well-studied example is the delivery of protein cargo vesicles from the secretory pathway to 
the lysosome, or vacuole in yeast, allowing for appropriate lipid and protein composition of 
the lysosomal membrane and their luminal content [16]. 
 
Vesicular trafficking ultimately leads to the delivery of cargo from one compartment or 
organelle to another via membrane-bound vesicle intermediates (Figure 1.3).  The process 
involves a vesicle that buds off the donor organelle and eventually fuses with the correct 
target organelle through the interaction of vesicle and target-SNAREs (called v- and t-
SNAREs respectively) [17].  The specificity of the delivery is enforced by specific SNARE 
interactions, and is also mediated by SNARE interacting proteins such as SM and Rab 
GTPase proteins, which modulate the interaction [6;18].  Further details of vesicle budding 
and fusion will be discussed later in section 1.7 after the necessary protein complexes have 
been introduced in the following sections. 
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Figure 1.3 – Schematic diagram of vesicular trafficking. 
Carrier or transport vesicles bud off the donor organelle and fuse with the correct target 
organelle.  Vesicular trafficking is cargo specific, which is regulated in part by vesicle or v-
SNARE and target or t-SNARE molecules. [19] 
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In general, there are two major routes of vesicular traffic within non-polarised cells depending 
on the direction of flow in relation to the plasma membrane.  These are termed the 
biosynthetic and endocytic routes.  Vesicular trafficking pathways in polarised epithelial cells 
are discussed later in section 1.12. 
 
1.4.1 – The Biosynthetic Pathway 
 
The biosynthetic route deals with the trafficking of de novo proteins synthesised in the 
cytosolic ribosomes to their final required destination.  In the endoplasmic reticulum (ER), the 
synthesised polypeptides are folded and sometimes can undergo oligomerisation to form 
multi-subunit protein complexes.  When these necessary events have occurred the proteins are 
sorted into transport vesicles by the cargo-sorting machinery and are transported to the cis 
side of the Golgi apparatus, where post-translational modifications tend to occur.  The 
proteins travel through the Golgi apparatus and emerge at the trans-Golgi network (TGN) 
where they are again sorted into vesicles for trafficking to their final destination [20].   
 
1.4.2 – The Endocytic Pathway 
 
The endocytic route is used to internalise molecules from the extracellular space and plasma 
membrane.  They are carried from their original location to peripheral early sorting 
endosomes where they are either recycled back to their original location via recycling 
endosomes, or degraded through the late endosome and lysosome pathway (Figure 1.4) 
[21;22]. 
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Early endosomes play a crucial role in co-ordinating vesicular transport between the plasma 
membrane, the TGN and the lysosome [23].  They have a pleiomorphic structure composed of 
vesicular and tubular domains that are physically connected, but maintain their separate 
identity due to their specific complement of Rab GTPases (see section 1.6.2) [24]. Over time, 
endocytosed proteins concentrate on intralumenal vesicles that accumulate in the vesicular 
structures of the early endosomes, giving rise to Multi-Vesicular Bodies (MVBs) [24].   
 
Accompanying the physical MVB maturation process, the MVB also moves towards the cell 
centre from the cell periphery.  Proteins that are not ubiquitinated, and hence destined for 
recycling back to the plasma membrane are removed from the MVB into the tubular 
structures of early endosomes [24].  Once all recycling proteins have been removed, all 
remaining ubiquitinated proteins are degraded by the MVB fusing with late endosomes and in 
turn lysosomes [25].  These fusion steps release the contents of the MVB vesicle into the 
lumen of lysosomes, where the vesicles and protein cargo are degraded by the action of 
lysosomal hydrolases (proteases and lipases) [23]. 
  
1.4.2.1 – The ESCRT Complexes 
 
In both yeast and mammalian cells, proteins that function in the MVB pathway are referred to 
as class E VPS proteins [23].  Deletion of any of the Class E VPS components results in the 
mislocalisation of MVB cargoes to the lysosome or vacuole and the accumulation of 
endosomal cargoes in large aberrant structures adjacent to the vacuole, called the class E 
compartment [26;27].   
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Figure 1.4 – An overview of the endocytic pathway. 
Proteins are endocytosed from the plasma membrane into Rab5 positive early endosomes.  
Over time, endocytosed proteins concentrate on intralumenal vesicles that accumulate in the 
vesicular structures of the early endosomes, giving rise to Multi-Vesicular Bodies (MVBs).  
The movement of the MVB from the cell periphery to the cell centre accompanies the 
maturation of the MVB.  Non-ubiquitinated proteins are removed from the MVB into tubular 
structures and are either recycled back to the plasma membrane through Rab4 or Rab11 
positive endosomes, or trafficked to the TGN.  Ubiquitinated proteins remain in the MVB, 
which fuse with late endosomes and in turn lysosomes, for degradation of the cargo. [Adapted 
from 24] 
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The majority of the class E VPS proteins form three distinct complexes called the Endosomal 
Sorting Complex Required for Transport (ESCRT) –I, -II and –III [23].  These complexes 
function sequentially in sorting endocytosed proteins into the MVB pathway and MVB 
vesicle formation [28;29].  Ubiquitinated proteins, destined for lysosomal degradation are 
recruited into the MVB by the direct interaction with ubiquitin binding domains within the 
ESCRT-I and -II complexes.   
 
The human homologues of the yeast class E VPS proteins have been identified and seem to 
function in the ESCRT complexes in the same manner as their yeast counterparts [23;28].  
This suggests that mechanism of endocytic trafficking is conserved from yeast to humans. 
 
1.5 – SNARE Proteins 
 
Söllner and Rothman first suggested the concept and the name of SNARE proteins over 15 
years ago [30;31].  There are 25 members of the protein superfamily in yeast, and 36 in 
humans.  SNARE proteins are central to the fusion of lipid membranes [32].  All SNARE 
proteins are formed by domain structures, which includes a central evolutionary conserved 
SNARE motif comprised of a stretch of between 60 and 70 hydrophobic amino acids arranged 
in heptad repeats [33].  SNARE proteins were first characterised by their preferred location on 
either vesicle (v-) or on target (t-) membranes, however over time this was proven to be too 
simplistic, as it did not take into account homotypic fusion and that SNARE proteins can have 
multiple sites of action [34].  An in-silico amino acid search and alignment of the SNARE 
proteins revealed that most v-SNAREs had an arginine (R) residue in the middle of the 
SNARE domain, and are now called R-SNAREs accordingly.  The other members of the 
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SNARE family (predominantly t-SNARES) have either a glutamine (Q) or aspartate residue 
present, and are now called Q-SNAREs [35].  Further classification of the latter group gave 
the Qa-, Qb- and Qc- sub groups (Figure 1.5). 
 
Upon membrane contact SNARE proteins form trans-SNARE complexes, also called 
SNAREpins [36].  Several groups have solved the crystal structure of trans-SNARE 
complexes, and in all cases it has been shown that the complex comprises of four SNARE 
domains forming helical coiled coils with each other [37;38].  Moreover the complex is made 
up of one R-SNARE and one of each of the Q-SNAREs.  It was first believed that formation 
of the trans-SNARE complex lead to lipid membrane fusion through the action of NSF (N-
ethylmalemide Sensitive Factor).  However, in a cell-free system where full-length SNARE 
proteins were reconstituted onto liposome membranes, fusion still occurs [39].  Nevertheless 
NSF greatly enhanced fusion in vivo, and was shown to be involved with the disassembly and 
recycling of the complex [40].  Taken together these findings suggest that the assembly of the 
complex drives fusion and NSF dissembles the complex so that it can function again, 
completing the cycle (Figure 1.6). 
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Figure 1.5 – Schematic diagram demonstrating the domain structure of SNARE proteins.  
Each SNARE protein has a characteristic SNARE domain with a variable N-terminal region. 
Dashed lines surrounding domains represent domains that are missing in some subfamily 
members.  Qa SNAREs have three antiparallel helix bundles in the N-terminal region.  The 
variable N terminal regions of Qb, Qc and R- SNAREs are represented as oval shapes. A 
SNARE complex is formed by one of each of these sub-families. [Adapted from 33] 
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Figure 1.6 – The SNARE cycle.  
In this example Q-SNAREs can be found on the target membrane and the R-SNARE on the 
vesicle.  Firstly, the acceptor complex is formed on the target membrane, from one of each of 
the Q-SNARES, by the proposed action of SM proteins.  This now interacts with the R-SNARE 
by making coiled coils and forming the loose then tight trans-SNARE complex. The free 
energy obtained by this conformational change drives membrane fusion. After fusion NSF and 
-SNAP disassemble the cis-SNARE complex, and through ATP hydrolysis returns the 
SNARE proteins to their original free state. [33] 
 
 
1.6 – SNARE Interacting Proteins 
 
The original hypothesis by Rothman et al. in 1994, suggested that SNARE proteins alone 
controlled the specificity of vesicle fusion, however, it was shown in the liposome system that 
SNARE proteins are much more promiscuous in vitro than they are in vivo [34;41].  Several 
families of proteins have now been suggested to both facilitate and regulate SNARE 
interactions, and the best characterised families are the SM proteins and small Rab GTPases 
[6;42;43]. 
 
1.6.1 – SM Proteins 
 
There are seven members of the SM (Sec1/Muc18) family of cytosolic proteins in vertebrates 
and these include munc18-1 munc18-2, mucn18-3, Sly1, VPS45, VPS33A and VPS33B. The 
exact function of SM proteins remains unclear, despite the crystal structure of some members 
being resolved [44].  There have been various mechanisms of action proposed depending of 
the family member.  Nevertheless, all are believed to bind either directly or indirectly to the 
Q-SNARE complex (predominantly t-SNAREs) in different states throughout the cycle [45]. 
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Based on structural information and biochemical studies, there are currently four different 
ways that SM proteins are proposed to bind SNARE proteins.  These include binding of SM 
proteins to the closed conformation of syntaxin, the assembled SNARE complex, the N-
terminal region of syntaxin and through a multi sub-unit complex [46].  See Figure 1.7 for 
more information and examples.  Binding of yeast Vps33 to its cognate syntaxin, Vamp3 is 
mediated by a 6-member protein complex, called the HOmotypic fusion and vacuole Protein 
Sorting (HOPS) Complex (see section 1.8 for more details) [47]. 
 
SM proteins were initially thought to exert an inhibitory effect on SNARE complex formation 
because of the binding pattern of SM proteins to monomeric SNARE molecules (Figure 1.7 - 
A, C and D).  This was certainly the case when these proteins were over-expressed alone in 
cells.  For example, when Munc18-2 was over expressed in Caco-2 cells, a polarised epithelial 
cell line, there was inhibition of the syntaxin 3 based SNARE complex formation and 
transport of P75, an apical membrane marker [48].  However, further experiments where the 
SM protein was co-over expressed with its’ cognate syntaxin released the inhibition [49]. 
These findings suggest that there is a delicate stoichiometric balance required for normal 
membrane trafficking, and that SM proteins are likely to exert a regulatory as opposed to 
purely an inhibitory effect.  
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            A          B                  C               D  
 
Figure 1.7 – Proposed mechanisms of binding of SM protein to the SNARE complex. 
The syntaxin is shown in blue and SM proteins in yellow. An example for each is given in 
brackets.  A: The SM protein binds to the closed conformation of syntaxin (Munc18-1 and 
syntaxin 1a).  B: Binding of the SM protein to the assembled SNARE complex (yeast Sec1 
with a complex of Sso, Snc and Sec9).  C: Binding to the N-terminal regions of syntaxin 
(Vps45 and Tlg2).  This mode of binding allows for interaction with SNARE molecules that 
are in and out of complex.  D: An indirect association of the SM protein with the SNARE 
molecule (Vps33 and Vamp3). [Adapted from 46] 
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1.6.2 – Rab GTPases 
 
These small GTPases are the largest family of the known membrane trafficking proteins.  In 
yeast there are 11 Rab isoforms, 29 in C. elegans and D. melanogaster and more than 60 
variants in humans.  Interestingly there are only 5 isoforms that are conserved from yeast to 
human which are Rab1 (Ypt1), Rab5 (Ypt5), Rab6 (Ypt6), Rab7 (Ypt7) and Rab11/Ypt31, 
suggesting an essential and conserved function for these proteins [50].  Furthermore, in 
several cases a mammalian Rab protein can functionally replace its’ yeast homologue 
demonstrating conserved functions of the proteins [51]. 
 
1.6.2.1 – Structural Features 
 
It is believed that the majority of different Rab proteins are a result of gene duplication, as 
sub-families of Rab isoforms have been identified with between 75% and 95% DNA sequence 
identity and overlapping protein functions [51].  Rab GTPases differ the most in their C 
termini, which have been shown to be involved in subcellular targeting, allowing for greater 
specificity between the Rab proteins [52].  In contrast, the GDP and GTP binding regions are 
highly conserved. 
 
The crystal structures for several Rab proteins, including mouse Rab3 [53], Plasmodium 
falciparum Rab6 [54] and yeast Ypt5 [55], have been solved.  These identified a fold that is 
essentially present in all Ras superfamily members, and is the region of the protein involved 
in GDP or GTP binding.  This region comprises of a six-stranded sheet, consisting of 5 
parallel and 1 antiparallel strands, surrounded by 5 -helices [53-55].  Furthermore, the 
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crystal structures of GDP- and GTP bound forms of yeast Sec4, revealed 2 different 
conformations of the proteins depending on the nucleotide status, giving rise to the first idea 
of a Rab GTPase cycle (Figure 1.8) [56]. 
 
Similar to that of other small Ras-like GTPases, Rab proteins function as a molecular switch 
by cycling between a GTP bound active form to a GDP bound inactive form (Figure 1.8) [20].  
There needs to be a delicate regulation between these 2 forms to achieve successful 
trafficking, and this is accomplished by 2 families of proteins.  These are called Rab Guanine 
nucleotide Exchange Factors (Rab GEFs) and Rab GTP Activating Proteins (Rab GAPs).  The 
GTP bound form recruits specific effector proteins, which usually links the vesicle and target 
membranes to the cytoskeleton [57;58].  Rab proteins and their tethers add another layer of 
complexity, specificity and regulation to SNARE mediated membrane fusion [59]. 
 
1.6.2.2 – Localisation and Function 
 
The majority of Rab proteins have a ubiquitous pattern of expression in all cells and tissues, 
however some have a tissue specific localisation, such as Rab3a and Rab27 (Table 1.1) [51].  
Within cells, Rab proteins are localised to the cytoplasmic surface of various distinct 
organelles (Table.1.1 and Figure 1.9) allowing specificity in vesicular trafficking. 
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Figure 1.8 – The Rab GTPase cycle.   
The Rab GTPase switches between GDP- and GTP- bound forms, which have different 
conformations.  Conversion from the GDP- to the GTP- bound form is caused by nucleotide 
exchange, catalysed by a GDP/GTP Exchange Factor (GEF).  Conversion from the GTP- to 
the GDP- bound form occurs by GTP hydrolysis, facilitated by a GTPase activating protein 
(GAP).  The GTP-bound form interacts with effector molecules, whereas the GDP bound form 
interacts with Rab escort proteins (REP) and GDP dissociation inhibitor (GDI). Pi = 
inorganic phosphate. [51] 
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Name Localisation Expression Function 
    
    
Rab1a ER + cis-Golgi Ubiquitous ER to Golgi transport 
Rab2a ER + cis-Golgi Ubiquitous Golgi to ER retrograde transport 
Rab3a SV Neuronal Regulation of neurotransmitter release 
Rab4a EE Ubiquitous Endocytic recycling 
Rab5a EE, CCV + PM Ubiquitous Budding, motility and fusion in endocytosis 
Rab6a Golgi Ubiquitous Retrograde Golgi traffic 
Rab7a LE Ubiquitous Late endocytic traffic 
Rab8a TGN + PM Ubiquitous TGN to PM traffic 
Rab9a LE Ubiquitous LE to TGN traffic 
Rab11a RE + TGN Ubiquitous Endocytic recycling via RE and TGN 
Rab27 Melanosomes 
Granules 
Melanocytes 
Platelets 
Lymphocytes 
Movement of lytic granules and 
melanosomes towards PM 
 
Table 1.1 – Localisation, expression and function of selected Rab GTPases. 
Abbreviations: ER – endoplasmic reticulum, SV – synaptic vesicle, EE – early endosome, 
CCV – clathrin coated vesicle, PM – plasma membrane, LE – late endosome, TGN – trans 
Golgi network and RE – recycling endosome. [42;51;60;61] See Figure 1.8 for a schematic 
diagram. 
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Figure 1.9 – Intracellular vesicular pathways and localisation of selected Rab proteins. 
The biosynthetic pathway transports proteins from the endoplasmic reticulum (ER) through 
the Golgi complex to the cell surface.  In the trans-Golgi Network (TGN), molecules can enter 
either constitutive secretory vesicles (CV) or regulated secretory vesicles (RV).  In the 
endocytic pathway, material internalised from outside the cell reaches the early endosomes 
(EE) first and can be recycled back to the surface, either directly or via a perinuclear 
recycling endosome (RE) compartment.  Proteins that are internalised can also be delivered 
to late endosomes (LE) and lysosomes for degradation.  The localisation of selected 
mammalian Rab proteins in the membrane compartments participating in these transport 
processes are indicated. [51] 
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Rab GTPases’ reversible membrane localisation is dependent on post-translational 
modifications of a cysteine motif at the extreme C termini.  These cysteine motifs include 
CXXX, CC, CXC or CCXXX, where X is any amino acid, with 1 or 2 highly hydrophobic 
geranyl-geranyl groups [62].  Rab Escort Proteins (REPs) present the newly synthesised Rab 
protein to geranyl-geranyl transferase, allowing the post-translational modification to occur 
[63].  REPs also chaperone the modified Rab proteins to their correct membrane, which is 
thought to involve membrane receptors that recognise the specific Rab-REP complexes 
[63;64].  Rab GTPases that are in complex with REPs are in the inactive GDP bound form, 
whereas insertion into the membrane and dissociation with the REP is associated with the 
exchange of GDP to GTP, catalysed by a Rab GEF (Figure 1.10) [63].  Upon GTP hydrolysis, 
which is catalysed by a Rab GAP, the Rab GTPase is released from the membrane.  A Rab 
GDP Dissociation Inhibitor (GDI) mediates the retrieval of geranyl-geranylated GDP bound 
form Rab proteins from the intracellular membranes [65].  GDI can also present geranyl-
geranylated GDP bound Rab proteins to specific membranes, and thus serves as a recycling 
factor that allows several rounds of membrane association and dissociation of the Rab protein 
[66]. 
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Figure 1.10 – The Rab GTPase nucleotide and membrane attachment cycle. 
Inactive, GDP-bound Rab GTPases are bound to GDI, which prevents membrane attachment 
and maintains cytoplasmic solubility.  Membrane attachment of Rab GTPases requires the 
function of GDF (GDI Displacement Factor), which dissociates the Rab from the GDI.  
Subsequently, a specific GEF exchanges the bound GDP for GTP on the Rab molecule.  This 
leads to its’ activation and allows the Rab GTPase to fulfil its function in membrane 
trafficking by binding to specific effector proteins.  Finally, a specific GAP inactivates the 
Rab GTPase by accelerating the hydrolysis of GTP to GDP.  The inactive GDP bound form 
dissociates from the membrane and re-binds to GDI and the process starts again. [Adapted 
from 59] 
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1.6.2.3 – Rab Effectors 
 
Rab GTPases function as regulators of specific intracellular trafficking pathways, and the key 
to their function is the recruitment of effector molecules that bind exclusively to their GTP 
bound form [42].  Rab effector molecules are a very heterogeneous group of proteins, of 
which some are coiled coil proteins involved in membrane tethering or docking, whilst others 
are enzymes or cytoskeleton- associated proteins [51].  The role of the yeast Vps33 
homologue, and the complexes in which it forms, as Rab effector molecules will be discussed 
in sections 1.8 and 1.9. 
 
Rab effector molecules can also have protein sorting functions.  The best-characterised 
example is the retrograde trafficking of the Mannose-6-Phosphate Receptors (MPRs) from 
late endosomes to the TGN [59].  TIP47, a Rab9 effector, directly binds to MPRs, thus 
leading to the accumulation of MPRs on late endosomes, and allowing their transport back to 
the TGN using the appropriate Rab GTPase (Table 1.1) [67]. 
 
1.7 – Vesicle Budding and Fusion 
 
The budding of transport vesicles off the donor compartment and the selective incorporation 
of cargo into the forming vesicle are both mediated by coat proteins [68]. These protein coats 
are macromolecular structures that are assembled from monomeric coat proteins located in the 
cytosol of cells [69].  The coat proteins recognise sorting signals in the cytosolic domains of 
transmembrane cargo proteins, with examples of such proteins being clathrin, and members of 
the COPI and COPII complexes [69].  The polymerised coat proteins deform flat regions of 
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membrane into round buds, eventually leading to the formation of transport vesicles, which 
contain the protein cargo and a R-SNARE (Figure 1.11) [70]. 
 
Once the vesicle has fully formed and closed, the coat proteins are disassembled and recycled 
back to the cytosol for future use.  The vesicle is then targeted to the appropriate acceptor 
compartment, using specific Rab proteins and their effectors for movement along the 
cytoskeleton [51].  The specific Rab protein also binds to tethering factors that are present on 
the acceptor compartment, and thus physically links the transport vesicle to the acceptor 
compartment [51].  The close proximity of the 2 compartments now allows the R- and Q-
SNAREs to interact with each other from their N- to their C-termini, creating a zippering 
action, bringing the 2 membranes closer together [33].  The formation of the trans-SNARE 
complex generates enough energy for the membranes to fuse and the cargo to be delivered to 
the acceptor compartment [33]. 
 
28 
 
 
 
 
 
29 
Figure 1.11 – Steps of vesicle budding and fusion. 
(1) Initiation of coat assembly:  The membrane-proximal coat components (blue) are 
recruited to the donor compartment by binding to a membrane-associated GTPase (red).  
Transmembrane cargo proteins and SNAREs begin to gather at the assembling coat. (2) 
Budding:  The membrane-distal coat components (green) are added and polymerise into a 
mesh-like structure.  Cargo becomes concentrated and membrane curvature increases.  (3) 
Scission:  The neck between the vesicle and the donor compartment is severed either by direct 
action of the coat or by accessory proteins.  (4) Uncoating:  The vesicle loses its coat due to 
various events including inactivation of the small GTPase, and the action of uncoating 
enzymes. Cytosolic coat proteins are then recycled for additional rounds of vesicle budding. 
(5) Tethering. The “naked” vesicle moves to the acceptor compartment, possibly guided by 
the cytoskeleton, and becomes tethered to the acceptor compartment by the combination of a 
GTP bound Rab and a tethering factor.  (6) Docking:  The Q- and R-SNAREs assemble into a 
four-helix bundle.  (7) This “trans-SNARE complex” promotes fusion of the vesicle and 
acceptor lipid bilayers. Cargo is transferred to the acceptor compartment, and the SNAREs 
are recycled as shown in Figure 1.5. [69] 
 
 
1.8 – The HOPS Complex 
 
The yeast class C VPS proteins (Vps11, Vps16, Vps18 and Vps33) combined with Vps39 and 
Vps41 form the HOmotypic vacuole Proteins Sorting (HOPS) complex. Studies in yeast 
showed that this complex binds Ypt7 (Rab7), which in turn initiates vesicle tethering or 
docking [47].  The HOPS complex is found in a larger cis-SNARE complex, until Sec18 
(NSF) primes the un-paired SNARE molecules, which then releases the HOPS proteins.  This 
then allows the HOPS complex to interact with the GTP bound Rab protein Ypt7, and causes 
vesicle transport to the vacuole or homotypic fusion of two vacuoles [47;71-73].  Therefore 
the probable function of the HOPS complex, which includes the SM protein Vps33, is to form 
a link between the Rab based tethering apparatus and SNARE based docking and fusion 
apparatus.   
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A recent study by Rink et al. [74] using fast, quantitative, live-cell imaging observed that over 
time Rab5 positive early endosomes grew in size and moved towards the centre of the cell.  
The movement of these vesicles was accompanied by the gradual and eventual complete loss 
of Rab5 and its’ effector molecule EEA1, and a gradual increase in Rab7 and its’ effector 
molecules (Figure 1.12) [74].  Proteins associated with the late endosome appeared within the 
same time scale as Rab exchange, and the late endosomes acquired typical degradative 
properties [74].  Vps11 has been shown to bind to GTP-bound Rab5 on early endosomes, and 
therefore has Rab5 effector properties [75].  Another member of the HOPS complex, Vps39, 
has been shown to have Rab7 GEF activity on late endosomes [73].  Thus a Rab5 – Rab7 
cascade is formed, with the HOPS complex possibly playing a key role in the conversion of 
early to late endosomes as demonstrated in Figure 1.12. 
 
Another recent finding suggests that the HOPS complex may also proofread the trans-SNARE 
complex, by not allowing fusion to occur if the SNARE complex is incorrect [76].  As 
mentioned in section 1.5, a trans-SNARE complex requires three Q-SNAREs and one R-
SNARE for optimal fusion to occur [33].  Alterations in this central layer greatly reduced 
membrane fusion.  This was shown to be due to the action of the HOPS complex, which 
firstly inhibited the trans-SNARE complex formation and secondly suppressed membrane 
fusion of altered central layers [76]. 
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Figure 1.12 – Rab5 to Rab7 conversion on early to late endosomes. 
Early endosomes are partially marked by the presence of Rab5 and its effectors, one of which 
is Vps11, a HOPS complex member.  A second subunit of this complex, Vps39, displays GEF 
activity towards the yeast Rab7 orthologue (Ypt7) on late endosomes.  Therefore, Rab5, the 
HOPS complex and Rab7 appear to form a Rab cascade on early endosomes.  There is a 
gradual inactivation and replacement of Rab5 and its effectors and concordant activation of 
Rab7 and its effectors as early endosomes mature to late endosomes. [Adapted from 59] 
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The mammalian HOPS complex counterpart is much less well characterised.  The human 
homologues (VPS11, VPS16, VPS18, VPS33A, VPS39 and VPS41) have been shown to 
localise to the late endosome and lysosome compartments of cells, and to interact with 
syntaxin-7 [77;78].  Kinchen et al. in 2008 showed that the HOPS complex is required for 
phagosome maturation and engulfment of apoptotic cells in C. elegans and mammalian cells 
[79].  Interestingly they suggested that the HOPS complex functions downstream of the Rab5 
to Rab7 endosome conversion in this system [79].  However, it was not specified which 
Vps33 homologue was used in this study, despite both VPS33A and VPS33B being present in 
C. elegans.  Therefore, whether or not VPS33B is a member of the mammalian HOPS 
complex remains unknown.  However, over-expression of either VPS18, VPS33B or VPS39 
all cause clustering of LAMP-1 positive late endosomes and lysosomes, suggesting that this 
maybe the case [1;80;81]. 
 
The naturally occurring buff (bf) mouse was identified as having a missense mutation 
(p.Glu251Asp) in Vps33a, and is the only known mammalian HOPS complex mutant to date.  
The phenotype of the bf mouse was suggested as a model for Hermansky-Pudlak syndrome 
(HPS), which is characterised by oculocutaneous hypopigmentation, a platelet aggregation 
defect, and in some cases pulmonary fibrosis [82].  The platelet defect was shown to be due to 
abnormalities in –granules, as opposed to -granule defects in ARC syndrome [83]. Taken 
together these findings suggest that VPS33A and VPS33B might be part of the same complex, 
but ultimately have a different function in cells. 
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1.9 – The CORVET Complex 
 
A novel complex was recently identified in yeast called the class C cORe Vacuole Endosome 
Tethering (CORVET) complex, which was shown to interact with the Rab GTPase Vps21 the 
yeast homologue of human Rab5 [84].  Both the HOPS and CORVET complexes contain the 
class C VPS proteins.  The CORVET complex additionally has Vps3 (a homologue of 
VPS39) and Vps8 (a homologue of VPS41).  The complex was shown to have Rab5 effector 
properties, whereas the authors suggest that the traditional HOPS complex is a Rab7 effector 
due to its preferential binding of specific GTP bound Rab molecules [84]. 
 
Peplowska et al. in 2007 showed that the HOPS and CORVET complexes could inter-convert, 
and also identified two intermediates depending on which proteins had been exchanged 
(Figure 1.13) [84].  Two models for the conversion have been postulated.  The first model 
(Figure 1.13A) assumes that the intermediates can assemble de novo and bind to different Rab 
GTPases on endocytic membranes.  The second model (Figure 1.13B) links the observed 
order of intermediates to the Rab GTPase cycle, displacing and recruiting Rab GEFs and Rab 
effectors as necessary [84]. 
 
The identification of the CORVET complex further demonstrates the maturation process of 
early to late endosomes associated with the conversion of the yeast homologues of Rab5 to 
Rab7.  The function of the complex has been suggested to be for the retrograde trafficking of 
material from late to early endosomes [84]. 
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Figure 1.13 – The HOPS and CORVET complexes and models for their intermediates. 
Two models for the conversion have been postulated, each with the same 2 intermediates, i-
CORVET and i-HOPS.  Both intermediates are where only one protein has been exchanged. 
A, The first model assumes that the intermediates can assemble de novo and bind to different 
Rab GTPases on endocytic membranes.  B, The second model links the observed order of 
intermediates to the Rab GTPase cycle, displacing and recruiting Rab GEFs and Rab 
effectors as necessary. [Adapted from 84] 
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1.10 – Polarised Epithelia 
 
Nearly all cell types in multi-cellular organisms are said to be polarised, a quality of the cells 
which is characterised by the generation of functionally distinct membrane domains. 
Epithelial cells are no exception and require distinct apical and basolateral plasma membrane 
domains to perform their various epithelial functions, including directional roles in absorption 
and secretion [85;86].  Generation of these distinct domains is termed polarisation, and 
requires complex sorting machinery in the cell to deliver proteins and lipids to the correct 
domain [87].  ARC syndrome patients seem to have abnormally polarised epithelial cells in 
their kidneys and liver as evidenced by the presence of apical membrane proteins found in the 
basolateral surface.  However, basolateral membrane proteins are not found in the apical 
surface [1;11].  These findings suggest a role of VPS33B in establishing polarity in epithelial 
cells. 
 
1.11 – The Apical Junction Complex 
 
Epithelial cells form a protective ion-selective barrier to the external environment.  The 
basolateral membrane contacts neighbouring cells and the underlying tissues, whereas the 
apical surface faces the lumen of an internal organ.  The apical junction complex (AJC) 
separates the two membrane domains, and is comprised of adherens junctions (AJs) and tight 
junctions (TJs).  This barrier function is highly dependent on the integrity of these two types 
of junctions, which link adjacent epithelial cells [88;89].  Many human disorders (including 
cancer, autoimmune diseases, asthma and neurodegeneration) have been associated with 
abnormalities of the AJC proteins [90-93]. 
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1.11.1 – Adherens Junctions  
 
The adhesion between epithelial cells is primarily generated by the adherens junction, forming 
an adhesive belt that encircles the cell just below the apical surface, but more basal to the TJ 
[94].  The AJ has numerous and varied functions including the initiation and stabilisation of 
cell-cell adhesion, regulation of the actin cytoskeleton, intracellular signalling and 
transcriptional regulation [89].  The proteins that constitute an AJ are members of the 
cadherin superfamily, such as E-Cadherin in epithelial cells, and the catenin superfamily, 
including p120-,- and catenin. 
 
E-Cadherin is a single membrane spanning glycoprotein, with five characteristic extracellular 
cadherin (EC) domains.  These domains interact with E-Cadherin molecules from the 
neighbouring cell.  E-Cadherin trans-dimerisation is calcium dependent, as the EC domain 
needs to bind Ca
2+
 ions to create the correct protein conformation to allow for trans-
dimerisation, initiating a weak cell-cell adhesion [95].  
 
The correct localisation of E-Cadherin to the lateral membrane is critical to epithelial cell 
polarisation, and the continuous delivery of newly synthesised protein is essential to ensure 
the dynamic nature of AJs [96].  E-Cadherin is trafficked from the TGN to the Rab11 positive 
Apical Recycling Endosomes (ARE) before being delivered to the lateral membrane [97].  It 
is proposed that formation of the AJ leads to the formation, but not the maintenance of the TJ 
[98].  It has recently been shown that the dimerisation of VE-Cadherin in vascular endothelial 
cells mediates the transcriptional upregulation of Claudin-5, through activation of 
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transcription factors and -catenin [99].  However HepG2 cells engineered not to have AJs 
still form functional tight junctions, but much more slowly than if AJs are present [100]. 
 
1.11.2 – Tight Junctions 
 
Epithelial cells form a cohesive layer of cells capable of physical and ion-selective barrier 
functions, known as the fence and gate functions respectively [88].  The former function is 
also responsible for the prevention of intermixing of apical and basolateral membrane lipids 
and proteins.  These functions are for the most part due to the TJ proteins, which are 
comprised of two types of transmembrane proteins, occludins and claudins, and their 
associated cytoplasmic proteins that link the TJ to the actin-cytoskeleton and AJs [89].  An 
important group of these scaffolding proteins are the zonula occludens proteins, ZO-1, ZO-2 
and ZO-3, which also interact with the AJ. 
 
Similar to E-Cadherin in the AJ, both the occludin and claudin family of proteins homo-
dimerise with each other, however this interaction is much stronger and generates very tight 
cell-cell adhesion.  Reduction of occludin expression by RNAi failed to reduce either the 
fence or the gate function in epithelial cells, but a reduced communication of apoptosis to 
neighbouring cells was evident [101].  This indicated that the claudin family is the key 
member of the tight junction complex that regulates the paracellular permeability.  
Furthermore, each one of the 24 members of the claudin family of proteins has a different 
expression and permeability pattern, allowing different tissues and cell types to fulfil their 
different functions [102]. 
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Interestingly both ZO-1 and ZO-2, but not ZO-3, determine where the Claudin family of 
proteins are dimerised with each other, and hence where functional tight junctions are formed 
[103].  Therefore this group of proteins maybe the link between the sequential formation of 
AJs and TJs, as the ZO group of proteins also interact with the AJ.  However, these ZO 
deficient, and in turn functional TJ deficient cells retained their apical basolateral polarity of 
membrane proteins [104;105]. 
 
1.11.3 – The Adhesion To Polarity Model 
 
The apical junction complex plays a complicated role in epithelial cell polarity, and is widely 
thought as the driving process for the generation of apical basolateral polarity (Figure 1.14).  
The classic model begins with the dimerisation of E-Cadherin between adjacent cells, which 
through the action of ,  and  catenin, reorganises the actin network to form an actin 
belt that surrounds the apical surface [106].  Meanwhile the TJ protein components are 
recruited to the AJ, forming spot-like adherens junctions.  The TJ components then migrate to 
a more apical position, and intracellular vesicles fuse with the lateral membrane leading to the 
vertical extension of the epithelial cells [94;107]. 
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Figure 1.14 – The adhesion to polarity model of epithelial polarisation.   
A, Initially the epithelial cells grown on filter supports are not in contact with each other and 
are relatively unpolarised.  B, After contact occurs, cells form initial cell-cell junctions, 
which function as a targeting patch for further junctions to form. C, E-Cadherin is trafficked 
to the lateral membrane, which in turn recruits the exocyst complex.  D, The lateral 
membrane then extends and tight junctions concentrate at the most apical region of the 
lateral surface. The cells then fully polarise along the apical-basolateral axis (grey arrows). 
[Adapted from 108] 
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The co-operation of two independent protein complexes, CRB (crumbs) and PAR 
(partitioning defective) regulate several steps of the epithelial polarisation process.  Activation 
of the PAR complex and the correct localisation of the CRB complex to the apical and sub-
apical region, are essential for apical membrane determination [94].  It has recently been 
identified that there is an asymmetric distribution of phosphoinositide molecules in the apical 
and basolateral membrane.  The apical membrane is rich in phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2), whereas the basolateral membrane has phosphatidylinositol 3,4,5-
trisphosphate (PI(3,4,5)P3) [109].  This difference was shown to be due the apical localisation 
of the enzyme PTEN which converts PI(3,4,5)P3 to PI(4,5)P2 [110].  The PAR complex has 
been linked with the asymmetric distribution of the lipid molecules, but at the present time it 
is unclear which asymmetry occurs first [111]. 
 
1.11.4 – The Polarity To Adhesion Model  
 
Although the classic adhesion to polarity model is favoured by most, recent evidence suggests 
that this might not necessarily be entirely correct, and that polarisation could occur 
independent of adhesion.  Activation of the PAR complex in contact naïve epithelial cells is 
sufficient to cause the remodelling of the actin cytoskeleton to a polarised state.  Furthermore, 
these cells formed an apical brush border and began to form primary TJs at single spots on the 
membrane [112].  Knockdown of the CRB complex proteins causes serious defects in TJ, and 
also AJ formation, as E-Cadherin fails to reach the membrane.  This was shown to be partially 
due to the mislocalisation of the exocyst complex [113].  The octomeric exocyst complex is 
an evolutionary conserved complex required for the tethering of exocytic vesicles with the 
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target membrane, and is proposed to selectively tether cargo vesicles directed towards the 
basolateral surface [114;115].   
 
Taken all together these findings suggest that there is an intimate and intricate interaction 
between adhesion and polarity complexes to establish and maintain polarity in epithelial cells. 
It is most likely that there is an increasingly stronger cyclic relationship between adhesion and 
polarity.  Early adhesion events cause the activation of the polarity proteins, which then 
reinforces adhesion, which in turn promotes further polarisation. This process continues until 
the cells become fully polarised. 
 
1.12 – Polarised Protein Trafficking 
 
The protein and lipid content of the apical and basolateral domains of epithelial cells needs to 
be tightly controlled so that the cells can undertake their correct function.  For example, 
inserting basolateral proteins into the apical domain in kidney epithelial cells would destroy 
the normal steep electro-chemical gradient across the cells, and also allow for the re-
absorption of waste products.  Similarly in hepatocytes, the delivery of basolateral unsaturated 
phospholipids to the apical membrane could disturb the normal resistance of the membrane to 
bile acid detergents [87]. 
 
In epithelial cells, there are three pathways that generate the polarised distribution of apical 
and basolateral membrane proteins.  These are the biosynthetic, endocytic and transcytosis 
pathways.  Until the newly synthesised proteins enter the TGN the steps in the biosynthetic 
pathway for polarised epithelial cells are the same as shown in section 1.4 for non-polarised 
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cells.  Whilst in the TGN a vast majority of proteins are sorted by the sorting machinery into 
apical and basolateral vesicles, which deliver the proteins to the correct surface [116].  The 
mechanisms of sorting at this level are discussed later in this section.  Some proteins exit the 
TGN unsorted and are put into common recycling endosomes (CREs), where they are then 
sorted into apical and basolateral cargo and delivered to the correct surface through apical or 
basolateral recycling endosomes [117-119].  Proteins that are not retained at the surface, 
usually through interaction of the C-terminal region with PDZ domain containing proteins, 
are rapidly endocytosed and delivered to early endosomes [120].  From here the proteins can 
be recycled back to the previous membrane, sent to the late endosome and lysosome 
compartments for degradation, or delivered to the opposite surface through the CRE [121].  
The latter process is termed transcytosis and is extensively used by hepatocytes, which first 
deliver some apical membrane proteins to the basolateral surface, and then transfer them to 
the apical membrane [122].  A diagram demonstrating the above pathways is given below in 
Figure 1.15. 
 
Proteins containing PDZ domains help anchor transmembrane proteins to the cytoskeleton 
and hold signaling complexes together.  The domain was named after the three original 
proteins shown to contain this domain, which were Post synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (DlgA), and Zonula occludens-1 (ZO-1).  The domain 
is also referred to as the GLGF domain, due to the importance of these amino acids to its’ 
function [123]. 
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Figure 1.15 – Protein trafficking pathways in polarised epithelial cells.  
From the TGN, protein cargo can be sorted directly to the apical and basolateral surface (red 
arrows).  Proteins can also reach their correct surface through sorting at the common 
recycling endosome (CRE, blue and green arrows). After initial trafficking of apical proteins 
to the basolateral surface, apical cargo can be delivered to the apical membrane through the 
transcytosis route (green arrows). The basolateral recycling pathway is shown with gold 
outlined arrows. The apical recycling and apical to basolateral transcytosis pathways are 
omitted for clarity (EE – early endosomes, ER – endoplasmic reticulum, LE – late endosomes, 
and TGN – trans-Golgi network). [Adapted from 87] 
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1.12.1 – Basolateral Protein Sorting 
 
Basolateral membrane proteins are sorted to their correct surface by having short amino acid 
sorting signals in their cytoplasmically exposed regions.  In 1986 Mostov and co-workers 
demonstrated that deletion of this sorting signal in the polymeric immunoglobulin-A receptor 
caused the apical localisation of the basolateral protein, and suggested that apical trafficking 
was the default pathway [124].  This group went on further and showed in 1991 that if this 
signal was transplanted into apical membrane proteins the protein was delivered to the 
basolateral membrane [125].  Since the identification of the basolateral sorting signal, 
numerous groups have pinpointed the actual amino acids that are required for correct 
trafficking.  These include tyrosine, leucine and dileucine motifs that are often found in close 
proximity to acidic amino acids, as well as other uncharacterised motifs [126-128].  
 
Several groups realised that the basolateral sorting signals shared a striking resemblance to 
sequences found in the receptors that were endocytosed from the plasma membrane through 
clathrin coated pits, or transported to the lysosome [126;129].  All the sorting signals are 
recognised by adaptor coat proteins, or adaptins, of which there are five, AP-1A, -1B, -2, -3 
and –4, each having an organelle specific localisation [130].  In polarised epithelial cells 
basolateral sorting signals are recognised by AP-1B and AP-4, which can be found in the 
TGN and endosomal compartments [131;132].  Transfection of the 1B sub-unit of the 
adaptor protein AP-1B complex into 1B deficient LLC-PKI cells restores the correct 
basolateral localisation of the LDL and transferrin receptors [131].  This suggests that these 
two adaptin proteins are responsible for the correct sorting of basolateral cargo in the 
biosynthetic and recycling endocytic pathways. 
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1.12.2 – Apical Protein Sorting 
 
In contrast to the basolateral sorting signals and receptors, the apical sorting signals and 
machinery are much less well understood.  It was first believed that delivery of membrane 
proteins to the apical membrane was the default process and that only proteins with 
basolateral sorting signals were directly trafficked to the basolateral surface, however this was 
shown not be strictly true [133]. 
 
Apical sorting signals are found in the exoplasmic, membrane and cytoplasmic regions of the 
sorted proteins.  It was noticed that glycosylphosphatidyl-inositol anchored proteins (GPI-
APs) were for the most part localised to the apical surface of polarised epithelial cells, and 
that transplantation of this region onto secreted cargo resulted in an apical localisation 
[134;135].  The transfer of a GPI moiety onto a protein is a post-translational modification 
and results in the protein being anchored to the outer membrane leaflet.  
 
A second group of the apical sorting signals are the N- and O-glycans, another post-
translational modification, but these were shown to be recessive to basolateral sorting signals 
[136;137].  Therefore, if a protein contained a basolateral sorting signal and had N- or O-
glycans attached, it would still be trafficked to the basolateral membrane.  Experiments 
carried out imply that there are apical sorting receptors similar to that of the basolateral 
system, as high-level expression of an apical membrane protein saturated the system, and 
could be out competed by a second apical protein [138].  Glycoproteins acquire their N-linked 
glycans whilst the polypeptide is being synthesised.  The 14-saccharide core is transferred to 
an asparagine (N) residue within a consensus sequence of N-X-T/S, where X is any amino 
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acid except proline (P) [139].  However, receptors for these apical sorting signals remain 
elusive, with only a couple of carbohydrate-binding proteins (lectins) being suggested with 
currently no direct evidence [139].   These two proteins are VIP36 and galectin-3, but their 
exact role in apical membrane protein trafficking remains unknown. [140].   
 
In 1988 van Meer and Simons presented an alternative to the conventional sorting receptor 
model for apical protein sorting in epithelial cells, which they termed the lipid-raft hypothesis. 
The hypothesis postulates that many proteins are sorted to the apical surface because they 
have an affinity for micro-domains of glycosphingolipids and cholesterol (lipid-rafts), which 
are assembled at the Golgi [133;141;142].  The apical membrane was known to be rich in 
sphingolipids and cholesterol, and depletion of these two molecules caused the mis-sorting of 
apical proteins [143].  However, very little more is known about how lipid rafts function due 
to a lack of suitable methods and the fact that they are very difficult to visualise using light 
microscopy because of their size and dynamic nature [87]. 
 
1.12.3 – The Cytoskeleton 
 
Vesicular trafficking relies heavily on the cytoskeleton of cells and in particular the 
microtubule and actin filament networks.  Microtubules are comprised of polymerised and 
tubulin molecules, and in polarised epithelial cells the fast growing plus end faces the 
basolateral surface, whereas the slow growing minus end faces the apical surface [144].  The 
microtubule motor protein families of kinesins and dyneins are involved in anterograde 
(towards the plus end) and retrograde (towards the minus end) transport respectively [145].  
The polarised nature of the microtubule network and different directions of motor protein 
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transport allows for specificity of apical and basolateral trafficking.  Polymers of globular 
actin form actin microfilaments with their barbed end toward the cell membrane and the 
pointed end toward the cell interior.  Unconventional myosin motor proteins, such as myosin-
V and –VI are involved in vesicular transport of cargo towards the barbed end and the pointed 
end respectively [146]. 
 
There is increasing evidence to support the idea that the cytoskeleton plays an important role 
in generating and maintaining apical and basolateral polarity in epithelial cells.  The 
cytoskeleton has been shown to be important at the sorting organelles, the TGN and recycling 
endosomes; however the function of different systems have different functions in polarity.  It 
seems that microtubules are essential for organisation of the apical membrane, whereas the 
actin cytoskeleton has a role in basolateral polarity [133]. 
 
In polarised epithelial cells the SNARE protein syntaxin-3 is localised to the sub-apical, or 
upper third of the cell, and syntaxin-4 is found in the lateral areas of cells.  However in non-
polarised cells this is not the case and both syntaxin molecules are found throughout the cell 
[133].  This apical basolateral polarisation of these two syntaxin proteins provides a possible 
mechanism of differential apical and basolateral membrane protein delivery.  Furthermore, 
depolymerisation of the microtubule network in epithelial cells results in the depolarisation of 
syntaxin-3 and the basolateral delivery of GFP-P75 in MDCK cells, with no change in the 
basolateral protein trafficking [116].  Similarly depolymerisation of the actin cytoskeleton 
cause the depolarisation of syntaxin-4 from the lateral surface and leads to apical delivery of 
basolateral proteins and deficiencies in the basolateral recycling [147].  The exact 
mechanisms of how both the actin and microtubule cytoskeleton and the polarised distribution 
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of syntaxin-3 and –4 have an effect on apical-basolateral membrane protein polarity remains 
poorly understood. 
 
1.13 – Summary 
 
Arthrogryposis Renal dysfunction and Cholestasis (ARC) syndrome is caused by mutations in 
VPS33B in around 75% of patients [1;2;4].  No detectable mutations have been identified in 
the remaining patients, and furthermore some consanguineous families with ARC syndrome 
do not link to the VPS33B 15q26.1 locus.  Thus suggesting locus heterogeneity and other 
causal genes for ARC syndrome, which are yet to be identified. 
 
The VPS33B gene encodes the VPS33B protein, which in multicellular organisms is one of 
two homologues of the yeast Vps33 gene and protein.  Both the VPS33A and VPS33B 
proteins contain a Sec1/Munc18 (SM) like domain throughout.  SM proteins are thought to 
tightly bind to members of the syntaxin family of target SNAREs (Soluble N-ethylmAlemide 
sensitive REceptors) and may alter interdomain interactions and influence vesicle to target 
SNARE complex formation [6].   
 
Yeast Vps33 alongside Vps11, Vps16, Vps18, and Vps39 belong to the class C vacuole 
protein sorting (VPS) group of proteins and is required for vacuole biogenesis [7].  The class 
C VPS proteins with VPS41 form the HOPS complex, which in yeast has been shown to be 
involved in the maturation of Rab5 positive early endosomes to Rab7 positive late endosomes 
[74].  The mammalian HOPS complex counterpart is much less well characterised.  The 
human homologues (VPS11, VPS16, VPS18, VPS33A, VPS39 and VPS41) have been shown 
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to localise to the early endosome, late endosome and lysosome compartments of cells, and to 
interact with syntaxin-7 [77;78].  Whether or not VPS33B is a member of this mammalian 
complex remains unknown, however, preliminary data suggests that this might be the case 
[1;80;81]. 
 
The function of VPS33B has not been extensively studied in mammals.  However, the 
identification of mutations in VPS33B in ARC syndrome patients might give an insight into 
the function of VPS33B.  ARC syndrome patients seem to have mislocalisation of apical 
membrane markers in polarised epithelial cells, predominantly in the liver and kidney [1;11].  
Taken together with the predicted function of VPS33B in vesicular trafficking, this suggests a 
function of VPS33B in the trafficking of these proteins to the correct pole of polarised cells. 
However, the intracellular action of VPS33B and how mutations in VPS33B lead to the 
pathogenicity of ARC syndrome remains unknown.  Elucidation of the role of VPS33B in 
polarised protein trafficking in epithelial cells will not only further the knowledge of how 
epithelial cells establish and maintain their polarity but may also reveal mechanisms for 
potential therapeutics for ARC syndrome patients. 
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CHAPTER 2 – MATERIALS AND METHODS 
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2.1 – Materials 
 
2.1.1 – DNA and RNA Analysis 
 
Patients that presented with a classical ARC phenotype including arthrogryposis multiplex 
congenita, renal tubular dysfunction and cholestasis with low GT activity were included in 
the study.  DNA was extracted from blood samples using standard protocols and stored at 500 
ngl-1 at -80oC until required.  Protein and RNA samples obtained at different stages of 
human foetal development were provided by Prof. M. Kilby (University of Birmingham, UK).  
The study was approved by the local research ethics committee.   
 
Standard PCR reagents (Taq DNA polymerase, buffer, MgCl2 and 100 M dNTP mix) were 
all purchased from Thermo Electron (Ulm, Germany) and the nuclease free water from 
Invitrogen (Paisley, UK).  De-salt purified primers were ordered from Sigma Aldrich (Poole, 
UK).  Agarose was purchased from Bioline (London, UK) and the 100 bp ladder from New 
England Biolabs (Hitchin, UK).  The Exo-SAP reagent was bought from USB (Staufen, 
Germany) and the BigDye Terminator (version 3.1) sequencing kit along with the HiDi 
formamide was purchased from Applied Biosystems (Warrington, UK). 
 
The RNAzol B reagent was procured from Campro Scientific (Birkenhead, UK) and the 
ImProm-II Reverse Transcription System Kit and oligo dT primers were purchased from 
Promega (Southampton, UK).  Primers for qRT-PCR were ordered from Thermo Electron and 
were dHPLC purified.  The Power SYBR Green master mix was purchased from Applied 
Biosystems. 
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2.1.2 – Cell Culture 
 
All cell culture plastic ware including the Transwell permeable supports were purchased from 
Corning (High Wycombe, UK), except the glass bottom dishes, which were obtained from 
Ibidi (Munich, Germany).  Foetal Bovine Serum (FBS) Gold and the dialysed equivalent 
along with the G418 sulphate solution were procured from PAA Laboratories (Yeovil, UK).  
Lipofectamine 2000 transfection reagent was bought from Invitrogen.  All other cell culture 
regents were obtained from Sigma-Aldrich. 
 
2.1.3 – Protein Reagents 
 
The Complete Mini Protease Inhibitors were purchased from Roche (Welwyn Garden City, 
UK) and the Dc Protein Concentration Assay Kit from BioRad (Hemel Hempstead, UK).  The 
lyophilysed Bovine Serum Albumin (BSA) was obtained from Sigma-Alridch, and the 
polyacrylamide mix was bought from Geneflow (Fradley, UK).  The transblot polyvinylidene 
difluoride (PVDF) membrane (Hybond-P) and ECL Plus western blot detection system kit 
were procured from GE Healthcare (Amersham, UK).  Protein G coupled Dynalbeads and the 
magnetic block was obtained from Invitrogen.  The EZ-link Sulfo-NHS-SS-Biotin was 
purchased from Thermo Scientific (Loughborough, UK) and the streptavidin-agarose beads 
from Sigma Aldrich. 
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2.1.4 – Cloning  
 
Where necessary IMAGE clones were purchased from Geneservice (Cambridge, UK) and the 
required dHPLC purified PCR primers were ordered from Thermo Electron.  The 
proofreading Platinum Taq Polymerase kit was obtained from Invitrogen.  A 2-log DNA 
ladder, all restriction enzymes, buffers and BSA were procured from New England Biolabs.  
The T4 DNA ligase and buffer were purchased from Promega.  The DH5 and XL-1 Blue 
competent cells were purchased from Bioline and Stratagene (Cambridge, UK) respectively. 
SOC medium was obtained from Invitrogen and plasmid mini and maxi prep kits were 
purchased from QIAGEN (Crawley, UK).  The pEGFP-P75 was a gift from E. Rodriguez-
Boulan (Cornell University, New York, NY). The pEGFP-CD63 was a gift from J. Jaiswal 
and the Rab4, Rab5 and Rab11a constructs were gifts from A. Benmerah and S. Benichou 
(Institut Cochin, Paris, France). The dominant-negative Rab11a plasmid, pEGFP-DN Rab11a, 
containing the S25N missense mutation was a gift from F. Barr (University of Liverpool 
Cancer Research Centre, Liverpool, UK). 
 
2.1.5 – Antibodies and Stains 
 
Monoclonal antibodies against -actin (clone AC-15) and against the HA (clone HA-7) and 
myc epitope tags (clone 9E10) were purchased from Sigma-Aldrich.  Rabbit polyclonal 
antibodies against ZO-1 and Claudin-1 and a mouse monoclonal antibody against E-Cadherin 
were procured from Invitrogen.  Rabbit polyclonal antibodies against VPS33B and CEA were 
respectively purchased from Proteintech Europe (Manchester, UK) and Dako (Ely, UK). The 
mouse monoclonal antibody against the Na+/K+ ATPase protein and the rabbit polyclonal 
antibody against cytokeratin-18 were provided by Millipore (Consett, UK).  The mouse 
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monoclonal antibodies against Rab11a and GM130 were purchased from BD Transduction 
Laboratories (Oxford, UK).  The rat monoclonal antibody against LAMP-1 was purchased 
from the Hybridoma Bank (Iowa, IA).  The rabbit polyclonal antibodies against GFP and -
catenin were purchased from Santa Cruz (Santa Cruz, CA) and Abcam (Cambridge, UK).  
The rabbit polycloanal antibody against zebrafish E-Cadherin was a kind gift from C.P. 
Heisenberg (Max Planck Institute, Dresden, Germany).  Goat anti-mouse IgG and anti-rabbit 
IgG conjugates with Alexafluor 488, 546, 568 and 633 secondary antibodies were used. All 
fluorescent products, including tetramethyl rhodamine isothiocyanate (TRITC)- conjugated 
phalloidin, the Texas Red-conjugated transferrin and the nuclear stain TOP-RO-3, were 
purchased from Invitrogen. Cells were mounted in ProLong Gold antifade solution from 
Invitrogen. 
 
2.1.6 – Zebrafish Reagents 
 
The AB* strain of zebrafish were used for all experiments.  The DIG Labelled RNA Probe 
Synthesis Kit and the alkaline phosphatase-conjugated rabbit anti-DIG antibody were both 
purchased from Roche.  Morpholino oligonucleotides were designed by and obtained from 
Gene Tools (Philomath, OR).  The Message Amp mRNA amplification kit was bought from 
Ambion (Warrington, UK), and the PED-6 reagent was purchased from Invitrogen. 
 
2.1.7 – General Chemicals 
 
Ethanol, methanol and isopropanol were bought from Fisher (Loughborough, UK) and 
Phosphate Buffered Saline (PBS) tablets from Oxoid (Basingstoke, UK).  All other general 
laboratory chemicals were purchased from Sigma Aldrich unless otherwise stated. 
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2.2 – Methods 
 
2.2.1 – Sequencing Analysis of ARC Patients 
 
2.2.1.1 – Polymerase Chain Reaction 
 
The Polymerase Chain Reaction (PCR) was carried out to amplify all coding and flanking 
intronic sequences of VPS33B in patients’ DNA.  VPS33B has 23 coding exons and 22 primer 
pairs were previously designed and are shown in Appendix 1 [1]. The reagents and volumes 
per reaction are given below.   
 
Reagent Volume per reaction (l) 
10x PCR buffer 1 
dNTP mix (10 M) 1 
MgCl2 (25 mM) 0.6 
Nuclease Free Water 5.3 
Taq. Polymerase (5 units l-1) 0.1 
Template DNA (50ngl-1) 1 
Forward Primer (10 M) 0.5 
Reverse Primer (10 M) 0.5 
Total 10 
 
A no template control was run with every primer pair to ensure specificity.  The PCR mix was 
then subjected to the following conditions to allow amplification to occur. 
 
 ---------------- 35 Cycles ----------------  
       
95
o
C 95
o
C      
5 minutes 30 seconds      
    72
o
C 72
o
C 
    30 seconds 10 minutes 
  58
o
C   
   30 seconds    
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The annealing temperature is variable depending on the melting temperature of the primers 
used in the reaction.  The extension time is also variable and depends on the processivity of 
the taq polymerase enzyme, which for this enzyme is 1000 base pairs per minute.  The primer 
pairs were designed to have an annealing temperature of 58
o
C, and the expected product size 
were all less than 500 base pairs, so an extension time of 30 seconds was adequate 
 
2.2.1.2 – Agarose Gel Electrophoresis 
 
Once the PCR reaction was complete, an agarose gel electrophoresis was carried out on the 
PCR products to ensure the reaction was successful and specific.  A 1% agarose gel was made 
by dissolving 1% w/v agarose in 1x TBE buffer (90 mM tris-base, 90 mM boric acid, and 2 
mM EDTA, pH=8.0) and 10 ngml
-1
 of ethidium bromide (EtBr).  An equal volume of 2x 
DNA loading buffer (2 mM EDTA, 50% glycerol and 0.1% orange G) was added to 2.5 l of 
the PCR product and loaded on the gel.  A 100 base pair ladder was added as a size standard, 
and the electrophoresis was carried out at 120 volts for 30 minutes. 
 
2.2.1.3 – Exo-SAP Reaction 
 
After the PCR reactions have been shown to be successful using agarose gel electrophoresis, 
the amplified DNA was diluted three fold and 7.5 l of the diluted DNA samples were added 
to 2.5 l of the Exo-SAP reagent.  The samples were heated to 37oC for 20 minutes and 80oC 
for 10 minutes.  The reagent contains two enzymes, Exonuclease 1 and Shrimp Alkaline 
Phosphatase, which removes any primers and dephosphorylates the dNTPs present in the 
reaction mixture, before the next step in the sequencing protocol.   
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2.2.1.4 – Sequencing 
 
Direct sequencing of Exo-SAP treated PCR products was carried out using the dideoxy 
termination method.  Each of the patients’ DNA was sequenced bi–directionally, therefore 
from this point the forward and reverse primers were kept separate and two reactions were 
carried out per patient per PCR product from above.  The composition of the reaction is given 
below.   
 
Reagent Volume per reaction (l) 
5x Sequencing Buffer 2 
PCR Product 4.4 
Primer (2 M) 1.6 
Nuclease Free Water 1.5 
BigDye 0.5 
TOTAL 10 
 
 
The total reaction mixture was then subjected to the following conditions for the sequencing 
reaction to occur. 
 
 ---------------- 30 Cycles ---------------- 
      
96
o
C 96
o
C     
30 seconds 30 seconds     
    60
o
C 
    4 minutes 
  50
o
C  
   15 seconds   
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2.2.1.5 – Sequencing Precipitation 
 
Once the sequencing reaction was complete any impurities needed to be removed from the 
sequencing products, and these included enzymes and any excess fluorescently labelled 
ddNTPS.  The DNA was precipitated by adding 1 l of 0.25 M EDTA and 32 l of 100% 
ethanol, followed by a 10 minute incubation at room temperature.  The samples were 
centrifuged at 4000 x g for 30 minutes at 4
o
C, and the resulting supernatant was removed by 
centrifuging the plate upside down at 500 x g for 20 seconds.  The DNA pellet was then 
washed with 125 l of 70% ethanol and the centrifugation steps repeated as above.  The 
resulting pellet was allowed to air dry for 10 minutes before 10 l of HiDi formamide was 
added to each well.  The plate was then heated to 95
o
C for 5 minutes to denature the DNA and 
cooled immediately on ice. 
 
2.2.1.6 – Sequencing Analysis 
 
The denatured DNA was then sequenced using an ABI 3730 capillary sequencer (Applied 
Biosystems), and analysed using Chromas v2.23 software (Technelysium, Shannon, Ireland).  
Any change in the patient sequence compared to the reference sequence was verified bi-
directionally and checked for the absence in SNP databases.   
 
2.2.2 – Cell Culture 
 
Control and patients’ skin fibroblasts were grown in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 1x MEM non-essential 
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amino acid solution and 1x penicillin-streptomycin.  Skin fibroblasts from an anonymous 
patient not affected with ARC were used as a control.  Human Embryonic Kidney, HEK293 
cells were grown in the same medium as fibroblasts.  Murine Inner Medullary Collecting 
Duct, mIMCD-3 cells (CRL2123; ATCC, Manassas, VA) were grown in a 1:1 mix of DMEM 
and Ham’s F12 medium, supplemented with 10% FBS and penicillin-streptomycin.  All cells 
were passaged using 0.25% trypsin for 5 minutes after being washed twice with pre-warmed 
PBS.  The cells were diluted as necessary in complete growth medium, and all cells were 
grown at 37
o
C with 5% CO2.  In order to induce mIMCD-3 cells to fully polarise, cells were 
seeded onto 0.4 m pore size transwell permeable supports at a density of 1 x 105 cells per 
cm
2
.  For selection purposes, mIMCD-3 cells were grown in medium containing 1.5 gml-1 of 
puromycin, 400 gml-1 of G418 sulphate, or a combination of both when necessary. 
 
2.2.2.1 – Transfection 
 
HEK293 and mIMCD-3 cells were seeded onto 6-well tissue culture plates and allowed to 
grow to around 80% confluence before being transfected with plasmid DNA constructs.  On 
the day of transfection the normal medium was removed and replaced with 2ml of antibiotic 
free medium.  A total of 4 g of DNA and was added to 250 l of unsupplemented medium, 
and 12 l of Lipofectamine 2000 (3x weight of DNA) was added to the same volume in 
separate tubes.  These tubes were incubated at room temperature for 5 minutes.  The 2 
solutions were mixed together and incubated at room temperature for 20 minutes, after which 
the resulting mixture was added to the cells, which were incubated at 37
o
C with 5% CO2 
overnight. 
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2.2.2.2 – Collagen Culture
 
To assess mIMCD-3 cell morphogenesis, cells were suspended in type I collagen gels in 96-
well plates.  Collagen gels were prepared by adding 5x10
5
 mIMCD-3 cells to 250 l of 
collagen mix (16 mM HEPES, 32 mM NaHCO3, 16% DMEM, and 3.5 mg/ml rat type 1 
collagen (all from Sigma Aldrich)).  Aliquots of 50 l were then seeded into one well of a 96-
well plate and allowed to solidify at 37
o
C, before being overlaid with 100 l of complete 
medium.  After 72 hours of culture the tubules were visualised using 10x phase-contrast 
optics on an Axioplan 2 microscope with images captured on an Axiocam CCD camera (both 
Carl Zeiss, Welwyn Garden City, UK). 
 
2.2.3 – RNA Analysis 
 
2.2.3.1 – RNA Extraction 
 
The required cells were seeded into 75 cm
2
 flasks and allowed to grow to confluence.  The 
cells were washed twice with ice cold PBS and scraped into 1 ml of RNAzol B reagent, after 
which 100 l of chloroform was added, inverted several times and incubated on ice for 10 
minutes.  The samples were then centrifuged for 15 minutes at 4
o
C and the clear upper 
aqueous phase was transferred to a clean tube.  An equal volume of isopropanol was added 
and incubated on ice for 15 minutes before being centrifuged for 30 minutes.  The supernatant 
was discarded and the pellet washed with 1.5 ml of 80% ethanol and centrifuged for 10 
minutes.  Again the supernatant was discarded and the pellet allowed to air dry before being 
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re-suspended in 50 l of nuclease free water.  All centrifugation steps were carried out at 4oC 
and at 4000 x g. 
 
2.2.3.2 – RNA Concentration Quantification 
 
To assess the concentration and quality of RNA obtained from the above procedure, the 
absorbance values of 70 fold diluted RNA samples were taken at 260 and 280 nm.  The ratio 
between the absorbance values at 260 and 280 should be between 1.8 and 2, which signifies 
good quality and pure RNA.  The concentration of RNA is calculated using the following 
formula: 
 
[RNA] (gl-1) = Absorbance at 260 nm x Dilution Factor x 40 
              1000 
 
2.2.3.3 – cDNA Synthesis 
 
For cDNA synthesis, 1g of total RNA was reverse transcribed using ImProm-II Reverse 
Transcription Systems and oligo dT primers.  The following reagents and volumes per 
reaction are shown on the next page: 
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Reagent Volume per reaction (l) 
5x Buffer 4 
MgCl2 (25 mM) 4 
dNTPs (10 mM) 2 
Oligo dT primer (0.5 gl-1) 2 
RT enzyme 0.8 
RNA (1 gl-1) 1 
H2O 6.2 
Total 20 
 
 
The above reaction mixture was incubated at 42
o
C for 60 minutes followed by 99
o
C for 5 
minutes to inactivate the enzyme.  To verify if this reaction was successful, a PCR reaction 
was carried out as in section 2.2.1.1, using -actin (ACTB), a house keeping gene, as the 
target and 1 l of the above reaction mixture as the template.  Primer sequences are shown in 
appendix 1. 
 
2.2.3.4 – Quantitative Real Time PCR 
 
Firstly, PCR primers were designed for human ACTB, VPS33A and VPS33B and mouse Actb 
and Plrn, using Primer 3 software available online (http://frodo.wi.mit.edu).  Primers were 
designed with an annealing temperature of 60
o
C, a product size of less than 500 base pairs and 
preferably with one of the primers spanning an intron so genomic DNA amplification was 
avoided.  The primer sequences generated were run through an nBLAST search to check for 
specificity to the gene of interest (www.blast.ncbi.nlm.nih.gov).  Each primer pair were 
denaturing HPLC purified and tested by PCR using control cDNA to ensure that they were 
specific and only one product was amplified at 60
o
C. 
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The SYBR green reagents binds to any double stranded DNA molecule, including primer 
dimers, therefore an optimisation experiment is required to determine the minimum 
concentration of primer required to amplify the target sequence.  A series of standard PCR 
reactions were carried out with decreasing primer concentrations (1 to 0.05 M) and the 
products were electrophoresed on a 4% w/v agarose gel, and assessed for the presence of 
primer dimers.  For all primer pairs designed the required final concentration was 0.1 M. 
 
Each assay requires a standard curve to be created so that different plates can be compared, 
and always had -actin amplified for each sample as a normalising control.  For all qRT-PCR 
reactions the cDNA previously synthesised was diluted 5 fold with nuclease free water.  A 
serial dilution of control cDNA was used for the standard curve, with concentrations of 1 
(undiluted cDNA), 0.4, 0.2 and 0.1 being used.  No template controls were run with each 
assay to ensure specificity, and each sample was run in triplicate.  The following reagents and 
volumes per reaction are shown below: 
 
Reagent Volume per reaction (l) 
SYBR Green Master Mix (2x) 12.5 
Forward Primer (10 M) 0.25 
Reverse Primer (10 M) 0.25 
Nuclease Free Water 9.5 
cDNA 2.5 
Total 25 
 
 
For an assay 2 master mixes were created, one for the -Actin and one for the gene of interest.  
This was aliquotted onto optical 96-well plates, the cDNA added and the plate sealed with 
optical film. The reaction conditions are given on the next page. 
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   -----------40 Cycles----------- 
      
  95
o
C 95
o
C   
  5 minutes 15 seconds   
    
   60
 o
C 
50
o
C    90 seconds 
2 minutes      
 
 
During the reaction, amplimer levels were continuously quantified using an iQ5 instrument 
(BioRad).  After the assay was complete a dissociation curve analysis was carried out, which 
measures the fluorescence intensity at temperatures between 55
o
C and 95
o
C with 0.5
o
C 
increments.  All samples were run out on a 4% agarose gel to assess the specificity of the 
reaction and to ensure that no primer-dimers were present.   
 
2.2.4 – Protein Analysis 
 
2.2.4.1 – Protein Extraction 
 
For direct immunoblotting fibroblasts, HEK293 and mIMCD-3 cells were grown to 
confluence in 75 cm
2
 tissue culture flasks, rinsed twice with ice-cold PBS and scraped into 1 
ml of RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Igepal CA 630, 
0.5% Sodium Deoxycholate, 0.1% SDS and complete mini protease inhibitor cocktail 
(Roche)).  The same lysis buffer was used for mIMCD-3 cells growing on transwell supports, 
but 250 l was used instead.  For co-immunoprecipitation experiments HEK293 cells were 
grown on 6-well plates, washed twice with ice-cold PBS and scraped into 250 l of MRC 
lysis buffer (50 mM Tris-HCl pH=7.5, 50 mM Sodium Fluoride, 5 mM Sodium 
Pyrophosphate, 1 mM Sodium Orthovanadate, 1 mM EDTA, 1 mM EGTA, 0.27 M Sucrose, 
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1% Triton - X - 100 and complete mini protease inhibitor cocktail (Roche)).  The resulting 
solution was centrifuged at 18,000 x g for 15 minutes at 4
o
C, and the supernatant transferred 
to a clean tube. 
 
2.2.4.2 – Protein Concentration Quantification 
 
Protein concentrations were assessed using the BioRad Dc Protein Assay kit.  For each assay 
a 2 fold serial dilution of a 3 gl-1 BSA standard with the appropriate lysis buffer was made.  
Lysis buffer alone was also loaded as a blanking control.  Reagent A’ was prepared by the 
addition of 10 l of reagent S and 500 l of reagent A.  Five microlitres of either standard or 
sample were added to a 96 well plate followed by 25 l of Reagent A’ and 200 l of reagent 
B.  The plate was then incubated in the dark at room temperature for 10 minutes, after which 
the absorbance at 690 nm for 1 second per well was read using a Wallac Victor
3
 fluorometer 
(Perkin Elmer, Waltham, MA).  
 
2.2.4.3 – Co – Immunoprecipitation 
 
Protein G Dynabeads (Invitrogen) are magnetic beads coupled to Protein G, a molecule that 
binds to various sub-types of immunoglobulin molecules, with strong binding to mouse IgGs.  
The magnetic beads are separated from the solution using a magnet block, so no 
centrifugation steps are necessary.  Due to immunoglobulin heavy and light chain interference 
with the pull-down antibody and the immunoblotting antibody, both of which were raised in 
the mouse, for over-expressed co-immunoprecipitation experiments the required antibodies 
were first conjugated to the beads.  This prevents their elution at the end of the experiment 
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and masking the signal of the proteins of interest.  All liquids were removed from the beads 
after 1 minute on the magnetic block and with the tube remaining on the magnet.  All 
solutions were added to tubes not on the magnet to allow mixing to occur.  Incubation steps 
were carried out at room temperature with end over end mixing unless otherwise stated.   
 
2.2.4.3.1 – Antibody Conjugation 
 
For antibody conjugation, 100 l of homogeneous re-suspended Dynabeads were transferred 
to a 1.5 ml tube, before being put on the magnet and the supernatant removed.  The beads 
were washed twice with 500 l of Citrate Phosphate Buffer (24.5 mM Citric Acid and 51.7 
mM Dibasic Sodium Phosphate, pH=5.0).  Forty micrograms of the required antibody was 
diluted in 100 l of PBS, added to dry beads and incubated for an hour.  The supernatant was 
removed and the beads were washed three times with Citrate Phosphate Buffer followed by 
three washes with 1 ml of 0.2 M Triethanolamine.  The antibody and beads were then 
covalently cross-linked by incubating the mixture for 30 minutes with 20mM Dimethyl 
Pimelimidate (dissolved in 0.2 M Triethanolamine).  The supernatant was removed and the 
reaction was quenched using 1 ml of 50 mM Tris (pH=7.5) and incubated for 15 minutes, 
after which the antibody conjugated beads were washed three times with 500 l PBST (PBS 
and 0.1% Tween-20).  Finally the beads were re-suspended in the 100 l of PBST and stored 
at 4
o
C until required. 
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2.2.4.3.1 – Immunoprecipitation 
 
HEK293 cells growing on 6-well plates and transfected with a total of 4 g of plasmid DNA 
constructs were allowed to recover for 48 hours before the protein was extracted as in section 
2.2.4.1.  For endogenous co-immunoprecipitation experiments mIMCD-3 cells were grown in 
75 cm
2
 flasks and the protein extracted as in section 2.2.4.1.  A 50 g sample of the 
supernatant was removed so an input western blot could be done.  One milligram of protein 
supernatant was added to 20 l of antibody conjugated beads, or 20 g of required antibody 
and 20l of beads that were pre-washed three times with 500 l of Citrate Phosphate Buffer 
and incubated at 4
o
C for 3 hours.   
 
The protein, antibody and bead complexes were placed on the magnet for 2 minutes and the 
liquid transferred to a clean tube and used later as the unbound fraction.  The complexes were 
then washed three times with 500 l of MRC lysis buffer supplemented with 150 mM NaCl.  
After the last wash all the liquid was removed and 20 l of 2x Lamelli sample loading buffer 
(62.5 mM Tris-HCl (pH=6.8), 25% Glycerol, 2% SDS, 0.5 % -Mecaptoethanol, 0.5% 
Bromophenol blue) was added, and the samples boiled for 10 minutes.  An equal volume of 
the 2x Lamelli sample loading buffer was added to the input and unbound fractions, and were 
loaded onto SDS PAGE gels alongside the eluted proteins for western blot analysis. 
 
2.2.4.4 – Membrane Protein Biotinylation 
 
mIMCD-3 cells were seeded onto 6-well transwell filters at a density of 1 x 10
5
 cells per cm
2
 
and allowed to grow for 7 days before the medium was removed and the cells washed once 
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with ice-cold PBS.  The biotinylation reagent, EZ-link Sulfo-NHS-SS-Biotin was dissolved in 
PBS to a concentration of 250 gml-1, cooled and added to the apical and basal surfaces of the 
transwell filters at 4
o
C for 30 minutes.  Any remaining unbound biotin was removed by 
incubating the filters in 250 l of 1 M ammonium chloride for 2 minutes, after which the cells 
were washed once using PBS for 2 minutes.  The cells were then lysed in 250 l of MRC lysis 
buffer as in section 2.2.4.1, and the protein concentration quantified as in section 2.2.4.2.   
 
One-hundred microlitres (50 l packed volume) of streptavidin agarose beads per reaction 
were washed twice using PBS and centrifugation.  All centrifugations steps were carried out 
at 13,000 x g for 1 minute.  Two-hundred and fifty micrograms of the protein lysates from 
above were added to the pre-washed beads and incubated at 4
o
C for 1 hour with end over end 
mixing.  The biotinylated protein - streptavidin agarose complexes were centrifuged, the 
supernatants removed and washed three times using 250 l of MRC lysis buffer.  The 
biotinylated proteins were released from the streptavidin beads by incubating the beads in 2x 
Lamelli sample loading buffer at 60
o
C for 30 minutes.  This was then centrifuged, the 
supernatant transferred to another tube and incubated at 95
o
C for 10 minutes.  An equal 
volume of the 2x Lamelli sample loading buffer was added to the input and unbound 
fractions, and were loaded onto SDS PAGE gels alongside the eluted proteins for western blot 
analysis. 
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2.2.4.5 – Western Blotting 
 
2.2.4.5.1 – SDS – PAGE 
  
Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoreses were run to separate proteins 
according to their molecular mass, for direct immunoblotting of protein samples and after co-
immunoprecipitation experiments. The following reagents were mixed together to form the 
resolving gel, and immediately transferred to 1 mm thick glass plates (BioRad).  The smaller 
percentage gels were used for large proteins and the larger percentage gels were used for 
smaller proteins. 
 
Reagent Volume 
8% 10% 12% 15% 
Acrylamide 2.7 ml 3.4 ml 4 ml 5 ml 
dH20 4.5 ml 3.8 ml 3.2 ml 2.2 ml 
1.5 M Tris-HCl (pH=8.8) 2.5 ml 
10% Ammonium Persulfate 200 l 
10% SDS 100 l 
TEMED 10 l 
 
 
The poured gels were overlayed with isopropanol and allowed to stand for 15 minutes to set, 
after which the gels were washed and dried.  The stacking gel was prepared as shown on the 
next page and pipetted on top of the resolving gel.  Before this gel set, combs were inserted 
which form the loading wells, and the gel allowed to set for 15 minutes. 
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Reagent Volume 
Acrylamide 1 ml 
0.5 M Tris-HCl (pH=6.8) 1.5 ml 
dH20 3.4 ml 
10% Ammonium Persulfate 90 l 
10% SDS 60 l 
TEMED 5 l 
 
 
Protein lysates had 2x Lamelli sample loading buffer added and boiled for 5 minutes prior to 
being loaded onto the gel.  A known molecular weight ladder (Page Ruler; Fermentas, York, 
UK) was also run on the gel, so that later protein sizes could be estimated. The electrophoresis 
was run in 1x SDS Running Buffer (192 mM Glycine, 250 M Tris-Base and 0.1% SDS) for 
around 1 hour at 30mA. 
 
2.2.4.5.2 – Transfer 
 
For immunoblotting the above separated proteins were transferred to PVDF (polyvinylidene 
difluoride) membranes, which were first activated in methanol for 30 seconds.  All required 
materials shown below were equilibrated in 1 x Transfer Buffer (192 mM Glycine, 250 mM 
Tris-Base and 20% methanol).  The blot was created as follows: 
 
Anode  Fibre Pad 
  Filter Paper 
 PVDF Membrane 
 Gel 
 Filter Paper 
Cathode  Fibre Pad 
 
 
The transfer of proteins from the gel to the PVDF membrane was done in 1x Transfer Buffer 
at 100 mA for 1 hour, with an ice pack and constant stirring. 
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2.2.4.5.3 – Immunodetection 
 
The membranes were blocked in 10% dried non-fat milk powder (Marvel) dissolved in PBST 
either overnight at 4
o
C or for 1 hour at room temperature on a roller.  Primary and secondary 
antibodies were added to an appropriate volume of 5% milk powder in PBST at a 
concentration determined empirically (see Appendix 2 for antibody dilutions).  The secondary 
antibodies were all Horse Radish Peroxidase (HRP) conjugates, to allow for detection.  After 
blocking, the membranes were incubated with the diluted primary antibody for 1 hour at room 
temperature on a roller, before being washed three times with PBST for 5 minutes each wash.  
The membrane was then re-blocked with 5% milk in PBST for 5 minutes, after which it was 
incubated with the secondary antibody for 1 hour.  The membrane was then washed as before 
and incubated with the enhanced chemo-luminescence plus (ECL+) western blotting detection 
system reagents (GE Healthcare) at a ratio of 1:40 for regent A:B for 5 minutes.  The bands 
were detected using X-ray film (Kodak). 
 
2.2.4.5.4 – Membrane Stripping and Re-probing 
 
When a loading control was necessary, the membrane was stripped by first washing the 
membrane twice in dH2O for 5 minutes, and twice with 0.2M NaOH for 20 minutes.  It was 
then rinsed twice in dH2O for 5 minutes before being blocked and immunodetection carried 
out as before. 
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2.2.4.5.5 – Densitometry  
 
Western blot films were scanned and imported into LabWorks (Version 2, UVP Corporation, 
Cambridge, UK).  The total absolute intensity was calculated for the band of interest and for 
-actin, the loading control.  The protein of interest band intensity was normalised to -actin. 
 
2.2.4.6 – Yeast – 2 – Hybrid Screen 
 
Human VPS33B was sub-cloned from pEYFP-VPS33B into the pGBT9 vector using EcoRI 
and BamHI so that the gene was in frame with the DNA-binding domain of GAL4 for the 
yeast-2-hybrid screen.  The Genomics and Proteomics Core Facility at the Deutsches 
Krebsforschungszentrum (Heidelberg, Germany) carried out the yeast-2-hybrid screen using 
human foetal brain and adult kidney cDNA libraries as sources of prey. 
 
2.2.5 – Cloning  
 
2.2.5.1 – IMAGE Clones 
 
Full-length cDNA transcripts were purchased from GeneService UK for various genes, shown 
on the next page.   
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Gene Species IMAGE ID 
PLRN Human 3920459 
Plrn Zebrafish 7407368 
VPS11 Human 6144541 
VPS16 Human 6182570 
VPS18 Human 2822780 
VPS39 Human 3078533 
VPS41 Human 4822048 
 
 
These transcripts were supplied ligated into plasmid shuttle vectors and transformed into 
bacteria to allow for amplification.  The bacteria were grown and the plasmids extracted as 
detailed in section 2.2.5.9. 
 
2.2.5.2 – Cloning Strategy 
 
The full-length transcripts were amplified using PCR so that the sequence had restriction sties 
on the 5’ and 3’ end to allow for ligation into expression vectors.  The required transcript 
sequence was run through WebCutter 2.0 software available online to identify restriction 
endonuclease sites within the transcript (www.na.lundberg.gu.se/cutter2).  The results of this 
search was cross-checked with the restriction map of the desired vector, so that a pair of 
enzymes could be used to for cloning without cutting the transcript.  Forward and reverse 
primers were designed to include the required restriction site tagged onto the native 
translation initiation (ATG) and stop codons, so that the transcript would be read in frame 
with the epitope tag in the vector.  A cap of CTT was added to the start of each primer to aid 
restriction digestion.  Primer sequences are shown in appendix 1. 
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2.2.5.3 – Proofreading PCR 
 
Platinum Taq. DNA Polymerase (Invitrogen) was used, as it has proofreading capabilities, 
which reduces the possibility that errors were incorporated into the PCR product.  The 
reaction was set up as follows, using the IMAGE clone plasmid as the template: 
 
Reagent Volume per reaction (l) 
10x PCR buffer 2.5 
dNTP mix (10 M) 2 
MgCl2 (50 mM) 0.75 
Nuclease Free Water 17.25 
Taq. Polymerase (5 units l-1) 0.5 
Template DNA (100ngl-1) 1 
Forward Primer (10 M) 0.5 
Reverse Primer (10M) 0.5 
Total 25 
 
 
 
This reaction mixture was then subjected the conditions below to allow amplification to 
occur. 
 
 ----------------------- 35 Cycles ---------------------  
       
94
o
C 94
o
C      
2 minutes 30 seconds      
    72
o
C 72
o
C 
    1 minute per kb 10 minutes 
  58
o
C   
   30 seconds    
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2.2.5.4 – Agarose Gel Extraction 
 
All of the PCR product from above was loaded onto a 1% agarose gel and electrophoresed as 
in section 2.2.1.2.  A 2-log DNA ladder (100 bp to 10 kb; New England Biolabs) was loaded 
onto the gel so that the size of the product could be estimated.  The correct size band was 
excised from the gel and extracted from the agarose using the QIAGEN gel extraction kit to 
purify the PCR product away from the template. 
 
The band of interest was excised from the gel using a clean scalpel, ensuring to minimise the 
amount of agarose taken from around the band.  Three times the weight of the gel slice in 
volume of Buffer QG was added, and heated at 55
o
C until the gel had melted after which one 
volume of isopropanol was added.  The resulting solution was applied to the column, 
centrifuged and the flow through discarded, followed by a 500 l wash with buffer QG. All 
centrifugation steps were carried out at 13,000 x g for 1 minute at room temperature.  To wash 
the bound DNA, 750 l of buffer PE diluted in ethanol was applied to the column, incubated 
for 5 minutes and centrifuged.  The flow through was discarded and the column centrifuged 
again to remove any remaining liquid.  The column was then transferred to a clean tube, had 
20 l of nuclease free water added, incubated for 1 minute and centrifuged to elute the DNA. 
 
2.2.5.5 – Restriction Digestion 
 
The above gel extracted PCR products and appropriate vectors were restriction digested with 
the necessary restriction enzymes in one reaction to create cohesive ends on both.  The 
enzyme combinations and buffers used are shown on the next page: 
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Gene Species 5’ Enzyme 3’ Enzyme Vector Buffer 
VPS33A Human SalI NotI pCMV-HA 
pEYFP C3 
3 + BSA 
VPS33B Human EcoRI KpnI pEYFP C3 
pCFP C3 
1 + BSA 
PLRN Human EcoRI KpnI PCMV-HA 
pCMV-myc 
pEYFP C3 
pmCherry C3 
1 + BSA 
Plrn Zebrafish BamHI EcoRI pCS2+ EcoRI + BSA 
VPS11 Human EcoRI XhoI pCMV-myc EcoRI + BSA 
VPS16 Human EcoRI NotI pCMV-myc EcoRI + BSA 
VPS18 Human EcoRI KpnI pCMV-myc 
pEYFP C3 
1 + BSA 
VPS39 Human SalI NotI pCMV-myc 3 + BSA 
VPS41 Human SalI NotI pCMV-myc 3 + BSA 
P75 Human ApaI EcoRI pmCherry N1 4 + BSA 
 
 
All restriction digests were carried out in 30 l reactions and done at 37oC for 3 hours.  The 
reaction mixture was set up as follows: 
 
Reagent Volume per reaction 
Insert Vector 
10x Buffer l l
100x BSA  l l
Enzyme 1 (20 unit l-1) l l
Enzyme 2 (20 unit l-1) l l
DNA  l l of 1 gl
H2O l 
Total l l
 
 
The restriction digest products were then loaded onto a 1% agarose gel using 6x loading 
buffer and the required bands extracted as in section 2.2.5.4. 
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2.2.5.6 – Ligation 
 
To ligate the DNA insert into the expression vector the following reaction was set up and 
incubated at room temperature overnight and at 4
o
C until required. 
 
Reagent Volume per reaction (l) 
10x Ligation Buffer 1 
T4 DNA Ligase (3 units l-1) 1 
Insert DNA 3 
Vector DNA 1 
dH2O 4 
Total 10 
 
 
2.2.5.7 – Transformation 
 
All of the above ligation reaction mixture was added to 50 l of DH5 E. Coli bacterial cells 
and incubated on ice for 15 minutes.  The cells were then heat shocked to 42
o
C for 45 
seconds, immediately cooled on ice for 2 minutes and had 500 l of SOC medium (2% 
tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2 and 20mM glucose) 
added.   The transformed cells were incubated at 37
o
C with 220 RPM shaking for either 1.5 
hours (ampicillin resistance) or for 3 hours (kanamycin resistance).  After the incubation the 
cells were centrifuged at 3000 x g for 1 minute to pellet the cells and 360 l of the supernatant 
was removed, leaving 200 l which was transferred to LB agar plates containing either 100 
gml-1 of ampicillin or 25 gml-1 of kanamycin.  These plates were then incubated at 37oC 
overnight. 
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2.2.5.8 – Site Directed Mutagenesis 
 
To introduce the L30P missense mutation into the pCMV-HA-VPS33B construct, two 
complementary primers were first designed to include the desired nucleotide change 
surrounded by 15 correct base pairs in either direction.  A proofreading PCR was carried out 
as in section 2.2.5.3 with the original vector used as the template.  The entire PCR product 
was run on a 1% agarose gel and the resulting band excised and purified as in section 2.2.5.4.  
In order to remove the original un-mutated template, the reaction was digested with Dpn1 as 
detailed in section 2.2.5.5.  This enzyme is methylation specific and will only digest the 
original template, leaving the mutated products intact.  The enzyme was inactivated by 
heating the reaction mixture to 80
o
C for 20 minutes, and after cooling 10 l was transformed 
into XL-1 Blue competent cells (Stratagene) as in section 2.2.5.7.   
 
2.2.5.9 – Colony Screening 
 
Single colonies were selected off bacterial plates and transferred to 10 ml of Luria Broth 
containing the appropriate selection antibiotics at the concentration used for plates.  These 
were then allowed to grow overnight at 37
o
C with shaking at 220 RPM.  An 8% glycerol 
stock of the grown bacteria was made and stored at -80
o
C until required.  The remaining 
liquid was centrifuged at 5000 x g for 5 minutes to pellet the bacteria.  Plasmids were 
extracted from the bacterial cells using a QIAGEN mini-prep kit.  The pellet of bacteria was 
re-suspended in 250 l of Buffer P1 (supplemented with RNase and LyseBlue) and lysed in 
250 l of Buffer P2, which contains NaOH and SDS.  The alkali was neutralised with Buffer 
P3, and the resulting solution was centrifuged at 13,000 x g for 10 minutes.  All subsequent 
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centrifugation steps were carried out at room temperature at 13,000 x g for 1 minute.  The 
supernatant was transferred to the spin column, centrifuged and the bound DNA washed with 
500 l of Buffer PB followed by 750 l of Buffer PE.  The column was then centrifuged 
again to remove any residual liquid, transferred to a clean tube and had 50 l of nuclease free 
water added and incubated for 1 minute.  The column was spun again to elute the plasmid 
DNA. 
 
A restriction digest was done on 5 l of the resulting plasmid using the same enzymes used 
for the original cloning step.  The products were run on a 1% agarose gel alongside the empty 
vector and undigested plasmids, which identified plasmids that had an insert.   
 
2.2.5.10 – Plasmid Sequencing 
 
Sequencing of plasmids is very similar to the method shown in sections 2.2.1.4 to 2.2.1.6, 
however the reaction volumes vary slightly as shown below.  Plasmid sequencing primer 
sequences are shown in appendix 1. 
 
Reagent Volume per reaction (l) 
5x Sequencing Buffer 2 
Nuclease Free Water 4.4 
BigDye 1 
Primer (2 M) 1.6 
Plasmid 1 
TOTAL 10 
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2.2.5.11 – Plasmid Purification 
 
Once the plasmid of interest was shown to contain an insert and be in frame with the epitope 
tag, the plasmid was amplified in bacteria cells.  An inoculation loop was dipped into the 
glycerol stock of the bacteria containing the plasmid of interest, and transferred to 10 ml of 
Luria Broth containing the appropriate antibiotics.  This was then incubated at 37
o
C with 
shaking at 220 RPM for around 6 hours, after which it was diluted to a total of 100 ml and 
grown overnight. 
 
The following day, plasmids were extracted using the QIAGEN maxi-prep kit.  The bacterial 
suspension was centrifuged at 5000 x g for 10 minutes to pellet the cells, which were then re-
suspended in 10 ml of Buffer P1 containing RNase and LyseBlue).  The cells were lysed in 10 
ml of Buffer P2 (containing NaOH and SDS) and incubated at room temperature for 5 
minutes, after which the solution was neutralised with Buffer P3 and immediately transferred 
to the filtration column.  The solution was pushed through the column after a 10 minute 
incubation and the cleared liquid was retained as this contains the plasmid DNA.  To remove 
the endotoxins from the solution, 2.5 ml of Buffer ER was added and the mixture incubated 
on ice for 30 minutes.  Meanwhile the DNA binding column was equilibrated with 10 ml of 
Buffer QBT, after which the plasmid solution was added to the column and allowed to pass 
through under gravity.  Bound DNA was washed twice with 30 ml of buffer QC and eluted 
from the column using 15 ml of Buffer QF.  The eluted DNA was precipitated using 10.5 ml 
of isopropanol and centrifugation at 11,000 x g for 30 minutes at 4
o
C.  The supernatant was 
removed and the resulting pellet was washed with 5 ml of 70% ethanol and centrifuged again 
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as before but for 15 minutes.  The plasmid DNA pellet was allowed to air dry and re-
suspended in 1 ml of nuclease free water. 
 
2.2.5.12 – DNA Concentration Quantification 
 
To assess the concentration of DNA obtained from the above procedure, the absorbance 
values of 70 fold diluted DNA samples were taken at 260 and 280 nm. The concentration of 
DNA is calculated using the following formula: 
 
[DNA] (gl-1) = Absorbance at 260 nm x Dilution Factor x 50 
               1000 
 
2.2.6 – Cell Analysis 
 
2.2.6.1 – Immunofluorescence Confocal Microscopy 
 
HEK293 cells were grown on glass coverslips, transfected as in section 2.2.2.1 and allowed to 
recover for 24h before being fixed in 4% paraformaldehyde (dissolved in PBS, pH=7.0) for 
30 minutes at room temperature.  The cells were then washed three times in PBS for 5 
minutes with shaking and permeablised with 0.1% Triton-X-100 (diluted in PBS) for 5 
minutes.  The coverslips were washed in PBS as before, followed by a 30 minute incubation 
with Blocking Buffer (1% BSA in PBS).  Transwell supports containing mIMCD-3 cells had 
their filters excised and were prepared as above for coverslips, except for immunolabelling for 
all TJ and AJ proteins, which required ice-cold methanol fixation for 5 minutes and 0.1% 
saponin permeabilisation. 
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The filters and coverslips were incubated with the necessary primary antibodies diluted in 
blocking buffer at the required concentration for 1 hour at room temperature (see Appendix 2 
for antibody dilutions).  The cells were then washed three times in blocking buffer as before, 
followed by an hour incaution in the dark with the appropriate fluorophore conjugated 
secondary antibodies diluted in blocking buffer at the required concentration.  Excess 
secondary antibody was removed by washing three times in blocking buffer as before.  Nuclei 
were stained with TOP-RO-3 diluted 1/500 in Blocking buffer in the penultimate wash.  
Coverslips and filters were mounted onto microscopy slides using ProLong Gold antifade 
solution (Invitrogen), sealed at stored in the dark at 4
o
C until required. 
 
Microscopic images were captured using an inverted Leica TCS SP2 AOBS confocal 
microscope (Leica, Milton Keynes, UK) with 10x and a 63x oil immersion objectives and the 
pinhole set to 1 Airy unit.  Series of optical sections were collected from the xy plane and 
merged into maximum projection images.  Single optical sections were averages of 3 scans at 
1024 x 1024 resolution, and individual fluorophores were scanned sequentially and merged.  
Single xz plane images were also obtained where necessary.  
 
2.2.6.1.1 – Co-localisation Analysis 
 
Individual xy optical sections with separate images for the green and red channels were used 
for co-localisation analysis.   The puncta in the red channel were selected and the intensity of 
the fluorescence in the corresponding green channel calculated using MetaMorph software 
(Molecular Devices, Downingtown, PA).  The selections were then shifted to another part of 
the cell so that they no longer aligned with the red puncta and the intensity of the fluorescence 
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in the green channel calculated as before.  At least 10 puncta were selected for each co-
localisation analysis.  Mean and standard error values were calculated for aligned and non-
aligned fluorescence intensity measurements. All non-aligned values were normalised to their 
corresponding aligned values and a Student’s two-tailed T test was carried out to test the 
statistical significance of the difference between the values. 
 
2.2.6.1.2 – Live Cell Imaging 
 
HEK293 and mIMCD-3 cells were seeded onto 35mm glass bottom dishes (Ibidi) and 
transfected as necessary as in section 2.2.2.1.  The cells were allowed to recover for 24 hours 
after transfection and medium changed to phenol-red free medium and overlaid with sterile 
mineral oil to prevent gaseous diffusion.  The confocal microscope as above and cabinet were 
heated to 37
o
C before the cells were transferred.  The pinhole was opened to 10 airy units and 
single optical sections were acquired in the xy plane over time (xyt).  For photobleaching 
experiments, a 3-dimensional area was defined for bleaching and iterations were created to 
bleach at full laser power for 1 second and acquire images as necessary. 
 
2.2.6.2 – Pulse Chase Experiments 
 
HEK293 cells growing on glass coverslips were transfected with pCMV-myc-PLRN and 
pEYFP-VPS33B, and allowed to recover for 24 hours before being incubated in serum free 
medium for 3 hours.  Texas Red-conjugated transferrin (Molecular Probes, Invitrogen) was 
pulsed into serum-starved cells at 1 mgml
-1
 for 30 minutes, after which the cells were rinsed 
an incubated with normal medium (chased) for a total of 60 min. The cells were then fixed at 
84 
various times (0, 5, 10, 15, 30 and 60 minutes) with 4% paraformaldehyde and processed for 
immunofluorescence confocal microscopy as in section 2.2.6.1.   
 
2.2.6.3 – shRNA  
 
A pSM2c and a pGIPZ plasmid containing shRNA hairpins were used for Vps33b and Polarin 
respectively.  Non-silencing hairpins were used as controls.  Plasmid shRNA constructs 
(Vps33b; V2MM_91195 and Polarin; V2LMM_9377) were purchased from Open Biosystems 
(Huntsville, AB).  mIMCD-3 cells were transfected with 4 g of plasmid and allowed to 
recover for 48 h before transfected cells were selected using 1.5 gml-1 of Puromycin. 
Individual clones were selected to reduce variability.  Level of knockdown was assessed by 
western blotting (Vps33b) or quantitative real time PCR (Plrn). 
 
2.2.6.4 – Trans-Epithelial Resistance Assay 
 
mIMCD-3 cells treated with non-silencing shRNA and with shRNAs against Plrn and Vps33b 
were seeded onto Transwell supports at a density of 1 x 10
5
 cells cm
-2
.  TER was measured 
every 24 hours thereafter with an EVOM AC square wave current (+/- 20mA, 12.5Hz) 
resistance meter (World Precision Instruments, Stevenage, UK). A no cell control was used to 
compensate for resistance across the filter.  TER values for individual cultures were 
calculated by subtracting the values measured for filters without cells incubated in the same 
conditions. 
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2.2.6.5 – Paracellular Diffusion Assay 
 
Non-silencing, Plrn and Vps33b shRNA treated mIMCD-3 cells were seeded onto transwell 
filters and allowed to grow for 7 days.  After which 1 mgml
-1
 of each 4kD FITC dextran and 
70kD Rhodamine B dextran (Sigma-Aldrich) were dissolved in medium, added to the apical 
chamber and incubated at 37
o
C for 3 hours.  Diffusion of each molecule to the basolateral 
compartment was assayed simultaneously using a Wallac Victor
3
 fluorometer (PerkinElmer).  
Wavelengths were 485nm and 560nm (excitation) and 535nm and 620nm (emission) for FITC 
and Rhodamine B respectively. 
 
2.2.6.6 – Calcium Switch Experiments 
 
mIMCD-3 cells treated with non-silencing shRNA and with shRNAs against Plrn and Vps33b 
were seeded onto Transwell supports and allowed to grow for 7 days.  On day 7 the culture 
medium was changed for low-calcium medium (Spinner’s Culture Medium, Sigma-Alrdich) 
supplemented with 10% dialysed FBS (PAA Laboratories).  The cells were incubated as 
normal for 24 hours, after which the medium was changed back to normal growth medium.  
TER and paracellular diffusion assays were carried out before, during and after the calcium 
switch took place as detailed above. 
 
2.2.7 – Zebrafish Experiments 
 
The day before zebrasfish embryos were required, adult zebrasfish were separated into male 
and female, and one of each were placed into separate compartments of mating tanks. After 
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being left overnight the separator between the fish was removed, and embryos were collected 
after 10 minutes.  These were then either transferred directly to, or injected with morpholino 
oligonucleotides (MOs) and re-suspended in Hank’s Solution (140 mM NaCl, 5.4 mM KCl, 
4.2 mM NaHCO3, 1.3 mM CaCl2, 1 mM MgSO4, 440 M KH2PO4, 250 M Na2HPO4).  The 
embryos were cleaned, dechorionated and allowed to further develop in Hank’s solution 
supplemented with 0.1% Methylene blue until required. 
 
2.2.7.1 – In-Situ Hybridisation 
 
2.2.7.1.1 – Probe Synthesis 
 
Ten g of the pCS2+-Plrn vector was linearised with BamHI (Buffer 3 and BSA) for the 
antisense probe and EcoRI (Buffer EcoRI and BSA) for the sense probe, as described 
previously in section 2.2.5.5.  The reaction mixture was then loaded and electrophoresed on a 
1% agarose gel (2.2.1.2), after which the linearised vector was purified from the gel as in 
section 2.2.5.4.  The concentration of the eluted DNA was assessed as in section 2.2.5.12. 
 
Digoxigenin (DIG)-labeled anti-sense and sense (control) RNA probes were made from 1 g 
of linearised pCS2+-Plrn vector, using Sp6 and T7 RNA polymerases respectively, from the 
DIG Labeled RNA Probe Synthesis Kit (Roche).  The reactions were setup as shown on the 
next page and incubated at 37
o
C for 2 hours: 
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Reagent Volume per Reaction (l) 
10x Transcription Buffer 2 
10x DIG Labelling Mix 2 
RNase Inhibitor 1 
Template (0.5 gl-1) 2 
T7/Sp6 Polymerase 2 
Nuclease free H20 11 
Total 20 
 
 
The template DNA was removed by adding 2 l of RNase free DNase to the reaction and 
further incubated at 37
o
C for 15 minutes.  The RNA was precipitated by adding 10 l of 7.5 
M ammonium acetate and 75 l of 100% ethanol to the reaction mixture and incubating at –
80
o
C for 20 minutes.  The resulting mixture was then centrifuged at 12,000 x g for 15 minutes 
at 4
o
C.  The supernatant was removed and the pellet washed with 1 ml of 80% ethanol.  After 
air-drying, the pellet was re-suspended in 20 l of Hybridisation Buffer (5x SSC, 9 mM Citric 
Acid, 50% Formamide, 0.05% w/v Heparin, 0.01% w/v yeast RNA, 0.001% v/v Tween-20).  
The concentration of the RNA probes were assessed as in section 2.2.3.2 and a sample was 
run on a 1% agarose gel to check for a single product as in section 2.2.1.2. 
 
2.2.7.1.2 – Hybridisation 
 
For in-situ hybridisation experiments the embryos were grown in Hank’s Solution containing 
0.2 mM PTU (1-phenyl-2-thiourea) to prevent pigmentation.  At 24 hours post fertilisation 
(hpf) embryos were fixed overnight at 4
o
C in Fixing Buffer (77 mM Na2HPO4, 23 mM 
NaH2PO4, 120 M CaCl2, 4% w/v Paraformaldehyde, and 4% w/v Sucrose).  Five-day post 
fertilisation (dpf) embryos were anaesthetised with 0.4% w/v MESAB (Ethyl 3 
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aminobenzoate MethylSulfonate) and fixed in Fixing Buffer for 15 minutes on ice followed 
by 75 minutes at room temperature.   
 
The embryos were transferred through increasing concentrations of methanol (25%, 50% and 
75% diluted with PBS) for 5 minutes at room temperature to dehydrate the embryos.  Finally 
the embryos were incubated in 100% methanol for at least 2 hours at –20oC.  The dehydrated 
embryos were re-hydrated using decreasing concentrations of methanol (75%, 50% and 25% 
diluted in PBST) for 5 minutes at room temperature, followed by 2 washes with PBST for 5 
minutes. 
 
Permeabilisation was achieved by incubating the embryos in 10 ngl-1 Proteinase K diluted in 
PBST for 1 minute for 24 hpf embryos and 2 hours for 5 dpf embryos.  The embryos were 
washed once in PBST before being fixed in Fixing Buffer for 20 minutes at room 
temperature, followed by a further 4 washes in PBST for 5 minutes.  The embryos were 
blocked by incubation in Hybridisation Buffer for at least 3 hours at 65
o
C, followed by 
incubation in the DIG labelled RNA probe at a 1 in 500 dilution overnight.  The optimal 
hybridisation temperature was empirically determined to be 65
o
C. 
 
Unhybridised probe was removed by washing the embryos twice for 40 minutes in Wash 
Buffer 1 (1x SSC, 50% Formamide and 0.1% Tween-20), once for 15 minutes in Wash Buffer 
2 (2 x SSC and 0.1% Tween-20) and twice for 30 minutes in Wash Buffer 3 (0.2x SSC and 
0.1% Tween-20).  The embryos were then washed in Blocking Buffer (2% Tween-20, 1% 
DMSO and 0.2% w/v BSA in PBS) once for 5 minutes.  The embryos were pre-blocked by 
incubation in Blocking Buffer for at least 3 hours at room temperature.  The rabbit anti DIG 
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alkaline phosphatase-conjugated antibody was diluted in Blocking Buffer at a concentration 
of 1 in 400 and pre-blocked in parallel to the embryos.  The embryos were then incubated 
overnight with the antibody at a concentration of 1 in 4000 at 4
o
C.  The unbound antibody 
was removed by rinsing the embryos once with PBST, followed by 6 washes for 15 minutes 
each in PBST.  The embryos were transferred to 24-well plates for staining. 
 
2.2.7.1.3 – Detection 
 
The probe and antibody bound embryos were then washed twice for 5 minutes with Staining 
Buffer (100 mM Tris-HCl pH=9.5, 100 mM NaCl, 50 mM MgCl2 and 0.1% v/v Tween-20).  
Staining was done by incubating the anti-sense and sense probe hybridised embryos in the 
dark in Staining Solution (400 M 5-Bromo 4-chloro 3-indolyl phosphate and 275 M Nitro 
Blue Tetrazolium dissolved in Staining Buffer) until staining was observed in the sense 
control embryos.  The staining reaction was quenched by rinsing the stained embryos in 
PBST and incubating in Fixing Buffer for 15 minutes.  For whole-mount images, the stained 
embryos were taken through a sequential increase in glycerol concentration (25%, 50% and 
75% diluted in PBS and 100%) to aid manipulation for visualisation.   Staining was visualised 
on a binocular SMZ800 microscope with a 6.3x objective and captured with a DXM200 CCD 
camera controlled by ACT-1 (version 2.7) software (Nikon, Kingston Upon Thames, UK).  
For histological sections, over-stained embryos were incubated for 4 hours in sequential 
increasing concentrations of sucrose (10%, 20% and 30% diluted in PBS) for cryoprotection. 
Larvae were oriented in OCT embedding medium in shallow 1 cm x 1 cm moulds, quickly 
frozen on dry ice, and stored at -80
o
C until required.  Eighteen micrometre transverse sections 
were taken using a Cryocut cryostat (Bright, Huntingdon, UK) and visualised with an 
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Axioplan 2 microscope with images captured on an Axiocam CCD camera (both Carl Zeiss, 
Welwyn Garden City, UK). 
 
2.2.7.2 – Morpholino Oligonucleotide Injections 
 
Morpholino oligonucleotides (MOs) against the transcription initiation (ATG) codon and the 
splice site for exon 3 of plrn were designed by and purchased from Gene Tools.  An exon 3 
mis-match MO was also used as a specificity control.  MO sequences are shown in appendix 
1.  The ATG, exon 3, and exon 3 mis-match MOs were injected into one-cell embryos in 
Injection Solution (58 mM NaCl, 5 mM HEPES, 700 M KCl, 600 M Ca(NO3)2, 400 M 
MgSO4 and 0.1% phenol red) at concentrations of 10, 100, and 100 M respectively.  The 
MOs were co-injected with CFP (Cyan Fluorescence Protein) mRNA at a concentration of 0.5 
mgml
-1
, so that the injected embryos could be sorted away from the non-injected embryos at a 
later stage.   
 
2.2.7.2.1 – mRNA Rescue 
 
Ten g of the pCS2+-Plrn, CFP and -RFP vector was linearised with NotI (Buffer 3 and BSA) 
as described previously in section 2.2.5.5.  The reaction mixture was then loaded and 
electrophoresed on a 1% agarose gel (2.2.1.2), after which the linearised vector was purified 
from the gel as in section 2.2.5.4.  The concentration of the eluted DNA was assessed as in 
section 2.2.5.12. 
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Polarin, Red Fluorescent Protein (RFP) and Cyan Fluorescent Protein (CFP) mRNA were 
produced using T7 RNA polymerase from the Message Amp mRNA amplification kit 
(Ambion).  The reactions were set up as follows and incubated at 37
o
C for 2 hours: 
 
Reagent Volume per Reaction (l) 
10x Transcription Buffer 2 
dNTP mix (+cap) 10 
RNase Inhibitor 1 
Template (0.5 gl-1) 2 
T7 Polymerase 2 
Nuclease free H20 3 
Total 20 
 
 
The template DNA was removed by adding 2 l of RNase free DNase to the reaction and 
further incubated at 37
o
C for 15 minutes.  The RNA was precipitated by adding 115 l of 
nuclease free water, 15 l of 7.5 M ammonium acetate and 150 ml of phenol chloroform mix 
(50:49:1 Phenol:Cholorofom:Isoamyl Alcohol, pH=4.5).  The tubes were shaken vigorously 
and centrifuged at 7000 x g for 15 minutes at 4
o
C before the upper clear aqueous layer was 
removed and transferred to a clean tube.  To the transferred liquid 150 l of chloroform was 
added and the centrifugation steps carried out as above.  The RNA was precipitated by adding 
150 l of isopropanol, incubating the mixture at –80oC for at least 15 minutes and 
centrifugation at 12000 x g for 15 minutes at 4
o
C.  The supernatant was removed and the 
resulting pellet was washed with 1 ml of 80% ethanol and centrifuged at 12000 x g for 15 
minutes at 4
o
C.  The air-dried pellet was re-suspended in 20 l of nuclease free water.  The 
concentration of the mRNA was assessed as in section 2.2.3.2 and a sample was run on a 1% 
agarose gel to check for a single product as in section 2.2.1.2. 
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When necessary, plrn mRNA diluted in Injection Solution at a concentration of 0.5 mgml
-1
 
was injected into one-cell embryos already injected with MOs against plrn to rescue the 
phenotype.  RFP mRNA was used a specificity control.  RFP mRNA was also injected 
alongside both the plrn and RFP mRNAs as an injected control and to allow sorting at a later 
stage. 
 
2.2.7.3 – PED-6 Treatment 
 
Liver-function and bile duct assays were carried out by bathing 5 dpf larvae in 2 M of PED-
6 (Invitrogen) overnight at 28
o
C.  The next day larvae were treated with 0.4% w/v MESAB 
and transferred to a prepared agarose gel plate containing small wells to allow the correct 
orientation of the larvae for examination of their gall bladders. Brightfield and PED-6 (green 
fluorescence) images were visualised using a SMZ1500 binocular microscope with a 10x 
objective and were captured using a DSQi1Mc CCD camera controlled by NIS Elements 
(version 3.0) software (all Nikon), which was also used to measure gallbladder area. 
 
2.2.7.4 – Immunostaining 
 
Morpholino and non-injected 5 dpf zebrafish larvae were anaesthetised with 0.4% w/v 
MESAB and fixed in Fixing Buffer as in section 2.2.7.1.2.  The fixed larvae were processed 
for histological sections as in section 2.2.7.1.3, and 18 m sections were taken.  The resulting 
slides were baked at 37
o
C for 30 minutes, stored at -20
o
C until needed and required 20 
minutes to thaw before use.  The required sections were first encircled using a delimiting pen 
(Dako, Ely, UK) and rehydrated twice for 20 minutes in PBS.  The sections were blocked in 
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2% w/v BSA dissolved in PBST for 90 minutes, after which the sections were incubated with 
primary antibody diluted in the previous blocking buffer at room temperature for 2 hours.  
The unbound primary antibody was removed by washing the slides 3 times in PBST for 20 
minutes.  The appropriate secondary antibody diluted in blocking buffer was added to the 
sections and incubated at room temperature for 2 hours, after which the slides were washed as 
before.  The sections were sealed and visualised as in section 2.2.6.1. 
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CHAPTER 3 – MOLECULAR INVESTIGATIONS 
OF ARC SYNDROME PATIENTS AND 
DEVELOPMENTAL EXPRESSION OF VPS33 
HOMOLOGUES 
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3.1 – Introduction and Overview 
 
3.1.1 – ARC Patients 
 
Arthrogryposis, Renal dysfunction and Cholestasis syndrome (ARC; MIM# 208085) is an 
autosomal recessive disorder associated with germline mutations in VPS33B. The gene 
encodes VPS33B protein, one of two (-A and -B) homologues of yeast Vps33 which form 
part of the HOmotypic Protein Sorting (HOPS) complex involved in assisting SNARE 
proteins in performing membrane fusion [1].  Characteristic features of ARC include severe 
failure to thrive, renal tubular acidosis, neonatal cholestasis, ichthyosis and platelet 
dysfunction. Liver abnormalities (cholestasis, intrahepatocyte deposition of lipofuscin 
granules and bile duct hypoplasia) are also frequent but the severity of failure to thrive 
exceeds that expected for the degree of liver and intestinal dysfunction. The identification of 
mislocalised apical membrane proteins in liver and renal biopsy materials suggests a 
possibility of a global abnormality in intestinal absorption and renal tubular reabsorption 
[1;11].  Although arthrogryposis in ARC syndrome appears to be at least partially neurogenic 
in origin, the degree of arthrogryposis may depend on the foetal position and severity of 
oligohydramnios [2]. Platelet function abnormalities are likely to be secondary to platelet α-
granule biosynthesis defect [12]. Additional features of ARC include corpus callosum 
dysgenesis (at least 20%) and congenital cardiac defects (~10%).  
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3.1.2 – Developmental Expression of VPS33 Homologues 
   
The expression pattern of VPS33B, along with other HOPS complex members, has been 
discerned in adult human tissues using northern blot analysis.  These studies revealed an 
ubiquitous pattern of expression with enrichment in the testis [5;77].  However, the 
developmental expression of VPS33B has not previously been studied, 
 
The naturally occurring buff mouse is a mouse model phenocopy of Hermansky-Pudlak 
syndrome (HPS), a severe disorder characterised by oculocutaneous albinism and a platelet 
aggregation defect secondary to a dense-granule defect [82].  The buff mouse is a result of a 
germline missense mutation in Vps33a, which causes a glutamic acid to aspartic acid 
substitution (p.Glu251Asp) in the mutant protein [82].  Thus the buff mouse phenotype 
suggests that Vps33a is involved in the biogenesis of membrane-bound organelles such as 
melanosomes and platelet dense granules, whereas the ARC syndrome phenotype points to its 
function in the formation of platelet -granules and trafficking of the apical membrane 
proteins in polarised epithelial cells.   
 
3.2 – Aims 
 
In a previous study of ARC syndrome, mutations in VPS33B were detected in 77% of patients 
(48 out of 62 individuals) [2].  Absence of VPS33B mutations in patients with a clinical 
diagnosis of ARC syndrome might result from locus heterogeneity or the presence of VPS33B 
mutations that are not easily detectable by direct sequencing analysis.  In order to investigate 
these possibilities further and to develop additional better methods for detecting ARC 
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syndrome, VPS33B mRNA and protein analysis in patients with a clinical diagnosis of ARC 
syndrome was performed.  Direct dideoxy sequencing was also carried out on VPS33B for 
newly referred patients presenting with an ARC syndrome phenotype.  This will help to 
identify common mutations in certain populations, which would aid future mutation screening 
of ARC patients. 
 
The developmental expression of Vps33 homologues have not previously been studied, and 
might give an insight into the pathogenesis of both ARC and HPS syndromes.  Therefore the 
objectives of this study were to investigate the level of expression of mammalian homologues 
of Vps33 at different stages of foetal development, and to gain an insight into the possible 
embryonic nature of the defects in HPS and ARC. 
 
3.3 – Results 
 
3.3.1 – Mutation Analysis of VPS33B in ARC Patients 
 
Mutation analysis was performed in 16 previously unreported patients with clinical features of 
ARC syndrome.  Eight novel mutations were identified in 12 probands (see Table 3.1). 
Strikingly, a splice site mutation (IVS6 ds+2 T>A) was detected in 7 of 9 apparently unrelated 
patients from South Korea.  Although haplotype analysis was not possible (due to insufficient 
DNA) all the Korean patients were homozygous for the T allele of the rs11073964 SNP 
(http://www.ensembl.org/Homo_sapiens/snpview?source=dbSNP;snp=rs11073964).  This has 
a prevalence of 100% in the Asian population in contrast to its prevalence of 10-30% in 
Europeans.  Among the novel mutations there were 4 insertions, 1 deletion that resulted in 
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frameshifting, 1 nonsense substitution, 1 splice site mutation and 1 missense substitution.  The 
c.728C>T (p.Ser243Phe) mutation was not present in 300 control chromosomes. The 
hydrophilic serine at position 243 is highly conserved in evolution [8] and the change for a 
strongly hydrophobic phenylalanine may affect protein conformation and subsequently the 
effect of VPS33B on SNARE complex formation.  Four Polish families were analysed and 2 
apparently unrelated probands were homozygous for a novel c.1235_1236delCCinsG 
frameshift mutation. In a further Polish family a c.1594C>T mutation that was previously 
identified in a large consanguineous UK Pakistani family was detected.  None of the missense 
or splice site mutations identified were detected in 300 ethnically matched chromosomes. 
 
3.3.2 – ARC Patient Expression of VPS33A and VPS33B 
 
 
To determine the potential diagnostic value of VPS33B mRNA and protein studies in cultured 
skin fibroblasts, expression was analysed in 9 patients with classical features of ARC (5 with 
a detectable VPS33B mutation) and one with a milder phenotype (Patient 21).  Quantitative 
RT-PCR (Figure 3.1) and western blotting (Figure 3.2) experiments demonstrated that 
patients with at least one VPS33B mutation had minimal VPS33B protein expression.  Of the 
4 patients without identified mutations, patient 15 also had minimal VPS33B levels, patient 
17 had mRNA levels of <50% compared with the control sample and patient 21 had normal 
levels of mRNA and protein.  Patient 21 initially presented with a triad of typical ARC 
features as well as some additional clinical characteristics (see section 3.3.2.1); however, his 
kidney and liver disease appeared transient.  
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Patient Ethnicity Nucleotide alteration Coding-sequence 
alteration 
Exon Status 
      
      
1 Korean NI 
2 Korean c.403+2 T>A  
c.1509_1510insG  
 
p.Lys504GlufsX23  
6+2 
20 
Het 
Het 
3 Korean c.740_741delAT  p.Tyr247X  10 Het 
4 Korean c.403+2 T>A   6+2 Hom 
5 Korean c.403+2 T>A   6+2 Het 
6 Korean c.403+2 T>A  
c.728C>T  
 
p.Ser243Phe  
6+2 
10 
Het 
Het 
7 Korean c.403+2 T>A   6+2 Hom 
8 Korean c.403+2 T>A  
c.1803_1804insA  
 
p.Val602SerfsX13  
6+2 
23 
Het 
Het 
9 Korean c.403+2 T>A   6+2 Hom 
10 Polish c.1235_1236delCCinsG  p.Pro12ArgfsX7  17 Hom 
11 Polish c.1235_1236delCCinsG  p.Pro12ArgfsX7  17 Hom 
12 Polish c.1221delA p.Asp414ValfsX5  17 Hom 
13* Polish c.1594C>T  p.Arg532X  21 Het 
14 Turkish c.352C>T  pGln118X  5 Hom 
15* Thai NI 
16* Portuguese c.853-2 A>G 
c.1519 C>T  
 
p.Arg507X  
12-2 
21 
Het 
Het 
17* Israeli Arab NI 
18* Pakistani c.1312C>T  p.Arg438X  18 Hom 
19* Pakistani c.1594 C>T  p.Arg532X  21 Hom 
20* Swedish c.498+1 G>A   7+1 Het 
21* Afro-Caribbean NI 
22* Turkish NI 
 
Table 3. 1 – Mutations in VPS33B identified in ARC Patients.  
Direct sequencing of VPS33B revealed 8 novel mutations and a common mutation in patients 
from South Korea.  Novel mutations are indicated in bold typeface.  Mutation nomenclature is 
based on GenBank entry NM_018668.3, with +1 corresponding to the A of the translation 
initiation codon ATG in the cDNA nomenclature.  Het - heterozygous, Hom – homozygous, 
NI- DNA alterations not identified and * - patients whose fibroblasts were used for expression 
analysis and who were reported previously [1;2].  (Some of the mutations shown here were 
identified by A. Straatman-Iwanowska, University of Birmingham, UK)   
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VPS33A is another homologue of yeast Vps33p in mammalian cells, which may bind to 
HOPS complex proteins in a similar way to VPS33B.  As it is not known whether VPS33A 
can partially substitute for the VPS33B function in ARC patients we, therefore, tested the 
expression of the -A homologue in VPS33B-deficient cell lines. No change in expression of 
VPS33A was detected in ARC fibroblasts compared with the control samples (Figure 3.1). 
 
3.3.2.1 – Patient 21 
 
Patient 21 is male, born at term to non-consanguineous Afro-Caribbean parents.  He presented 
with arthrogryposis in both knees, spina bifida (with a lipomeningocele and tethered cord), 
cholestatic jaundice and renal tubular acidosis.  Low GT typical of ARC was found and liver 
biopsy findings were consistent with ARC, including abnormal distribution of apical 
canalicular markers such as carcinoembryonic antigen and alanyl aminopeptidase.  Additional 
features included bilateral sensorineural deafness, severe diarrhoea, pancreatic insufficiency 
and malabsorption, which were initially treated with parenteral nutrition.  Jaundice resolved 
by the age of 12 months and the child is now fed enterally with pancreatic enzyme 
supplementation.  He is not facially dysmorphic but has bilateral accessory auricles.  He 
continues to have mild metabolic acidosis, which is treated by sodium bicarbonate 
supplementation.  At the age of 2.5 years the patient growth is parallel to 0.4
th
 percentile for 
his weight and height. His arthrogryposis has resolved. He has global developmental delay.  
The results of investigations for ARC included negative mutation screening of VPS33B.  No 
abnormalities were found on quantitative real-time PCR and western blotting (see Table 3.1, 
Figure 3.1 and Figure 3.2). 
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Expression of VPS33A and VPS33B in ARC Patient Fibroblasts 
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Figure 3.1 – Quantitative Real Time PCR (qRT-PCR) of VPS33A and VPS33B in ARC 
syndrome patients’ fibroblasts.   
Bar chart showing the results from the quantitative real-time PCR experiments. Values shown 
are mean values of expression levels of the VPS33 homologues normalised to -actin and 
relative to a control sample (n=3 independent assays run in triplicate for each sample).  
Error bars represent ± 1 standard error of the mean. 
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Patient Control 13  15 16 17 18 19 20 21 22 
           
           
VPS33B           
           
 Actin           
           
           
OD VPS33B 0.26479 - - - 0.10871 - - - 0.26089 - 
OD  Actin 0.53731 0.5627 0.54747 0.53577 0.53534 0.53489 0.56086 0.54627 0.53386 0.53309 
           
       
% Expression 49.3 %  20.3 %  48.9%  
% Expression to Control 100 % 41.2% 99.1% 
    
 
Figure 3.2  – Immunoblotting of VPS33B in control and ARC patients’ fibroblasts.   
Loading was controlled by immunoblotting the same membrane with an anti-β-actin antibody.  Densitometry on bands were carried where 
possible and necessary, and final expression values are normalised to -actin and relative to the control sample.  Results here are 
consistent with qRT-PCR results shown in Figure 3.1.  (Some of the western blots shown here were carried out by A. Straatman-
Iwanowska, University of Birmingham, UK)  
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3.3.3 – ARC Patients’ Cellular Phenotype 
 
 
The cellular phenotype of skin fibroblasts from patient 13 was assessed by transmission 
electron microscopy (TEM; Figure 3.3).  Multiple heterogeneous granules were identifiable in 
almost all of the patient’s cells.  These granules were found to be osmiophilic in nature and 
contained multilamellar membranes and multiple vesicular aggregates. 
 
3.3.4 – Developmental Expression of VPS33 Homologues 
 
3.2.4.1 – Human Expression 
 
Analysis of developmental expression of VPS33A and VPS33B in human kidneys, liver and 
brain by quantitative real time PCR (Figure 3.4 and 3.5) and immunoblotting of VPS33B 
(Figure 3.6) revealed a similar pattern of expression for both homologues.  In the kidney, the 
highest expression level can be seen between 11 and 16 weeks gestation with a greater than 4 
fold increase for both genes. There is a gradual increase in expression of both genes during 
foetal liver development, and very low expression of both at all stages in the brain.  As is also 
seen in the mouse in-situ hybridisation (Figure 3.7), during foetal development expression of 
VPS33A is much higher than the B homologue.  This pattern is reversed in adult kidney and 
liver.  The highest expression in the liver is seen in the neonatal liver specimen.  Foetal 
samples were not available after 20 weeks gestation, therefore the expression of both VPS33 
homologues could not be studied after this stage in develoibpment. 
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A B 
  
 
Figure 3.3 – Cellular phenotype of ARC patient fibroblasts.  
 A, Transmission electron micrograph of patient 13 cultured skin fibroblasts.  N – nucleus, G 
– Golgi apparatus, ER - endoplasmic reticulum and M – mitochondria appear normal.  Scale 
bar represents 1μM. B, An atypical granule enlarged from A (asterisk), filled with lamellar 
membranes (arrow heads) and vesicular aggregates (arrows).  Scale bar represents 200 nm. 
(Electron microscopy was carried out by R. Sougrat, NIH, Bethesda, MD on fibroblasts grown in 
Birmingham, UK) 
  
 
 
 
 
 
 
 
 
 
 
 
105 
Expression of VPS33A in Development
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Figure 3.4 – Expression of VPS33A in human foetal and adult kidney, liver and brain samples.   
Values shown are mean values of expression levels of VPS33A normalised to -actin (n=3 independent assays in triplicate for each 
sample).  Numbers on the x-axis represent weeks of gestation.  Error bars represent ± 1 standard error of the mean. 
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Expression of VPS33B in Development
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Figure 3.5 – Expression of VPS33B in human foetal and adult kidney, liver and brain samples.   
Values shown are mean values of expression levels of VPS33B normalised to -actin (n=3 independent assays in triplicate for each 
sample).  Numbers on the x-axis represent weeks of gestation.  Error bars represent ± 1 standard error of the mean. 
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 Developmental Stage 
7-8 9-10 11-12 13-14 15-16 17-20 Neonatal Adult 
Kidney     
NA 
 
NA 
 
       
VPS33B 
      
 Actin 
      
% Expression 0.8% 0.6% 69% 51% 4.3% 84% 
       
Liver   
NA 
 
NA 
   
       
VPS33B 
      
 Actin 
      
% Expression - 1.2% 3.4% 3.8% 91% 62% 
       
Brain       
NA 
 
        
VPS33B 
       
 Actin 
       
% Expression - - - - - - 7.9% 
        
 
Figure 3.6 – Analysis of VPS33B expression in human foetal kidneys, liver and brain by immunoblotting.   
Loading was controlled by immunoblotting the same membrane with an anti-β-actin antibody.  Developmental stage numbers represent 
weeks of gestation.  Densitometry on bands was carried where possible and necessary, and final expression values are normalised to -
actin.  NA - sample not available.  Results here are consistent with qRT-PCR results shown in Figure 3.5.
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3.3.4.2 – Mouse Expression 
 
Non-radioactive in-situ hybridisation using antisense digoxygenin-labelled RNA probes for 
Vps33a and Vps33b on sectioned mouse embryos showed that prior to E14.5 expression of 
both genes is very low being undetectable at E10.5 (data not shown).  By E12.5 expression of 
Vps33a and Vps33b is just apparent in the peripheral nervous system, although Vps33b 
expression is much lower.  By E14.5, low-level widespread expression of Vps33a and Vps33b 
is readily apparent throughout many embryonic tissues (Figure 3.7).  The expression patterns 
between the two genes seem similar, but Vps33a appears to show higher levels of expression 
than Vps33b.  
 
On closer examination of Vps33a and Vps33b expression in individual mouse embryonic 
tissues at E14.5 (Figure 3.8), staining can be seen in various ganglia, including the dorsal root, 
sympathetic chain, trigeminal and vestibulocochlear ganglia.  While noticeable expression of 
Vps33a can be seen in the neural retina, outer layer of the cortex, pons, medulla, striatum and 
cerebellar primordium and olfactory epithelium, expression of Vps33b appears much reduced 
in these tissues.  In non-neural tissues, Vps33a shows substantial expression in the kidney 
(particularly the cortex), adrenal gland, liver, lung, ribs, submandibular gland and thymus. 
While expression of Vps33b can be discerned in many non-neural tissues, expression is very 
much lower or absent, for example in the liver. 
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A B 
 
 
 
Figure 3.7 – Mouse embryonic expression of Vps33a and Vps33b at E14.5.  
Non-radioactive in situ hybridisation using antisense digoxygenin-labelled RNA probes for A, 
Vps33a and B, Vps33b on sectioned mouse embryos. DRG- Dorsal root ganglia. (In-situ 
hybridisation carried out by D Tannahil, Cranfield University, UK.) 
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                 Vps33a                       Vps33b      Vps33a                 Vps33b 
 
 
 
Figure 3.8 – Expression of Vps33a and Vps33b in individual mouse embryonic tissues at 
E14.5.   
Non-radioactive in situ hybridisation using antisense digoxygenin-labelled RNA probes for 
Vps33a and Vps33b on sectioned mouse embryos.  A, dorsal root ganglia (drg), sympathetic 
chain ganglia (scg) B, trigeminal and vestibulocochlear ganglia (tg and vc) C, spinal cord 
(sc) D, medulla (md), pons (po), cerebellar primordium (cb) E, lens (le), retina (re) F, cortex 
(co), striatum (st) G, kidney (ki), adrenal (ad), liver (li) H, ribs (ri), lung (lu), sympathetic 
chain ganglia (scg) I, thymus (th) J. midgut (mg) K, submandibular gland (smg) L, olfactory 
epithelium (oe), striatum (st).  (In-situ hybridisation carried out by D Tannahil, Cranfield 
University, UK.) 
A B 
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3.4 – Discussion 
 
3.4.1 – ARC Patients 
 
ARC syndrome is a severe multisystem disorder leading to death in infancy.  Early diagnosis 
is important for correct clinical management.  However, the traditional method of diagnosis 
(liver biopsy) is associated with a substantial risk of morbidity and mortality in ARC 
syndrome patients due to haemorrhage.  Direct sequencing of VPS33B is a good method to 
provide molecular diagnosis in ARC patients.  However, in routine clinical practice, mutation 
analysis results may not be available for months and substantial numbers of patients do not 
have a detectable mutation.  Markedly reduced levels of VPS33B were found in skin 
fibroblasts from all patients with a classical ARC phenotype and disease course.  The only 
patient with normal VPS33B expression had a milder clinical course and transient liver 
abnormalities.  This child is alive and well on nasogastric tube feeding at 2.5 years despite 
having an initial clinical diagnosis of ARC syndrome.  This suggests that analysis of VPS33B 
protein expression in cultured fibroblasts may provide a useful initial diagnostic screening 
investigation to facilitate acute medical management.  
 
Novel mutations were identified in Turkish, South Korean and Polish patients with ARC 
syndrome.  One of the mutations was present in 7 South Korean patients.  This is the first 
report of VPS33B mutations in the East European and South East Asian populations. 
Identification of population-specific mutations improves the ability to provide rapid molecular 
diagnosis and makes molecular studies more affordable.  
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The study of patient skin fibroblasts using transmission electron microscopy identified 
multiple granules containing lamellar and vesicular structures.  Careful examination of their 
identity using specific organelle markers will provide better insight into the origin of these 
granules.  This finding is in line with the accumulation of hepatocyte lipofuscin granules and 
skin keratinocyte lamellar bodies in ARC syndrome [148;149] and may reflect abnormal 
processes of vesicular trafficking and membrane biogenesis.  
 
Low expression of VPS33B may potentially trigger a cellular feedback mechanism and 
stimulate VPS33A expression as some functional overlap between the 2 homologues was 
previously suggested.  Thus VPS33A mRNA levels in ARC patients’ fibroblasts were 
quantified.  Compared to a control there was no discernable change in VPS33A expression, 
thus suggesting that this mechanism does not spontaneously come into play.  However, future 
attempts at cellular therapies in this disorder may include compensatory overexpression of 
VPS33A.  
 
3.4.2 – Developmental Expression 
 
Vps33 homologues belong to a family of Sec1/Munc18 proteins, which are thought to provide 
specificity to the SNARE-complex formation reactions.  The phenotypes of their deficiency 
(ARC syndrome in humans and HPS in mice) suggest their importance to the biosynthesis of 
lysosome-related organelles such as platelet granules and melanosomes, and also specific 
apical membrane trafficking of proteins in the liver and kidneys [1;82] . VPS33B is clearly 
important to the nervous system development as its’ deficiency potentially results in 
hypotonia and congenital joint contractures in ARC syndrome [1].  
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The analysis of developmental expression of Vps33 homologues showed an upregulation of 
the expression of both proteins in the kidneys between 11 and 16 weeks gestation in the 
human foetus, which suggests a possible correlation with active development of renal tubular 
system that occurs at this point [150;151].  In ARC syndrome, there is a renal tubular defect, 
thus having defective proteins at this point in development may explain the defect observed.  
Particularly high neonatal liver expression of VPS33B correlates with the development of 
biliary ductular structures in the first few weeks of life [152].  In concordance with this 
expression pattern, a reduced number of bile ducts are found in ARC syndrome patient livers.  
The foetal liver is predominantly a haemopoietic organ, and does not undertake any polarised 
epithelial activity until after birth [152].  In light of the expression pattern observed in the 
foetal and neonatal liver and kidney samples, a role of Vps33b in the epithelialisation of these 
organs would be expected.   
 
Although low level of expression of both VPS33 homologues was found in human brain, 
mouse in-situ hybridisations show that there is high expression of both genes in specific 
ganglia.  This may explain the hypotonia in ARC syndrome patients.  In line with the 
expression of Vps33a in the cerebellar primodium, a recent study by Chintala et al. showed 
that the buff mouse mutant had significant motor deficits, specifically grip strength and the 
righting reflex, which worsened with age [153].  Furthermore, they showed that this was due 
to cerebellar Purkinje cell loss, a region of the brain responsible for the generation of motor 
co-ordination and posture [153].  On the other hand, the surprisingly mild renal phenotype in 
the buff mouse may be explained by the relatively weak effect of the genetic alteration on the 
Vps33a protein product.   
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The identification of additional and population specific mutations in VPS33B in ARC 
syndrome patients alongside the detection of VPS33B expression will help to expedite the 
diagnostic process for patients and their families.  Both the VPS33 homologues seem to be 
expressed in similar tissues during human and mouse development, but have different 
functional effects on cells and on whole organisms.  Elucidation of these functions will help 
identify the pathogenicity of both ARC and HPS syndrome, with the former being examined 
in the following chapters. 
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CHAPTER 4 – VPS33B INTERACTING 
PROTEINS 
 
116 
4.1 – Introduction and Overview 
 
Germline mutations in VPS33B are found in approximately 75% of ARC patients [4]. VPS33B 
encodes the VPS33B homologue of yeast class C vacuolar protein sorting (VPS) protein 
Vps33p, which belongs to the Sec1/Munc18 (SM) family of proteins.  SM proteins are 
thought to modulate Soluble N-ethylmalemide sensitive factor Attachment REceptor 
(SNARE) protein interactions and ensure specificity in formation of vesicle- to target- 
SNARE complexes and in fusion of two apposed membranes [154;155].  Vps33p is unique in 
that, unlike other SM proteins, it functions as part of the HOmotypic fusion and vacuole 
Protein Sorting (HOPS) complex [47].  The HOPS complex includes class C VPS proteins 
(Vps11, Vps16, Vps18 and Vps33) and also Vps39 and Vps41.  It interacts with the yeast 
Rab7 homologue Ypt7p, and is required for vacuolar biogenesis and for protein trafficking 
from the Golgi apparatus to the vacuole [76].   
 
The mammalian HOPS complex counterpart is much less well characterised.  The human 
homologues (VPS11, VPS16, VPS18, VPS33A, VPS39 and VPS41) have been shown to 
localise to the endosome, late endosome and lysosome compartments of cells, and to interact 
with syntaxin-7 [77;78].  Whether or not VPS33B is a member of this mammalian complex 
remains unknown.  However, over-expression of either VPS18, VPS33B or VPS39 all cause 
clustering of LAMP-1 positive late endosomes and lysosomes, suggesting that this maybe the 
case [1;80;81]. 
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4.2 – Aims 
 
Although previous studies suggested that the mammalian homologues of class C yeast VPS 
proteins are involved in intracellular trafficking at the level of early and late endosomes in the 
endocytic pathway, this work included investigations of only the VPS33A homologue of 
yeast Vps33p [156].  Furthermore, the HOPS complex, as well as Rab5 and Rab7, have been 
implicated in the pathway of phagosome maturation during apoptosis [79].  Therefore this 
chapter describes the investigations performed in order to identify VPS33B interacting 
proteins and to elucidate its functional pathway. 
 
4.3 – Methodologies 
 
4.3.1 – Yeast–2–Hybrid System 
 
Proteins rarely work alone, and usually form part of a complex network to fulfil their 
function.  Identification of proteins which interact with an uncharacterised protein can often 
give insight into the biological function, as if an uncharacterised protein interacts with a 
protein whose role is known, they are likely to have a related function.  Co-
immunoprecipitation and affinity chromatography can be used to identify protein-protein 
interactions, but these techniques require the identification of physically interacting proteins 
by mass spectroscopy [19].  The yeast-2-hybrid system allows the simultaneous isolation of 
interacting proteins and along with the gene which encodes them [157]. 
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The yeast-2-bybrid system uses a reporter gene to identify protein-protein interactions in the 
nucleus, and takes advantage of the modular nature of gene activator proteins. The cDNA 
encoding the target protein or bait is cloned into an expression vector to be in frame with a 
DNA binding domain using recombinant DNA techniques.  The cDNA of putative interacting 
proteins are ligated into another expression vector with a transcriptional activator domain, 
producing prey libraries.  The libraries are usually produced from reverse transcribed RNA 
from specific sources, for example human adult kidney [158].   
 
The bait expression vector is introduced into yeast cells, where the fusion protein is produced, 
which will bind to the regulatory region of the reporter gene.  Individual prey expression 
vectors are also introduced into these yeast cells.  If the two proteins interact, the two halves 
of the transcriptional activator come together, which switches on the expression of the 
reporter gene, which usually allows the growth of the yeast cells on selective media (Figure 
4.1) [157].   
 
The clones of yeast cells that grow on the selective media therefore contain a protein that 
interacts with the protein of interest.  These colonies are scaled up, and the identity of the 
putative interacting protein is found by sequencing the cDNA inserts in the prey expression 
plasmids [158].  The yeast-2-hybrid system produces numerous false positives, so any 
putative interacting protein that is identified must be confirmed using conventional co-
immunoprecipitation experiments [19]. 
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Figure 4.1 – Yeast-2-hybrid method of identifying putative protein-protein interactions. 
The target or bait protein is fused to a DNA binding domain that localised it to the regulatory 
region of a reporter gene.  When this target protein binds to another specially designed 
protein in the cell nucleus, their interaction brings together the two halves of the transcription 
activator, which then switches on the expression of the reporter gene.  The reporter gene is 
often one that will permit growth on a selective medium.  Bait and prey fusion proteins are 
generated by standard recombinant DNA techniques.  In most cases, a single bait protein is 
used to identify interacting proteins among a large collection of prey proteins by ligating 
DNA encoding the activation domain of a transcriptional activator to a large mixture of DNA 
fragments from a cDNA library. [19] 
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4.3.2 – Live Cell Imaging 
 
The use of fluorescent tags for proteins has been widely used to elucidate the function of 
proteins in living cells.  Fluorescent proteins such as Green Fluorescent Protein (GFP) and its’ 
variants (BFP (Blue), CFP (Cyan), YFP (Yellow) and RFP (Red)) can essentially be fused to 
any protein of interest to analyse protein localisation, movement and chemistry in living cells 
[159]. 
 
Recent advances in fluorescence microscopy methods have allowed the examination of the 
localisation and kinetic behaviour of fluorescent protein tagged proteins.  The most important 
methods include, 3D – imaging (2 spatial dimensions over time ), 4D- imaging (3 spatial 
dimensions over time), Fluorescence Recovery After Photobleaching (FRAP), and 
Fluorescence Loss In Photobleaching (FLIP) [159].   
 
Traditional time lapse live cell imaging techniques involved the collection of images over 
time and can give information about the steady state localisation and changes in the protein’s 
distribution over time [160].  However, this method does not give information about the 
protein’s kinetic properties, for example, whether the protein is immobilised on a scaffold, 
free to diffuse or undergoing constant exchange between compartments.  To obtain this 
information, a selected pool of the fluorescently tagged protein is distinguished from the other 
pool and the fluorescence monitored as the two pools re-equilibrate [159].  This can be 
accomplished by FRAP and FLIP experiments.  For the FRAP technique, a selected region of 
fluorescence is selected and photobleached using a high intensity laser pulse and the 
movement of unbleached molecules into the photobleached region (recovery) is assessed 
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using time-lapse microscopy (Figure 4.2A) [159].  The FLIP technique is similar, however 
there is repetitive photobleaching of one area of the cell, whilst images are collected for the 
entire cell using time lapse microscopy (Figure 4.2B) [159].  Making a selected pool of 
fluorescently labelled protein invisible, using FRAP or FLIP, allows the steady state of the 
protein to be altered  without disrupting protein pathways or creating protein gradients.  
Photoactivatable GFP, which requires activation at a shorter wavelength before being 
detectable at the usual wavelength, allows the detection of a protein throughout its’ lifetime 
independently of newly synthesised proteins (Figure 4.2C) [161]. 
 
4.3.3 – FRET 
 
GFP and its different colour variants amongst other fluorescent proteins can be used to study 
protein - protein interactions within cells.  The technique called Förster (or Fluorescence) 
Resonance Energy Transfer (FRET) uses the emission of one fluorophore to excite the other 
fluorophore.  The two proteins of interest are first cloned into expression vectors containing 
two different and suitable fluorescent proteins.  The two fluorophore proteins, or FRET pairs 
need careful consideration so that the emission spectrum of the first protein overlaps with the 
excitation spectrum of the second fluorophore.  However, at the same time the emission 
spectrum must be far enough apart so that the light emission from the two fluorophores can be 
collected separately.  Examples of commonly used FRET pairs include BFP and GFP, CFP 
and YFP or GFP and RFP (or mCherry). 
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Figure 4.2 – Live cell imaging techniques. 
A, FRAP – a region of the cell (indicated in red) is selected and intensively irradiated to 
photobleach fluorescent molecules.  The recovery of fluorescent molecules into that region is 
assessed quantitatively to determine diffusion coefficients and mobile fractions.  B, FLIP – a 
region of the cell (indicated in red) is repeatedly photobleached.  Movement of fluorescent 
molecules into the region being photobleached results in loss of fluorescence from the area 
outside of the box and can be used to access the boundaries for a protein’s diffusional 
movement within a cell.  C, Photoactivation – selective irradiation of a selected area 
(indicated in red) leads to the molecules in this region becoming fluorescent.  These 
molecules can then be monitored as they move out of this region and throughout the cell. 
[159] 
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The FRET pair example given in Figure 4.3 is BFP and GFP.  BFP requires ultra-violet light 
for excitation and emits blue light, whereas GFP requires blue light for excitation and emits 
green light.  If protein X coupled to BFP and protein Y coupled to GFP do not interact within 
the cell, illuminating the sample with ultra-violet light will result in the emission of only blue 
light.  If protein X and Y do interact FRET can occur between the fluorophores, and 
illuminating the sample with ultra-violet light will excite the BFP whose emission in turn 
excites the GFP, resulting in the emission of blue and green light from the sample.  However, 
the two fluorophores must be close together, between 1 and 10 nm apart, for FRET to occur.  
FRET experiments require careful controls to be done such as no transfection and single 
transfections to be meaningful; however it is a useful way of showing protein-protein 
interactions within cells. 
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Figure 4.3 – FRET analysis of protein interactions. 
To determine whether and when two proteins interact inside the cell, the proteins are first 
produced as fusion proteins attached to different variants of GFP.  A, In this example protein 
X is coupled to blue fluorescent protein (BFP), which is excited by ultraviolet light (370 - 440 
nm) and emits blue light (440-480 nm).  Protein Y is coupled to green fluorescent protein 
(GFP), which is excited by blue light and emits green light (510 nm).  B, If protein X and Y do 
not interact, illuminating the sample with ultraviolet light yields fluorescence from the BFP 
only.  C, When protein X and Y interact, FRET can now occur.  Illuminating the sample with 
ultra-violet light excites the BFP whose emission in turn excites the GFP, resulting in the 
emission of blue and green light from the sample.  The fluorophores must be close together, 
between 1 and 10 nm apart, for FRET to occur. [Adapted from 19] 
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4.4 – Results 
 
4.4.1 – Yeast – 2 – Hybrid Screen 
 
Although VPS33A, a homologue of yeast Vps33, is known to interact with the mammalian 
equivalent of HOPS complex proteins, the functional partners of VPS33B have not been 
established [79;156].  Therefore a yeast-2-hybrid screen was performed by The Genomics and 
Proteomics Core Facility at the Deutsches Krebsforschungszentrum (Heidelberg, Germany), 
to identify VPS33B-interacting proteins.  Human foetal brain and adult kidney cDNA 
libraries were chosen for screening due to the marked renal and CNS phenotype in ARC 
syndrome.  The screen yielded 18 candidates, which were assessed for the likelihood for 
interaction by the number of times the interaction was observed and the promiscuity rating of 
that protein (Table 4.1).  These proteins were then prioritised on the basis of in-silico analysis 
of their putative functions.  Highest priority was given to a novel protein, POLARIN, encoded 
by the gene C14orf133 (renamed PLRN), due to the number of times this protein was isolated 
from the yeast-2-hybrid screen and based on similarity to other proteins. 
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Gene Symbol Gene Name Isolation 
Number 
Promiscuity 
Rating 
 
     
C14orf133 chromosome 14 open reading frame 133 16 1 Likely 
Interactors C1orf149 chromosome 1 open reading frame 149 2 1 
CDK10 Cyclin-dependent kinase (CDC2-like) 10 1 1 
Uncertain 
Interactors 
CCDC22 Coiled-coil domain containing 22 1 1 
CKLF chemokine-like factor 1 2 
NTF3 Neurotrophin 3 1 2 
MARVELD2 MARVEL domain containing 2 1 3 
MRPL33 mitochondrial ribosomal protein L33 1 3 
SNRPB small nuclear ribonucleoprotein polypeptides B and B1 7 5 
Likely 
False 
Positives 
FXYD3 FXYD domain containing ion transport regulator 3 1 9 
GH2 growth hormone 2 2 13 
MYBPC1 myosin binding protein C, slow type, transcript variant 1 mRNA. 1 13 
CYB cDNA: known chromosome:NCBI35:MT:14748:15882:1 1 18 
HBB Haemoglobin beta mRNA 1 23 
KIF1A kinesin family member 1A mRNA. 1 38 
False 
Positives 
CDCA4 cell division cycle associated 4 2 4 
EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1 mRNA. 2 9 
WDR42A WD repeat domain 42A mRNA 2 29 
 
Table 4.1 – Yeast–2–hybrid results for VPS33B. 
VPS33B was used as bait and human foetal brain and adult kidney cDNA libraries were screened for putative interacting proteins.  
Highest priority was given to C14orf133 (renamed PLRN) encoding a novel protein, POLARIN, due to the number of times this protein was 
isolated from the yeast-2-hybrid screen. 
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4.4.2 – In-silico Analysis of POLARIN 
 
A species protein alignment for POLARIN homologues revealed conservation through 
evolution down to multicellular organisms, similar to that for VPS33B (Figure 4.4).  A 
peptide-sequence BLAST search revealed similarity to VPS16 and ClustalW alignments 
showed 15% identity between the two proteins. Alignments repeated individually for the 
VPS16 N- and C- terminal domains found proportionate identities of 5% and 16% 
respectively (Figure 4.5).  Bioinformatic analysis of the POLARIN sequence using Pfam and 
SMART databases found the C-terminal VPS16 domain and a Golgin subfamily A member 5 
domain, both in the C-terminal region of POLARIN.  Golgin family members are coiled-coil 
motif-containing proteins known to interact with Rab GTPases [162;163] 
 
Two splice variants have been identified (which differ depending on the presence of exon 16), 
resulting in proteins of 480 and 493 amino-acid residues long.  The larger transcript was used, 
with a predicted unglycosylated weight of 57 kDa, as the reference sequence for DNA and 
protein.  The reference cDNA and protein sequence along with all other in-silico analysis of 
POLARIN are shown in Appendix 3.  Analysis of the amino acid composition of POLARIN 
revealed that over 32% of the protein is hydrophobic, and that it is predominantly a folded 
protein, with protein disorder in the N-terminus.  Further analysis of the amino acid sequence 
of POLARIN suggests that the protein is predominantly coiled, most of which being -
helices, and also predicts 2 coiled-coiled regions between amino acids 1-50 and 150-200.  The 
hydrophobicity and the coiled nature of POLARIN suggest that POLARIN is likely to form a 
stable complex with another protein or other proteins. 
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Figure 4.4 – Species alignment of POLARIN.   
ClustalW amino acid alignment for multicellular organisms with dark shading representing identical amino acids.  POLARIN is conserved 
down to multicellular organisms.  The region of POLARIN absent in Rat, Mouse and Drosophila equivalent to human amino acids 159 to 
192 correspond to the exon 16 splice variant of PLRN.
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Figure 4.5 – Amino acid alignment of POLARIN and VPS16 C- terminal domain. 
 ClustalW amino acid sequence alignment for POLARIN and VPS16 C-terminal domains.  
There is 16% identity between the two.  Identical amino acids are shaded in dark grey and 
marked with asterisk. Similar amino acids are shaded in light grey. 
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4.4.3 – Confirmation of Interaction 
 
Co-immunoprecipitation and immunofluorescence experiments were performed to investigate 
the reliability of the yeast-2-hybrid findings, and whether there is a redundancy in the 
interaction between VPS33A and VPS33B homologues and POLARIN and its distant 
homologue VPS16.  Co-immunoprecipitation confirmed that VPS33B interacts with 
POLARIN but not with VPS16, and in parallel, POLARIN did not interact with VPS33A 
(Figure 4.6).  Both results demonstrate the specificity of the VPS33B-POLARIN interaction 
and make it unlikely that VPS33B is involved in the conventional HOPS complex function.   
 
As no anti-POLARIN antibody was available for immunofluorescence studies, epitope-tagged 
VPS33B and POLARIN constructs were used.  These, when overexpressed individually in 
HEK293 cells, displayed a general cytoplasmic localisation with some clusters (Figure 4.7A).  
Live cell imaging of mIMCD-3 cells transfected with YFP-VPS33B showed a similar general 
cytoplasmic localisation.  However when a FLIP experiment was carried out and hence the 
free diffusible VPS33B was removed from sight within the cell, discrete clusters of VPS33B 
could be seen within the cytoplasm (Figure 4.8 and Movie on CD). 
 
Co-overexpression of both proteins strikingly affected their localisation (Figure 4.7B).  Wild-
type VPS33B and POLARIN colocalised in large discrete cytoplasmic clusters.  A 
specifically constructed VPS33B-L30P mutant protein (modelled on a missense mutation 
identified in a patient with ARC) did not cluster with POLARIN; both proteins remained 
generally distributed throughout the cytoplasm.  Similarly, no clustering was seen with co-
overexpression of POLARIN and VPS33A.  
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Figure 4.6 – Co-immunoprecipitation of VPS33 homologues with VPS16 and POLARIN. 
HEK293 cells were co-transfected with HA-tagged VPS33B, VPS33B-L30P mutant, or 
VPS33A and with myc-tagged POLARIN or VPS16 constructs. Co-immunoprecipitation 
experiments show that HA-VPS33B and HA-VPS33B-L30P interact with myc-POLARIN and 
that HA-VPS33A interacts with myc-VPS16. No interaction is seen between HA-VPS33B and 
myc-VPS16 or between HA-VPS33A and myc-POLARIN.  Quantification revealed that 28.1% 
(VPS33B), 22.8% (VPS33B-L30P), and 27.7% (VPS33A) of the myc-POLARIN or myc-VPS16 
input was recovered. 
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Figure 4.7 – Confocal fluorescence photomicrographs of VPS33 homologues with 
POLARIN 
Confocal fluorescence photomicrographs of A, HEK293 cells transfected with YFP-VPS33B 
and Cherry-POLARIN constructs individually and B, HEK293 cells co-transfected with both 
Cherry-POLARIN and YFP-VPS33B, YFP-VPS33B (L30P), or YFP-VPS33A. Nuclei are 
stained with TO-PRO-3. Scale bar = 10 m.  When co-overexpressed, Cherry-POLARIN and 
YFP-VPS33B form cytoplasmic clusters (insert).  No clusters are seen when Cherry-
POLARIN is co-overexpressed with YFP-VPS33B (L30P) or YFP-VPS33A.  (Experiment 
carried out in collaboration with A Straatman Iwanowska, University of Birmingham, UK) 
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Figure 4.8 – YFP-VPS33B FLIP confocal live-cell microscopy. 
YFP-VPS33B was transfected into mIMCD-3 cells and a Fluorescence Loss In 
Photobleaching (FLIP) experiment was carried out in live cells.  Bleaching was done using a 
514 nm laser set to 100% every 5 seconds in an area of one cell (white rectangle), with an 
image captured every 2.5 seconds for a total of 5 minutes.  Images shown are at A, t = 0 
minutes and B, t = 5 minutes.  Scale bar = 10 m. Removal of the free cytoplasmic YFP-
VPS33B pool (by photobleaching) reveals occasional cytoplasmic clusters (white arrows), 
which are not as pronounced as when VPS33B is co-over expressed with POLARIN, 
suggesting endogenous interaction with POLARIN.   
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4.4.4 – Co-localisation of VPS33B-POLARIN Clusters with Organelle Markers 
 
In the previous section, it was shown that when co-overexpressed in HEK293 cells, VPS33B 
and POLARIN form large cytoplasmic clusters.  In order to determine the sub-cellular 
localisation of the VPS33B-POLARIN clusters, immunostaining was performed with various 
organelle markers.  For all the following experiments HEK293 cells were transfected with 
HA-VPS33B and Cherry-POLARIN and either stained or transfected with various organelle 
markers.  Firstly, to ensure the VPS33B-POLARIN cluster was not an artefact of transfection, 
the transfected cells were stained for GM130, a Golgi membrane marker.  No significant co-
localisation was observed (p=0.84) suggesting that both proteins were released into their 
native environment (Figure 4.9).  Co-localisation was assessed as described previously [164] 
and in section 2.2.6.1.1 
 
The HOPS complex components have been shown to localise to early and late endosomes and 
lysosomes within yeast and mammalian cells [74;79].  However in light of the findings that 
VPS33B specifically interacts with POLARIN and not with VPS16, a HOPS complex 
member, the VPS33B-POLARIN cluster was assessed for co-localisation with markers of 
these organelles.  No significant co-localisation was observed with Rab5 (early endosome, 
p=0.39), LAMP-1 (late endosome, p=0.34) or CD63 (lysosomes, p=0.22), further suggesting 
that VPS33B does not function as part of the conventional HOPS complex (Figure 4.9).  
However, significant but partial colocalisation was observed with the VPS33B-POLARIN 
clusters and Rab11a (p<0.001), which is present in apical recycling endosomes (AREs), and 
Rab4a (p<0.05), which is thought to be present on some early endosomes and also to be 
involved in ARE biogenesis [165;166] (Figure 4.10).   
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Figure 4.9 – Negative co-localisation of VPS33B-POLARIN clusters with organelle 
markers. 
HEK293 cells were transfected with HA-VPS33B (not stained) and with Cherry-POLARIN; 
they were then either immunolabelled (GM130 and LAMP-1) or co-transfected with GFP-
tagged organelle markers. Nuclei are stained with TO-PRO-3. Scale bar = 10 m.  No 
significant co-localisation (by Student’s T test) was seen with markers for the Golgi 
apparatus (GM130), early endosome (Rab5), or late endosome and lysosomes (LAMP-1, 
CD63).  Bar graphs compare the average organelle marker fluorescence per unit area ± 1 
standard error of the mean, in regions within 25 Cherry-POLARIN puncta (in single optical 
section for each marker) to an equivalent number of regions outside of Cherry-POLARIN 
spots. (Experiment carried out in collaboration with A Straatman Iwanowska and J. 
Rappoport, University of Birmingham, UK) 
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Figure 4.10 - Positive co-localisation of VPS33B-POLARIN clusters with organelle markers. 
HEK293 cells were transfected with HA-VPS33B (not stained), Cherry-POLARIN and GFP-Rab4 or GFP-Rab11.  Nuclei are stained with 
TO-PRO-3. Scale bar = 10 m.  Significant co-localisation (by Student’s T test) was observed with Rab4 (early endosome) and Rab11a 
(recycling endosome).  Bar graphs compare the average organelle marker fluorescence per unit area ± 1 standard error of the mean, in 
regions within 25 Cherry-POLARIN puncta (in single optical section for each marker) to an equivalent number of regions outside of 
Cherry-POLARIN spots. (Experiment carried out in collaboration with A Straatman Iwanowska and J. Rappoport, University of 
Birmingham, UK) 
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4.4.5 – The VPS33B-POLARIN Complex Interacts with Rab11a 
 
The previous co-localisation of the VPS33B-POLARIN clusters with Rab11a was observed 
with over-expressed proteins, and as antibodies against both VPS33B and Rab11a are 
commercially available, the co-localisation could be assessed at the endogenous level.  
HEK293 and mIMCD-3 cells were stained for both proteins (Figure 4.11).  Again significant 
but partial colocalisation of endogenous VPS33B and Rab11a was also detected in HEK293 
cells (p<0.001) and in mIMCD-3 cells (p<0.05).  
 
When Texas Red conjugated transferrin was pulsed into HEK293 cells and chased for a total 
of 1 hour, no co-localisation was observed at any time point (Figure 4.12).  The transferrin 
receptor is a marker of the basolateral recycling endosomes, and this result suggests that the 
VPS33B-POLARIN clusters are not present in the basolateral recycling endosomes and 
furthermore are specifically localised to the apical recycling endosomes [167]. 
 
 
 
 
138 
 Rab11a VPS33B Merge  
H
E
K
2
9
3
 
   
 
p<0.001 
 
    
m
IM
C
D
-3
 
   
 
p<0.05 
 
Figure 4.11 – Endogenous co-localisation of VPS33B and Rab11a. 
Confocal immunofluorescence photomicrographs of HEK293 and mIMCD-3 cells stained for endogenous Rab11a (green) and VPS33B 
(red).  Nuclei are stained with TO-PRO-3. Scale bar = 10 m. Partial co-localisation (inserts) of both markers can be seen. Bar graphs 
comparing the average Rab11a fluorescence per unit area ± 1 standard error of the mean in regions within 25 VPS33B puncta (in single 
optical section for each marker) to an equivalent number of regions outside of VPS33B spots. (Experiment carried out in collaboration 
with A Straatman Iwanowska, University of Birmingham, UK) 
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Figure 4.12 – Co-localisation of the VPS33B-POLARIN clusters with the transferrin 
receptor. 
Texas Red-conjugated transferrin was pulsed for 30 minutes into HEK293 cells co-
transfected with YFP-VPS33B and myc-POLARIN (not immunostained) and was chased for a 
total of 60 minutes (scale bar = 10 m).  No co-localisation was observed at any time. 
(Experiment carried out in collaboration with A Straatman Iwanowska, University of 
Birmingham, UK) 
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Since the VPS33B-POLARIN clusters at both the overexpressed and endogenous level at 
least partially co-localises with Rab11a, the co-localisation was further investigated using 
Fluorescence Resonance Energy Transfer (FRET).  This technique allows the assessment on 
how close 2 proteins and their fluorescent tags are to one another, by using light emitted from 
the first fluorophore (GFP) to excite the next fluorophore (Cherry).  For a positive FRET 
result the 2 fluorophores must be between 1 and 10 nm apart.  HEK293 cells were transfected 
with HA-VPS33B, Cherry-POLARIN (to form clusters) and GFP-Rab11a and a FRET 
experiment was carried out.  Red emission light could be collected from the Cherry 
fluorophore when the GFP molecule was excited with the 488 nm laser; suggesting that FRET 
was occurring, and that VPS33B, POLARIN and Rab11a are in close proximity to each other 
(Figure 4.13).  No red emission light was detected in control samples. 
 
The conventional HOPS complex has Rab effector and Rab GEF properties [73;75], so the 
interaction between this new complex and Rab11a was assessed.  VPS33B and Rab11a 
reciprocally co-immunoprecipitate at the endogenous level in mIMCD-3 cells (Figure 4.14).  
Furthermore, HEK293 cells were co-transfected with GFP-Rab11a and either HA-VPS33B or 
myc-POLARIN or both HA-VPS33B and myc-POLARIN together, and co-
immunoprecipitation experiments were carried out on these lysates, which revealed a weak 
interaction between Rab11a, VPS33B and POLARIN (Figure 4.15A).  Both VPS33B and 
POLARIN need to be over-expressed for this interaction to be observed and quantification of 
the IP revealed only 7.6% (IP  HA) and 7.9% (IP  myc) of the Rab11a input was 
recovered.  However, when the same experiment was carried out with a dominant negative 
Rab11a (DN-Rab11a) construct carrying a S25N mutation, which locks Rab11a in the Rab-
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GDP state, no interaction was observed, suggesting that the newly identified VPS33B-
POLARIN complex has Rab effector properties (Figure 4.15B). 
 
4.4.6 – POLARIN Interacts with the HOPS Complex Proteins 
 
Previous work by other groups has shown that VPS33A and VPS16 do indeed interact with 
the other members of the HOPS complex [79], but the data presented in section 4.4.3 suggests 
that VPS33B does not interact with VPS16 and VPS33A does not interact with POLARIN.  
Therefore, whether the newly identified VPS33B-POLARIN complex forms a larger complex 
with the remaining members of the conventional HOPS complex remains unknown.  To 
address this question, POLARIN was sub cloned into the HA tagged vector and the other 
members of the HOPS complex (VPS11, VPS18, VPS39 and VPS41) were cloned into the 
myc tagged expression vector.  Co-immunoprecipitation experiments revealed that POLARIN 
interacts with VPS18 and weakly interacts with VPS11, VPS39 and VPS41 (Figure 4.16).  
These findings suggest that the VPS33B-POLARIN complex does interact with the remaining 
members of the HOPS complex.  Confocal immunofluorescence microscopy of HEK293 cells 
transfected individually with myc tagged VPS39 or VPS41 revealed a general cytoplasmic 
localisation for both proteins, similar to that of VPS33B and POLARIN alone (data not 
shown).  In contrast VPS11 and VPS18 localised to large discrete vesicular structures in the 
cytoplasm of cells.  When HEK293 cells were co-transfected with Cherry-POLARIN and 
myc-VPS11, VPS39 or VPS41, the localisation observed with single transfections remained 
unchanged (Figure 4.17).  However, when POLARIN was co-transfected with myc-VPS18, 
POLARIN formed large cytoplasmic clusters which co-localised with VPS18 (Figure 4.17 
and 4.18). 
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Figure 4.13 – FRET analysis of VPS33B-POLARIN complex and Rab11a. 
A, mIMCD-3 cells were triple transfected with HA-VPS33B (not stained), Cherry-POLARIN 
(red) and GFP-Rab11a (green). The GFP-Rab11a was excited using the 488 laser line and 
red emission collected using laser excitation and FRET.  B, Control transfections for FRET 
experiment in A. The same settings were used as in A, and all red emission light was collected 
by FRET after excitation using the 488 laser line. No red light was collected in any control 
sample. Scale bar = 10 m. 
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Figure 4.14 - Reciprocal co-immunoprecipitation of endogenous VPS33B and Rab11a. 
Co-immunoprecipitation of endogenous VPS33B and Rab11a from mIMCD-3 cells after pull-
down with A, Rab11a antibody and B, VPS33B antibody.  Control (IgG molecules) failed to 
pull down the relevant protein despite being present in the lysates. 
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Figure 4.15 – Co-immunoprecipitation of the VPS33B-POLARIN complex and Rab11a. 
A, HEK293 cells were co-transfected with HA-tagged VPS33B or empty vector, myc-
POLARIN or empty vector, and GFP-tagged Rab11a.  Co-immunoprecipitation experiments 
using HA-VPS33B or myc-POLARIN as bait show that both VPS33B and POLARIN 
immunoprecipitate in the same complex as Rab11a. Both HA-VPS33B and myc-POLARIN 
needed to be over-expressed for the interaction with GFP-Rab11a to occur. Quantification of 
the immunoprecipitation revealed 7.6% (IP  HA) and 7.9% (IP  myc) of the Rab11a input 
was recovered. B, same experiment as in A, but GFP-tagged dominant negative (DN) Rab11a 
was used.  No interaction between the VPS33B-POLARIN complex and the GDP-locked 
dominant negative Rab11a can be seen. 
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 IP: m  HA 
HA-Empty + + + +     
HA-POLARIN     + + + + 
myc-VPS11 +    +    
myc-VPS18  +    +   
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Figure 4.16 – Co-immunoprecipitation of POLARIN with the HOPS complex. 
HEK293 cells were co-transfected with HA-empty or HA-POLARIN and myc tagged VPS11, 
VPS18, VPS39 or VPS41.  Co-immunoprecipitation experiments were carried out, which 
revealed a strong interaction between POLARIN and VPS18, and weaker interactions with 
VPS11, VPS39 and VPS41.  None of these proteins were pulled down with HA-empty despite 
being present in the lysates. 
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Figure 4.17 – Confocal immunofluorescence of POLARIN with the HOPS complex. 
Confocal immunofluorescence photomicrographs of HEK393 co-transfected with Cherry-
POLARIN (red) and myc-VPS11, VPS18, VPS39 or VPS41 (green).  Nuclei are stained with 
TO-PRO-3. Scale bar = 10 m. No change in localisation was observed for VPS11, VPS18, 
VPS39 and VPS41 from their single transfections. POLARIN formed large discrete clusters 
that co-localised with VPS18 when co-transfected with VPS18.  (Experiment carried out in 
collaboration with A Straatman Iwanowska and Guanmei Luo, University of Birmingham, 
UK) 
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The clustering and co-localisation of POLARIN with VPS18 and the stronger interaction 
between POLARIN and VPS18 for the co-immunoprecipitation experiment, suggests that this 
may be a direct interaction.  In ARC syndrome, the gene encoding VPS33B is mutated in 75% 
of patients and there is reduced expression of VPS33B in all patients (chapter 3) [4].  
Therefore, assuming the expression levels of POLARIN in these patients are normal, the 
effect of VPS33B on the interaction between VPS18 and POLARIN needs to be further 
investigated. 
 
Co-immunoprecipitation was carried out on lysates from HEK293 cells co-transfected with 
myc-VPS18 and HA-POLARIN with or without the addition of YFP-VPS33B (Figure 
4.18A).  Confocal immunofluorescence microscopy was also carried out on cells transfected 
with YFP-VPS18, Cherry-POLARIN with and without the co-transfection with HA-VPS33B 
(Figure 4.18 B and C).  Again, POLARIN strongly interacts and co-localises with VPS18 
when VPS33B is not being over-expressed.  However, when VPS33B is being over-
expressed, the VPS18-POLARIN interaction is greatly reduced, shown by the faint band on 
the co-immunoprecipitation.  Furthermore, the localisation of POLARIN dramatically 
changes from co-localisation with VPS18 to VPS33B when VPS33B is being over-expressed.  
In the triple transfected cells, POLARIN predominantly co-localises with VPS33B which are 
present in completely separate clusters to VPS18, however, there are regions of triple co-
localisation. 
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HA-POLARIN  + + 
YFP-Empty + +  
YFP-VPS33B   + 
myc-VPS18 + + + 
    
    
IP: m  HA 
WB: m  myc  
Input 
WB: m  HA  
Input 
WB: Rb  VPS33B  
Input  
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YFP-VPS18 Cherry-POLARIN Merge 
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YFP-VPS18 Cherry-POLARIN HA-VPS33B Merge 
    
 
Figure 4.18 – POLARIN interaction with VPS18. 
A, HEK293 cells were co-transfected with HA-empty or HA-POLARIN, YFP-empty or YFP-
VPS33B and myc-VPS18.  A co-immunoprecipitation experiment was carried out, which 
again revealed a strong interaction between POLARIN and VPS18 when only endogenous 
levels of VPS33B present.  When VPS33B is also over-expressed this interaction diminishes.  
B, Confocal fluorescence photomicrographs of HEK393 co-transfected with YFP-VPS18 
(green) and Cherry-POLARIN (red), showing clustering and co-localisation of both proteins.  
C, Confocal immunofluorescence photomicrographs of HEK393 co-transfected as in B plus 
HA-VPS33B (stained using Alexa 633, shown in blue).  POLARIN now co-localises with 
VPS33B (purple in merge image) and not with VPS18.  However, there are regions of triple 
co-localisation (seen as white in the merge image).  Scale bars = 10 m. 
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4.4.7 – PLRN Mutation Analysis of ARC Syndrome Patients. 
 
To investigate whether a deficiency in POLARIN may cause clinical features of ARC 
syndrome, consanguineous families with ARC syndrome in which linkage to the VPS33B 
locus was excluded were analysed.  A genomewide linkage screen using 10K and 250K 
Affymetrix SNP microarrays was performed in 4 unrelated consanguineous patients.  
Homozygosity for the PLRN locus was identified in 3 patients from Turkish and Israeli Arab 
ethnic backgrounds (data not shown).  The genome wide linkages scans were carried out by F. 
Rahman (University of Birmingham, UK).  Mutation screening of all PLRN coding exons and 
flanking intronic sequence was then performed using DNA from all available ARC patients 
lacking demonstrable VPS33B mutations.  Eight mutations, 6 nonsense, one frameshift and 
one missense (changing the start ATG codon to AGG) were detected in 7 unrelated patients 
(Table 4.2).  Mutations were verified by segregation with disease status within the families 
and by screening at least 200 chromosomes from ethnically matched controls for each 
mutation. All detected mutations are predicted to cause absence of POLARIN expression. 
 
 
 
 
 
 
 
 
 
150 
Patient 
Number 
Ethnic 
Origin 
Nucleotide 
Alteration 
Peptide 
Alteration 
Status  
      
      
22 Turkish 535C→T Q179X Hom * 
23 Croatian 748_752delACAGA T250ArgfsX279 Hom  
24 Turkish 658C→T 
873C→T 
R220X 
Q291X 
Het 
Het 
 
25 Turkish 1273C→T Q425X Hom * 
26 Italian 658C→T R220X Hom  
27 Israeli 
Arab  
808C→T R70X Hom * 
28 Turkish 2T→G M1R Hom * 
 
Table 4.2  – PLRN is mutated in ARC syndrome.   
Nucleotides are numbered from the A of the ATG initiation codon. None of these mutations 
were identified in more than 200 chromosomes from healthy ethnically matched controls. 
Patient numbers continue from Table 3.1 (VPS33B mutations).  Patient 22 had reduced 
expression of VPS33B at the RNA and protein level.  (* = used for genome-wide scan, del = 
deletion, fs = frameshift, X = stop, hom = homozygous, and het = heterozygous).  Mutation 
screening carried out by A. Straatman-Iwanowska, University Birmingham, UK. 
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4.5 – Discussion 
 
The conventional HOPS complex, including VPS33A, was recently found to be involved in 
the Rab5/Rab7-dependent pathway of phagosome biogenesis during apoptosis in mammalian 
cells [79].  Another complex, the class C cORe Vacuole/Endosome Tethering (CORVET) 
complex can be formed by class C VPS proteins in yeast [168].  Unlike other SM proteins, 
VPS33 homologues require additional proteins to interact with SNARE complexes.  Presented 
here is a novel protein, POLARIN, possessing 16% identity to the C-terminal domain of the 
HOPS complex member VPS16.  However, VPS33B specifically interacts with POLARIN 
and not with VPS16.  Although the experiments shown in this chapter suggest that VPS33B 
and POLARIN are unlikely to form active parts in the conventional HOPS complex function, 
there are likely to be other components of the new VPS33B-POLARIN complex.  Indeed the 
VPS33B-POLARIN complex interacts with the remaining members of the HOPS complex 
(VPS11, VPS18, VPS39 and VPS41).  Furthermore, the VPS33B-POLARIN complex is 
unlikely to function at the early endosome, late endosome or lysosome level, since neither 
endogenous VPS33B nor co-overexpressed VPS33B-POLARIN clusters significantly co-
localised with Rab5, LAMP-1 or CD63.  This suggests the presence of a novel complex that 
possibly utilises members of the conventional HOPS complex, but through the specific action 
of VPS33B and POLARIN has a different function within cells (Figure 4.19). 
 
In light of the experimental findings it is likely that the VPS33B-POLARIN complex is 
associated with the Rab4/Rab11 intracellular trafficking pathway in mammalian cells, as 
evidenced by co-localisation, positive FRET and co-immunoprecipitation.  The interaction 
between VPS33B and POLARIN is required for the complex to interact with Rab11a, and 
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furthermore the dominant negative (GDP locked) version of Rab11a failed to interact with the 
complex.  This suggests that the newly identified complex has Rab11a effector properties, as 
Rab11a must be GTP bound for the VPS33B-POLARIN complex to interact [42].  However, 
this cannot account for the partial co-localisation observed between the VPS33B-POLARIN 
complex and Rab11a in both HEK293 and mIMCD-3 cells.  There are VPS33B-POLARIN 
clusters that do not contain Rab11a and vice versa.  GDP bound Rab molecules are not 
membrane bound [63], and so should not appear as discrete clusters within the cytoplasm of 
cells.  Rab11a vesicles not containing the newly identified complex can clearly be observed at 
the over-expressed and endogenous level.  Therefore there are likely be other factors 
regulating the interaction between the VPS33B-POLARIN complex and Rab11a, resulting in 
a subset of Rab11a vesicles containing the VPS33B-POLARIN complex and vice versa.  
Furthermore, the interaction between VPS33B-POLARIN and Rab11a is potentially transient, 
therefore cannot always be seen in fixed cells. 
 
POLARIN is a predominantly coiled protein with 2 predicted coiled-coiled domains, and has 
similarity to Golgin subfamily A member 5.  The Golgin family of proteins are coiled-coil 
motif-containing proteins known to interact with Rab GTPases [162;163].  Recently another 
novel protein was identified, SCYL1BP1, which contains a Golgin domain and that 
specifically binds to the GTP bound form of Rab6 [169].  This is similar to the VPS33B-
POLARIN interaction with Rab11a, suggesting a common mechanism of action of Golgin 
domain containing proteins. 
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Figure 4.19 – Model for conventional HOPS complex and VPS33B-POLARIN complex. 
The conventional HOPS complex contains VPS11, VPS16, VPS18, VPS33A, VPS39 and 
VPS41, which functions at Rab5 and Rab7 early and late endosomes.  The newly identified 
VPS33B-POLARIN complex utilises VPS11, VPS18, VPS39 and VPS41 from the conventional 
complex, but replaces VPS33A and VPS16 with VPS33B and POLARIN.  This replacement is 
associated with the newly identified complex’s interaction and co-localisation with Rab4 and 
Rab11a on recycling endosomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
The weak interaction between POLARIN and VPS11, VPS39 and VPS41 may be due to 
endogenous limitations of other members of the complex, which must also be over expressed 
for complete interaction to occur.  In contrast, the interaction between POLARIN and VPS18 
is much stronger, but only when VPS33B is not being co-overexpressed.  This would mimic 
the effect of reduced expression of VPS33B seen in ARC syndrome patients, as demonstrated 
in chapter 3.  When VPS33B is over-expressed, the POLARIN is predominantly displaced 
from VPS18 clusters and co-localises with VPS33B, suggesting a competitive binding 
mechanism of action between POLARIN and VPS33B or VPS18.  However, there are regions 
of triple co-localisation, suggesting the complex can come together under certain and 
currently unknown circumstances. 
 
The identification of pathogenic mutations in PLRN, the gene encoding POLARIN in ARC 
syndrome patients without detectable VPS33B mutations, is consistent with the idea that 
VPS33B and POLARIN are required for each other’s function in the cell.  There are no 
distinguishable phenotype differences between ARC syndrome patients with VPS33B or 
PLRN mutations, further suggesting the 2 proteins co-operate to achieve the same function 
within cells.  However, the exact function of these 2 proteins remains unknown and will be 
investigated in the next chapter. 
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CHAPTER 5 – EFFECT OF VPS33B AND 
POLARIN KNOCKDOWN ON AN EPITHELIAL 
CELL LINE 
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5.1 – Introduction and Overview 
 
Epithelial cells contain distinct apical and basolateral plasma membrane domains.  Generation 
of these segregated domains is termed polarisation and is essential for various epithelial 
functions, including absorption and secretion [85;86].  Epithelial cells form a cohesive layer 
that acts as a physical ion-selective barrier.  This barrier function is highly dependent on the 
integrity of apical junctional complexes (AJCs), comprising of tight junctions (TJs) and 
adherens junctions (AJs) that link adjacent epithelial cells [88;89].  TJs, which lie apically to 
AJs, separate apical and basolateral membrane domains and constitute a partially permeable 
site of intercellular molecular transport.  In the process of epithelial differentiation AJs appear 
earlier than TJs. AJs form an adhesive belt that encircles each cell and binds the neighbouring 
epithelial cell membranes [170].  Although the importance of AJCs to generation and 
maintenance of epithelial polarity is well known, the molecular pathways determining the 
biogenesis of polarised membranes are not fully characterised.  Elucidation of the key 
pathways for cell polarisation is essential for understanding the development and the 
molecular and cellular physiology of the many structures, including gut, urinary tract, and 
central nervous system (CNS), that rely on intact cell polarity for their function [94].  There 
appears to be a defect in epithelial cell polarisation in ARC syndrome patients.  Therefore 
clarification of these polarisation pathways may help to explain the pathophysiology of ARC 
syndrome. 
 
Clinical features in ARC syndrome patients differ from the phenotype of hypopigmentation 
and immune deficiency found in organisms with HOPS complex protein defects [9;171;172].  
Furthermore, the data presented in chapter 4 suggests that VPS33B and POLARIN form a 
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different complex to that of the conventional HOPS complex and does not function at the 
endosome or late endosome.  This suggests that VPS33B is involved in an intracellular 
trafficking pathway different from the conventional HOPS complex.   
 
5.2 – Aims 
 
We hypothesised that the VPS33B pathway plays an important role in directing the 
intracellular traffic of apical membrane proteins in hepatocytes, epithelial cells of the renal 
tubules, and other polarised epithelial cells.  To test this hypothesis, clones of mIMCD-3 cells 
(a mouse polarised epithelial cell line) were created that had a stable reduced expression of 
either the novel protein Polarin or Vps33b.  Characterisation of these knockdown cell lines 
will be presented in this chapter.   
 
These knockdown cell lines will help elucidate the pathways POLARIN and VPS33B belong 
to and how these proteins are involved in apical membrane protein trafficking in polarised 
epithelial cells.  Additionally, these knockdown cell lines should mimic the effect of PLRN or 
VPS33B mutations seen in ARC syndrome patients’ epithelial cells, and thus allow the 
investigation of molecular pathophysiology of ARC syndrome. 
 
 
 
 
 
158 
5.3 – Results 
 
5.3.1 – Polarin and Vps33b shRNA in mIMCD-3 cells 
 
In order to investigate further the molecular mechanisms affected by ARC syndrome in 
polarised epithelial cell models, clones were developed of mouse Inner Medullary Collecting 
Duct (mIMCD-3) cells stably transfected with silencing shRNAs for Vps33b or Polarin.  One 
hairpin sequence for Vps33b and 2 sequences for Polarin (sequences shown in Appendix I) 
were individually transfected into mIMCD-3 cells and expression of the shRNA selected for 
by puromycin resistance.  A control shRNA containing a scrambled sequence was used as a 
specificity control.  Several individual clones were grown for each hairpin sequence and the 
level of knockdown assessed by quantitative real-time PCR (Polarin) or by western blotting 
(Vps33b, Figure 5.1).  No knockdown of either gene was observed in the Control shRNA 
cells.  Clones with the greatest knockdown were used for further experiments.  A 90% 
knockdown was achieved for Polarin (Polarin-shRNA) and a 92% was achieved for Vps33b 
(Vps33b-shRNA) 
 
Immunostaining of endogenous Vps33b in wild type mIMCD-3 cells, compared with the 
mIMCD-3 clones with stable Polarin knockdown (Figure 5.2), demonstrated a greatly reduced 
expression of Vps33b, which supports the hypothesis that Polarin is required for the 
stabilisation of Vps33b. 
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Figure 5.1 – Assessment of Polarin or Vps33b knockdown in mIMCD-3 cells. 
A, Quantitative Real Time PCR (qRT-PCR) for Polarin.  Values shown are mean values of 
expression levels of the Polarin normalised to -actin and relative to wild type cells (n=3 for 
each sample).  Error bars represent ± 1 standard error of the mean.  Two shRNA hairpins 
were used, E and F. Clone E4 was used for all future experiments, due to greatest level of 
knockdown of Polarin (90%, renamed Polarin-shRNA).  B, Western blot for Vps33b.  Loading 
was controlled by immunoblotting the same membrane with an anti-β-actin antibody.  
Densitometry on bands was carried out, and final knockdown values are normalised to -
actin and relative to wild type (WT) cells.  Clone 1 was used for all future experiments, due to 
greatest level of knockdown of Vps33b (92%, renamed Vps33b-shRNA).  No reduction in 
either Polarin of Vps33b expression was seen in control-shRNA treated cells. 
 
Clone WT 1 2 3 4 5 6 Control 
         
         
Vps33b 
 
   
-Actin 
 
         
         
OD Vps33b 82.200 6.407 50.113 74.432 7.691 55.295 61.609 80.944 
OD -Actin 98.877 98.722 97.757 96.092 97.864 98.733 99.057 97.948 
         
         
% Expression 83.13% 6.49% 51.26% 77.46% 7.86% 56.00% 62.20% 82.64% 
% Knockdown - 92.19% 38.34% 6.83% 90.55% 32.63% 25.19% 0.59% 
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 Control-shRNA Polarin-shRNA Vps33b-shRNA 
Vps33b 
   
 
 
Figure 5.2 – Endogenous Vps33b staining in Control-, Polarin- and Vps33b-shRNA cells. 
Confocal immunofluorescence photomicrographs of Control-, Polarin- and Vps33b-shRNA mIMCD-3 cells stained for endogenous Vps33b 
growing of transwell supports. Large cytoplasmic clusters seen in the wild type cells (arrow) are no longer present in either of the 
knockdown cell lines. Nuclei are stained with TO-PRO-3. Scale bar = 10 m. (Experiment carried out in collaboration with A Straatman 
Iwanowska, University of Birmingham, UK
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5.3.2 – Mislocalisation of Apical Membrane Proteins 
 
The mislocalisation of apical membrane proteins were observed in liver and kidney biopsies 
taken from ARC syndrome patients [1;11], therefore, the ability of Polarin- and Vps33b-
shRNA cells to maintain correct localisation of apical membrane proteins was tested by 
immuno-fluorescence confocal microscopy.  Obvious loss of specific apical localisation of 
P75 (exogenous) in both Polarin- and Vps33b-shRNA cell lines was detected.  The apical 
recycling endosome (ARE) marker, Rab11a, also lost its apical localisation in Polarin- and 
Vps33b-shRNA cells (Figure 5.3).  However, the basolateral protein Na/K ATPase 
maintained its correct basolateral position in the absence of Vps33b or Polarin (Figure 5.3).  
 
The localisation of carcinoembryonic antigen (CEA, endogenous) was also tested as its’ 
apical expression is lost in ARC patients.  The fluorescent microcopy did not show a very 
clear distinction between the control and knockdown cell lines. Therefore, the sulfo-NHS-SS 
biotin reagent was then used to detect whether CEA was present in the membrane or 
cytoplasm of the control and knockdown cells.  Immunoblotting of CEA on protein lysates 
from Control-, Polarin and Vps33b-shRNA cells, revealed an absence of the major 180 kDa 
CEA band in the Polarin and Vps33b deficient cells (Figure 5.4A).  The sulfo-NHS-SS biotin 
reagent binds covalently to the -amine of lysine residues in proteins, but cannot cross the 
plasma membrane, and therefore only binds to proteins on the plasma membrane.  This 
reaction is quenched, the cells lysed and the biotinylated proteins separated from the 
unlabelled (non-membrane) proteins using streptavidin agarose.  On closer inspection of the 
photomicrographs and using a membrane protein biotinylation binding assay, the 180 kDa 
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protein that was present in the apical membrane of the control cells, corresponded to the band 
that was undetectable in the knockdown cells (Figure 5.4B).   
 
To investigate whether the Vps33b-Polarin complex may be directly involved in trafficking of 
CEA and P75, pre-polarised wild type mIMCD-3 cells were immunolabelled for CEA and 
P75.  This revealed that there was co-localisation of the Polarin-Vps33b clusters with the 
apical membrane markers (P75 and CEA) mislocalised in the shRNA cells (Figure 5.5).   
 
5.3.3 – Apical Junction Complex Defects 
 
A characteristic of all epithelial cells is their ability to maintain an electrochemical gradient 
across a monolayer of cells [173].  To test whether Polarin and Vps33b-shRNA cells 
maintained this characteristic, Trans-Epithelial Resistance (TER) experiments were performed 
by placing electrodes in the apical and basal compartments of transwell supports which had 
control and knockdown cell lines growing on them, every 24 hours for 12 days (Figure 5.6).  
Significant reductions (50% for Polarin-shRNA and 75% for Vps33b-shRNA compared with 
control cells) in maximum TER achieved were detected in both knockdown cell lines, 
suggesting that a TJ defect and abnormal trafficking of proteins to TJs, as well as to the apical 
membrane, may account for the overall cellular phenotype. 
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Figure 5.3 – Abnormal localisation of apical markers in Polarin- and Vps33b-shRNA cells. 
Confocal immunofluorescence xz plane photomicrographs of transwell support cultured 
mIMCD-3 cells treated with shRNA (Control-shRNA, Polarin-shRNA and Vps33b-shRNA). As 
these knockdown cell lines do not grow in monolayers, marker localisation can be difficult. 
Only the top layer is shown.  Transfected Cherry-P75 and endogenous CEA can be found 
throughout the basolateral membrane and cytoplasm in Polarin- and Vps33b-shRNA cells, in 
contrast to their predominantly specific localisation to apical membranes in Control-shRNA 
cells. The apical recycling endosome marker Rab11a can be seen in the apical region of 
control-shRNA cells but this localisation is lost in knockdown cells.  The basolateral marker 
Na
+
K
+
 ATPase (endogenous) is correctly localised in all 3 cell types. Nuclei are stained with 
TO-PRO-3. Scale bar = 10 m.  (Experiment carried out in collaboration with A Straatman 
Iwanowska, University of Birmingham, UK 
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Figure 5.4 - Reduced expression of membrane CEA in Polarin- and Vps33b-shRNA cells 
A, Over exposed immunoblot of CEA on protein lysates from Control-, Polarin and Vps33b-
shRNA mIMCD-3 cells.  In both knockdown cell lines the major 180 kDa CEA band is not 
detectable, despite the gel being equally loaded (shown by -actin).  B, Membrane protein 
biotinylation assay showing the band absent in A is present in the membrane of control-
shRNA cells.  No -actin could be detected in the membrane fraction suggesting the biotin 
had not got inside the cells, and that the reaction was sufficiently quenched before the cells 
were lysed.  No CEA could be detected in the pulled down membrane protein fraction where 
no biotin reagent was used, but was seen in the unbound fraction. 
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Figure 5.5 – Co-localisation of apical membrane markers with Polarin-Vps33b clusters in 
mIMCD-3 cells. 
Confocal photomicrographs of cultured pre-polarised wild type mIMCD-3 cells transfected 
with HA-Vps33b (not stained), Cherry-Polarin and GFP-P75 or stained for endogenous CEA.  
Nuclei are stained with TO-PRO-3. Scale bars = 10 m.  (Experiment carried out in 
collaboration with A Straatman Iwanowska, University of Birmingham, UK.) 
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As functioning TJs are essential to control paracellular flux of macromolecules, fluorescently 
labelled dextrans were used to test whether Polarin or Vps33b deficiency would lead to a 
defect in TJ formation and to abnormal barrier function of the mIMCD-3 cell monolayer. Two 
types of dextran, small and large (4 and 70 kDa), were used for the experiments, which were 
added simultaneously to the apical chamber of transwell supports and allowed to diffuse 
through to the basolateral chamber for 3 hours [173].  The ratio of each fluorophore between 
the apical and basal compartments was measured and the paracellular diffusion of each 
dextran calculated relative to a transwell filters without cells.  Polarin-shRNA allowed twice 
as much 4kDa dextran, whilst Vps33b-shRNA treated cells allowed 2.5 times as much 4kDa 
dextran through the monolayer compared to controls.  No such significant change was 
detected for the larger dextran (Figure 5.7) 
 
TJ formation is dependent on the presence of calcium; therefore, to show that the changes in 
cell layer permeability and polarity are analogous to the physical disruption of TJs, the TER 
and dextran experiments were performed in cells grown in low-calcium medium [174].  All 3 
cell types were cultured in normal growth medium for 6 days, followed by incubation in low 
calcium medium for 24 hours.  After the control mIMCD-3 cells were cultured in low-calcium 
medium for 24 hours, the values for TER (not shown) and dextran permeability (Figure 5.8) 
became similar to those for Vps33b-shRNA cells.  In Polarin-shRNA cells grown in low 
calcium medium for 24 hours, the TER decreased and the paracellular permeability increased 
to similar levels to Vps33b-shRNA cells when grown in normal medium.  Both TER and 
permeability returned to values expected for the Control- and Polarin-shRNA cells after 
reintroduction of normal-calcium medium, suggesting that these effects were due to loss of 
functional TJs. 
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Trans-Epithelial Resistance of mIMCD-3 Cells Grown on Transwell Supports
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Figure 5.6 – Trans Epithelial Resistance (TER) in Control-, Polarin- and Vps33b-shRNA 
cells. 
Values shown are average trans-epithelial resistance readings every 24 h after seeding the 
cells onto Transwell supports (n=4, error bars = ± 1 standard error of the mean).  Polarin- 
and Vps33b-shRNA cells failed to establish TER to the extent of the control-shRNA cells. 
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Paracellular Flux Of Dextran Molecules In Between mIMCD-3 Cells Grown on Transwell Supports 
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Figure 5.7 – Paracellular diffusion in Control-, Polarin- and Vps33b-shRNA cells. 
Paracellular flux of 4 kDa dextran fluorescein isothiocyanate conjugate (FITC), and 70 kDa dextran Rhodamine B conjugate for all 3 cell 
types.  Cells were seeded onto Transwell supports and allowed to grow for 7 days.  n=4, error bars = ± 1 standard error of the mean, * = 
p<0.05, ** = p<0.001 by Student t-test.  Polarin- and Vps33b-shRNA cells allowed a significantly greater amount of 4 kDa dextran 
through the paracellular space.  No significant change was seen for 70 kDa dextran. 
*        ** 
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Paracellular Flux Of Dextran Molecules In Between mIMCD-3 Cells Grown on Transwell Supports  In Low Calcium
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Figure 5.8 – Paracellular diffusion in Control-, Polarin- and Vps33b-shRNA cells grown in low calcium medium. 
Paracellular flux of 4 kDa dextran fluorescein isothiocyanate conjugate (FITC), and 70 kDa dextran Rhodamine B conjugate for all 3 cell 
types.  Cells were seeded onto Transwell supports and allowed to grow for 6 days in normal medium, after which the medium was changed 
to low calcium medium 24 hours prior to the experiment.  n=4, error bars = ± 1 standard error of the mean.  No significant difference was 
observed between the Control-, Polarin-, and Vps33b-shRNA cells as in Figure 5.8 (by Student t-test). 
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Having demonstrated functional defects of TJs, the effect of decreased expression of Polarin 
and Vps33b on the localisation of some of the AJC proteins known to be involved in 
epithelial cell differentiation and human disease were studied.  Surprisingly, no 
mislocalisation was detected on immunostaining of the Polarin-shRNA and Vps33b-shRNA 
cells for ZO-1, which is normally confined to the cytoplasmic surface of TJs and associates 
with the actin cytoskeleton (Figure 5.9). More in keeping with the defect in TJ formation, 
mislocalisation of Claudin-1 to the plasma membranes and cytoplasm was identified in the 
knockdown cells, whilst in controls Claudin-1 was specifically localised to TJs (Figure 5.9).  
 
E-Cadherin is a calcium-dependent cell adhesion molecule with a functional extracellular 
domain that forms a part of the AJ adhesive belt.  Therefore, following on from the results of 
the calcium switch dextran assay (Figure 5.7 to 5.8) the effect of decreased Polarin and 
Vps33b expression on E-Cadherin localisation was analysed.  In Polarin- and Vps33b-shRNA 
cells, E-Cadherin localised predominantly to the cytoplasm whereas in the control cells, E-
Cadherin was localised in the lateral membrane (Figure 5.9).  Furthermore, it was reported 
previously that transfection of a dominant-negative Rab11a (DN-Rab11a) construct into 
Madin-Darby canine kidney (MDCK) cells causes mislocalisation of E-Cadherin and loss of 
the ability of these cells to form cysts [175].  To further explore the functional relationship 
between the Polarin-Vps33b complex and Rab11a identified in chapter 4, the phenotype of 
control mIMCD-3 cells expressing a DN-Rab11a construct was evaluated.  mIMCD-3 cells 
stably transfected with the DN-Rab11a construct failed to polarise, as shown by 75% 
reduction in maximum achieved TER (similar to Vps33b-shRNA) and by mislocalisation of 
AJC proteins (Figure 5.9). 
 
171 
 Control-shRNA Polarin-shRNA Vps33b-shRNA DN-Rab11a 
Z
O
-1
 
    
    
    
     
C
la
u
d
in
-1
 
    
    
    
     
E
-C
ad
h
er
in
 
    
    
    
 
Figure 5.9 – Immunostaining of tight and adherens junction proteins in Control-, Polarin-, 
Vps33b-shRNA and dominant negative Rab11a cells. 
Confocal immunofluorescence photomicrographs in xy and xz planes of ZO-1, Claudin-1, and 
E-Cadherin in Control-, Polarin-, Vps33b-shRNA and DN-Rab11a cells (scale bar = 10 m). 
No change is seen for ZO-1 staining in any of the cell types.  However, the specific 
localisation of Claudin-1 and E-Cadherin are lost in the knockdown and dominant negative 
Rab11a cells. Note the lack of a monolayer in the Polarin- and Vps33b-shRNA cells.  
(Experiment carried out in collaboration with A Straatman Iwanowska, University of 
Birmingham, UK.) 
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To assess the expression level of these AJC proteins, western blotting was carried out on 
protein lysates extracted from wild type, Control-, Polarin- and Vps33b-shRNA cells grown 
on transwell supports for 7 days (Figure 5.10).  This revealed a decrease in Claudin-1 with a 
concomitant increase in ZO-1 expression in the knockdown cells compared to wild type or 
control cells.  The 120 kDa E-Cadherin band was undetectable in the knockdown cells.  E-
Cadherin that is bound to another E-Cadherin molecule can also bind -Catenin, which leads 
to -Catenin being protected from degradation [99].  With the reduction of E-Cadherin 
expression detected above, the level of -Catenin expression could also be altered.  However, 
interestingly -Catenin expression was comparable to wild-type and control-shRNA cells. 
 
Due to the potential TJ defects identified in Figures 5.6 to 5.10, freeze fracture electron 
microscopy was used in order to appreciate the three dimensional perspective of the TJs in the 
knockdown cells (Figure 5.11).  This technique allows splitting of the layers of frozen cell 
membranes into two half-membrane leaflets [176].  The faces of each of the membrane 
leaflets can then be metal-replicated and visualised by transmission electron microscopy.  The 
extracellular leaflet adjacent to the extracellular space and observed from inside the cell is 
conventionally called the exoplasmic or “E-face” and the leaflet adjacent to the cytoplasm is 
the protoplasmic or “P-face” as observed from outside the cell. Examination of the TJs in both 
Polarin- and Vps33b-shRNA treated cells showed reduced complexity, disturbed P-face 
association, and an increase of particle-free pores corresponding to overall TJ disruption 
compared with control cells (Figure 5.11).  Vps33b-shRNA cells showed a greater reduction 
in complexity compared to that of Polarin-shRNA cells.  These results were consistent with 
results of TER and fluorescent dextran studies of TJ function (Figures 5.6 to 5.8). 
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Figure 5.10 – Western blots of tight and adherens junction proteins in wild type, Control-, 
Polarin-, and Vps33b-shRNA cells. 
Immunoblots of the tight junction proteins revealed a reduction in expression of Claudin-1 
and an increase in ZO-1 in both knockdown cell lines.  E-Cadherin expression is undetectable 
in these cells.  Interestingly there is no change in expression of -Catenin.  Loading was 
controlled by immunolabelling the same membrane with -actin. 
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Figure 5.11 – Freeze fracture electron micrographs of Control-, Polarin- and Vps33b-
shRNA cells. 
Freeze fracture images of Control-, Polarin-, and Vps33b-shRNA cells showing TJ strands 
(scale bar = 0.2 m). In Polarin- and Vps33b-shRNA cells, there is a strong decrease of tight 
junction strand complexity and/or a decrease of the P-face association leading to interrupted 
and blindly ending strands (arrows) when compared with the control cells.  Experiment 
carried out on cells created in section 5.3.1 by H. Wolburg, University of Tübingen, 
Tübingen, Germany. 
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Having detected defects in apical junction complex formation and function in the Polarin and 
Vps33b deficient cell lines, E-Cadherin was immunostained on ARC syndrome patient liver 
biopsies (Figure 5.12).  This revealed a marked reduction in E-Cadherin expression similar to 
that observed in the knockdown cell lines (Figure 5.10).  The remaining E-Cadherin present in 
the ARC syndrome patient biopsies also seems to be mislocalised from the basolateral 
surfaces in the control biopsy to a localisation throughout the membrane and in the cytoplasm.  
Again this is consistent with the knockdown cell mIMCD-3 cell lines (Figure 5.9) 
 
5.3.4 – Abnormal mIMCD-3 Cell Differentiation and Growth 
 
Observation of mIMCD-3 cell lines’ growth in culture and immunofluorescence experiments 
with antibodies against AJC proteins such as claudin-1 suggested that the knockdown cells 
failed to maintain epithelial characteristics when grown on Transwell supports.  Instead of 
forming well-defined monolayers, cultured cells formed multilayered structures; cells lost 
their distinct columnar appearance, becoming flatter.  Control-shRNA mIMCD-3 cells start to 
form cavities after 5 days of culture on Transwell supports (Figure 5.13A) and organise into 
tubules after 72 hours of growth in collagen gels (Figure 5.13B) [177]. These characteristics 
were completely lost in Polarin- and Vps33b-shRNA treated cells (Figure 5.13).  
 
After discovering the abnormal morphology in knockdown cells, the effect of decreased 
expression of Polarin and Vps33b on cell proliferation was analysed.  In agreement with other 
studies that investigated reduced E-Cadherin expression [178], the number of cells detached 
from transwell supports after 7 days in culture was significantly increased in Polarin- and 
Vps33-shRNA cells (p<0.05 by Student’s t-test ; Figure 5.14).  
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Figure 5.12 – Immunostaining of ARC syndrome patient liver biopsies for E-Cadherin. 
Control and ARC syndrome patient liver tissue stained for E-Cadherin (brown staining).  
Expression of E-Cadherin is greatly reduced in the ARC syndrome patients biopsies 
compared to the control biopsy. The remaining E-Cadherin present in the patients’ biopsies is 
also mislocalised to a predominant cytoplasmic localisation, compared to a basolateral 
localisation in the control sample. A 200x original magnification was used for each, and the 
specimens were counterstained with haematoxylin.  (Experiment carried out by A Straatman 
Iwanowska, University of Birmingham, UK.) 
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Figure 5.13 – Abnormal cell growth of Polarin- and Vps33b-shRNA cells. 
A, Control-, Polarin- and Vps33b-shRNA cells grown on Transwell supports were stained for 
-actin with phalloidin-TRITC conjugate (scale bar = 100 m).  Cavitations (arrow) are 
present only in control cells. B, mIMCD-3 cells growing in collagen gels (10x magnification).  
Control-shRNA cells form highly branched tubules after 3 days in culture, whereas Polarin- 
and Vps33b-shRNA cells form no tubules. 
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Figure 5.14 – Abnormal cell proliferation in Polarin-, and Vps33b-shRNA cells 
Values shown are mean number of cells detached, using trypsin, from Transwell supports 
after 7 days in culture (3 experiments, error bar = ± 1 standard error of the mean, * = 
p<0.05 by Student’s t-test). (Experiment carried out in collaboration with A Straatman 
Iwanowska, University of Birmingham, UK.) 
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5.4 – Discussion 
 
Abnormal localisation of AJC proteins such as E-Cadherin in Polarin- and Vps33b-shRNA 
cell lines, like mislocalisation of specific proteins in patient liver biopsy specimens (see 
below), suggests a disturbance in a Rab11a/Rab4a-dependent trafficking pathway as the major 
cellular defect in ARC syndrome.  Rab11a-expressing AREs may indeed be involved in E-
Cadherin trafficking as well as in trafficking of some apical ATP-binding-cassette transporters 
[97;175;179].  Whilst Rab11a predominantly localised in proximity to the apical membrane in 
control cells, it was distributed throughout the cytoplasm in Polarin- and Vps33b-shRNA 
treated mIMCD-3 cells (Figure 5.3).  This suggests that the Polarin-Vps33b complex may be 
involved in directing AREs towards apical membranes, although this finding may be 
secondary to the generalized loss of polarity in the knockdown cell lines. 
 
Previously, mislocalisation of apical membrane proteins was demonstrated in kidney- and 
liver-biopsy specimens from patients with ARC syndrome harbouring VPS33B mutations 
[1;11].  Similarly, mislocalisation of apical membrane proteins in ARC syndrome patients 
harbouring PLRN mutations were identified.  Furthermore, differences in the immunostaining 
of two apical membrane transporters were detected.  BSEP, which is a major hepatocyte bile 
salt transporter, was mislocalised in the ARC syndrome patients’ livers, whereas another 
apical membrane transporter, MRP2, was correctly localised (immunostaining performed by 
AS Knisely, King's College Hospital, London, UK; images shown in Appendix 4 for 
completeness).  This difference is consistent with the suggestion that MRP2 and BSEP are 
trafficked to the apical membranes via different intracellular routes [180].  BSEP is trafficked 
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to the apical membrane through Rab11a-positive AREs whereas MRP2 is trafficked to the 
basolateral membrane first before being transcytosed to the apical membrane [180].   
Cultured mIMCD-3 cells with decreased expression of Polarin or Vps33b demonstrated 
abnormal formation of the apical membrane and of AJCs.  Moreover, Polarin- and Vps33b-
deficient cell lines failed to polarise as evidenced by reduced TER measurements and by 
failure of tubule formation in culture.  Functional investigations of Polarin and Vps33b in an 
epithelial cell line suggest that they work synergistically in the trafficking of proteins to the 
apical membrane and in AJC formation.  The requirement of Polarin for Vps33b function and 
stabilisation is supported by the finding that Vps33b expression and distribution changed in 
cells with Polarin knockdown. 
 
Immunoblotting of TJ proteins in Polarin- and Vps33b-shRNA cells revealed a decrease in 
expression of Claudin-1 and an increase in ZO-1 expression.  An equivalent result was seen 
when bile ducts were artificially ligated to mimic the effect of cholestasis, as seen in ARC 
syndrome [181].  Claudins are the key member of the tight junction complex that regulate the 
paracellular permeability, and each one of the 24 members, of which Claudin-1 is expressed 
in kidney IMCD cells, has a different expression and permeability pattern [102;182].  The TJ 
protein ZO-1, localises correctly in control and knockdown cells, giving a characteristic 
cobble stone image in the xy plane and correct localisation in the xz plane.  However, the 
remaining Claudin-1 appears to lose its specific localisation and was present in all plasma 
membranes in both knockdown cell lines. Claudin-1 is a transmembrane protein, whereas ZO-
1 is a cytoplamsic protein that associates with the actin cytoskeleton.  This coupled with the 
mislocalisation of apical membrane proteins gives a possible explanation for the difference in 
localisation of ZO-1 and Claudin-1. 
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Inactivating mutations in CLDN1, encoding Claudin-1, were found in patients with neonatal 
sclerosing cholangitis associated with ichthyosis syndrome (NISCH; MIM607626), a 
syndromic form of cholestasis associated with ichthyosis, two obligate features of ARC 
syndrome [1;183].  Although NISCH patients survive into adulthood, Cldn1 knockout mice 
die on the first day of life with dehydration due to defective skin barrier function [184].  Thus 
the similarities between the phenotypic features of the two human disorders further support 
the hypothesis that the defect in AJC formation is a major pathological feature in ARC. 
 
The Polarin- and Vps33b-shRNA cells when grown on transwell supports grow on top of each 
other and became much shorter, suggesting they have lost their contact inhibition 
characteristic of epithelial cells.  This was never seen in the Control-shRNA treated cells.  
This effect is usually seen due to epithelial-to-mesenchymal transition (EMT) and is normally 
brought about by either reduced expression or altered localisation of E-Cadherin [178;185], as 
seen in ARC syndrome patient liver biopsies and in the Polarin- and Vps33b-shRNA cells.  
Thus suggesting that an EMT could be occurring in ARC syndrome patients polarised 
epithelial cells. 
 
Similar results on E-Cadherin and Claudin-1 expression as presented here were recently seen 
in vascular endothelial cells, where knockdown of VE-Cadherin leads to a decreased 
expression of Claudin-5 due to the effects of both -catenin and FOXO1 transcription factors 
and repressors [99].  The remaining E-Cadherin in both the knockdown cell lines and in ARC 
syndrome patient liver biopsies is unlikely to be dimerised due to lack of membrane 
localisation, and therefore unable to bind and hold -Catenin in the cytoplasm.  -catenin is 
believed to be the molecular switch between proliferation and polarisation in epithelial cells, 
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mediated by adherens junction formation leading to a characteristic contact inhibition [185]. 
Immunoblotting of -catenin in knockdown cells showed no change in the level of expression 
(Figure 5.10).  Therefore the lack of functional E-Cadherin is likely to cause the down-
regulation of Claudin-1 through the action of -catenin in the nucleus.  Consistent with the 
EMT effect, there was a significant increase in the number of Polarin- and Vps33b-shRNA 
cells detached from transwell supports, coupled with a dramatic decrease in polarisation in 
these cells. 
 
The data presented in this chapter advances the knowledge of the molecular pathways 
determining cell polarity and provides new evidence on the role of intracellular trafficking 
proteins in formation of functional AJCs and in epithelial polarisation.  Furthermore, the 
fundamental defects in growth and differentiation of epithelial tissues observed in ARC and in 
Polarin and Vps33b deficient epithelial cell lines emphasise the importance of the 
Vps33b/Polarin pathway for organ development and function. 
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CHAPTER 6 – USE OF MORPHOLINOS 
AGAINST PLRN IN ZEBRAFISH EMBRYOS 
MIMICS THE ARC SYNDROME LIVER 
DISEASE  
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6.1 – Introduction and Overview 
 
6.1.1 – Zebrafish as a Model Organism 
 
The zebrafish, Danio rerio, is a tropical freshwater fish that is native to the streams of the 
south-eastern Himalayan region.  The zebrafish gets its’ name from the five uniform, 
pigmented, horizontal blue stripes on the side of the body, all of which extend to the end of 
the caudal fin.  Male fish have gold stripes between the blue stripes, whereas the females have 
silver stripes instead of gold.  The approximate generation time for the zebrafish is 3 to 4 
months.  Adult fish rarely grow larger than 4 cm in length in captivity and on average 
zebrafish live for 2 to 3 years, with a maximum of around 5 years [186].   
 
For the ovulation and spawning of eggs from the female to occur there must be a male present 
[187].  Females are able to lay eggs as often as every 2 to 3 days with hundreds of eggs being 
laid in each clutch [186].  Upon release from the female, the first developmental steps will 
begin; however without the presence of sperm, growth will stop after the first few embryonic 
cleavages.  Once fertilised, the embryos develop rapidly with precursors to all major organs 
appearing within 36 hours post fertilisation (hpf), and hatching will occur between 48 to 72 
hpf [188]. 
 
Pioneering work by George Streisinger and his colleagues which began over 40 years ago at 
the University of Oregon established the zebrafish as a model organism for biomedical 
research [188].  The zebrafish is a common and useful model organism for studies of 
vertebrate development and gene function, and may supplement higher vertebrate models, 
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such as rats and mice.  Although the overall generation time of zebrafish is comparable to that 
of mice, zebrafish embryos develop rapidly, progressing from eggs to larvae in less than three 
days [186].  The zebrafish model has other advantages over higher vertebrate models, notably 
that the embryos are large, robust, transparent and develop externally to the mother; 
characteristics which all facilitate experimental manipulation and observation [186]. 
 
A vast majority of the genetic code for the zebrafish has been completed, which further 
facilitates the use of this animal as a model organism.  A common and useful reverse 
genetics technique is used to reduce gene expression or modify splicing in zebrafish 
using Morpholino antisense technology [186;188].  Morpholino Oligonucleotides (MOs) are 
stable, synthetic macromolecules that contain the same nucleotide bases as DNA, and by 
binding to complementary RNA sequences, reduce the expression of specific genes.  MOs are 
directly injected into one cell of a zebrafish embryo producing an organism in which gene 
expression is reduced [186].  However there are known common problems with MOs, 
including off target effects and their occasional inability to knockdown the gene.  The latter 
problem is due to a genome duplication in the zebrafish, and reducing the expression of one 
gene can lead to the compensation of the other paralogue causing no noticeable phenotype 
[186].  Nevertheless, with careful controls and screening of the zebrafish genome for these 
paralogue genes the zebrafish can be a very useful model for biomedical research. 
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6.1.2 – ARC Syndrome Zebrafish Model Using vps33b 
 
Following the identification of mutations in VPS33B in the majority of ARC syndrome 
patients [1;2], Matthews et al. in 2005 investigated the expression pattern of vps33b in 
zebrafish embryos and larvae [189].  The group also examined the effect of knocking down 
vps33b on zebrafish development, and established that vps33b functions downstream of the 
onecut transcription factor htf6 [189].  Further details of the results from this study will be 
presented in the following sections 
 
6.1.2.1 – Expression Pattern of vps33b 
 
Staged in-situ hybridisation in embryonic and larval zebrafish revealed a ubiquitous and 
widespread expression pattern of vps33b at the sphere stage (4 hpf) up until 24 hpf (Figure 
6.1A to C).  At 48 hpf, vps33b expression localised to the brain, retina, ear, liver and proximal 
intestine (Figure 6.1D).  This expression pattern was more pronounced at 72 hpf (Fig 6.1E) 
and remained detectable through to 5 dpf (not shown).  On closer examination of 3 dpf (not 
shown) and 4 dpf (Figure 6.1F) larvae revealed a reticular pattern of vps33b expression in the 
liver in contrast to the ubiquitous expression pattern of the hepatocyte gene ceruloplasmin.  
This suggested the possibility that vps33b is predominantly expressed in the developing 
biliary epithelial cells. Neither kidney nor spinal cord expression was evident in the 
wholemount specimens at any stage analysed. 
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Figure 6.1 – In-situ hybridisation of vps33b in zebrafish embryos and larvae. 
Wholemount RNA in-situ hybridisation of A, spherical stage, B, 10 somites and C, 24 hpf 
show diffuse vps33b expression. D, vps33b expression at 48 hpf is evident in the developing 
liver (black arrow) and proximal intestine (blue arrow).  E, Lateral view of a 72 hpf larva 
showing vps33b expression in the liver (black arrow) and proximal intestine (blue arrow).  
Weak pancreas staining (white arrow) is also evident.  High power lateral views of 4 dpf 
larvae processed for F, vps33b and G, cerruloplasmin whole-mount RNA in-situ 
hybridisation.  F, Liver (black arrow) demonstrates a reticular pattern of vps33b expression 
compared with G, a homogenous pattern of cerruloplasmin expression.  Intestinal vps33b 
expression is also evident (blue arrow, F). [Adapted from189] 
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6.1.2.2 – Effect of vps33b Knockdown on Zebrafish Development 
 
Knockdown of vps33b using an ATG and 2 splice site MOs did not affect the overall 
appearance or liver size of larvae at 5 dpf (Figure 6.2A and B). However, gallbladder 
fluorescence following ingestion of the quenched fluorescent lipid, PED-6, was reduced in 
vps33b MO injected larvae (Figure 6.2C and D).  Transport of this compound to the 
gallbladder can serve as an indicator of biliary secretion [190], biliary morphology [191] and 
intestinal lipid absorption [189].  
 
Immunohistochemistry of Cytokeratin-18, a specific marker of the cholangiocytes, on 5 dpf 
morpholino injected larvae strongly suggest that altered biliary development contributed to 
the defects of PED-6 processing (Figure 6.2E-G).  More precisely the number of intrahepatic 
bile ducts was reduced compared with control, whereas the extrahepatic biliary tree appeared 
normal in all of the morpholino-injected larvae.   Within the intrahepatic biliary system, 
defects of the interconnecting and terminal ducts were most pronounced (Figure 6.2H-J) 
[189].  Ultrastructural analysis revealed cell type specific defects in vps33b deficient 
zebrafish. In the liver, cytoplasmic vesicles were present within vps33b deficient biliary 
epithelial cells, whereas they were absent in the biliary cells of control larvae (Figure 6.3A 
and B) [189].  
 
In contrast to the biliary defects present in the vps33b-deficient larvae, neither renal nor motor 
axon defects were identified.  Normal renal tubular epithelial cell morphology was confirmed 
histologically and using ultrastructural analyses. Thus, no evidence was given to show that 
vps33b knockdown in zebrafish phenocopies the motor axon and renal defects associated with 
ARC [189]. 
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Figure 6.2 – vps33b knockdown disrupts zebrafish intrahepatic biliary development. 
A and B, Left lateral views of A, wild-type and B, vps33b morpholino-injected 5 dpf larvae.  
Liver size (black arrowheads) is comparable in these larvae.  C and D, Right lateral 
fluorescent images of C, wild-type and D, vps33b morpholino injected 6 dpf larvae following 
ingestion of the PED-6 lipid reporter.  Gallbladder fluorescence (white arrow) is decreased 
in D, morpholino-injected larva relative to C, wild-type larva (i - intestinal fluorescence; y - 
endogenous yolk fluorescence).  E, F and G, Confocal projections through the liver of E, 
wild-type and F and G, vps33b 5 dpf larvae processed for keratin 18 immunohistochemistry. 
There are fewer bile ducts in F than in E; ducts are sparse, with fewer interconnecting ducts 
and terminal ductules.  H, I and J, Coloured schematics of bile ducts from E, F and G.  Long 
ducts depicted in blue, interconnecting ducts in green and terminal ductules in red. [189] 
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Figure 6.3 – vps33b knockdown disrupts the ultrastructure of biliary epithelial cells. 
A and B, Electron micrographs of biliary epithelial cells from A, wild-type and B, vps33b 
morpholino injected 5 dpf larvae.  A, The wild-type biliary cell cytoplasm has a homogeneous 
appearance.  B, A small bile duct comprising two bile duct cells from a vps33b morpholino-
injected larva. Cytoplasm appears heterogeneously with multiple vesicles (black arrows).  
hep - hepatocyte; bd - bile duct lumen and bdc - bile duct cell. [189] 
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6.2 – Aims 
 
The data presented in chapter 4 shows that VPS33B interacts with a novel protein, POLARIN 
and that pathogenic mutations can be identified in the PLRN in ARC syndrome patients 
without VPS33B mutations.  The cell culture experiments described in chapter 5 implicated 
VPS33B and POLARIN in epithelial cell differentiation and function.  Previously, in an 
animal model, it was found that MO knockdown of the zebrafish vps33b orthologue resulted 
in abnormal development of the biliary tract [189].   
 
Based on the indistinguishable phenotype of ARC syndrome patients who have mutations in 
either VPS33B or POLARIN and the cell culture experiments shown in chapter 5, we 
hypothesise that polarin will function in the same way as vps33b in zebrafish development.  
To test this hypothesis, RNA in-situ hybridisation was carried out on zebrafish embryos and 
larvae to identify where and when polarin is being expressed. Furthermore MO knockdown of 
polarin in the developing zebrafish was also carried out to identify the effect of reduced 
expression of polarin in a whole organism. 
 
6.3 – Results 
 
The results of experiments presented in the following chapters was supervised by F. Mueller, 
and all MO injections were carried out A. Zaucker (both University of Birmingham, UK) 
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6.3.1 – Expression Pattern of polarin 
 
A full length sense and anti-sense digoxigenin (DIG) labelled RNA probes for plrn was 
transcribed from the pCS2+ vector containing the zebrafish plrn orthologue (si:ch211-
20b12.1).  Staged in-situ hybridisation of plrn revealed a ubiquitous pattern of expression in 
24 hpf embryos (Figure 6.4A) and weak but discrete staining in 5 dpf larvae in the brain, 
retina, ear, liver and proximal intestine (Figure 6.4B).  The sense probe was used to assess 
overall specificity of the anti-sense probe, and due to the weak expression of plrn have been 
included in Figure 6.4A and B.  Neither kidney nor spinal cord expression was evident in the 
wholemount embryos or larvae at any stage analysed.  Histological sections of 5 dpf larvae 
revealed a reticular pattern of expression in the liver (Figure 6.4C and D).  The expression 
pattern of plrn is comparable to that observed for vps33b by Matthews et al. [189]. 
 
6.3.2 – Effect of polarin Knockdown in Zebrafish 
 
MOs were designed against the zebrafish PLRN orthologue (si:ch211-20b12.1) with the 
intention to reduce the expression of plrn in developing embryos and larvae.  A MO was 
designed to target the sequence corresponding to 25 base pairs upstream of the start (ATG) 
codon to prevent translation and another MO to affect the splicing of exon 3 in the plrn 
transcript.  A mis-match MO which differed in 5 nucleotides from the exon 3 splice site MO 
was purchased, to serve as a specificity control.  The concentration of each MO injected into 
the zebrafish embryos was determined empirically so that either the same concentration of the 
mis-match MO did not give an observable phenotype (exon 3 MO) or that wild-type plrn 
mRNA could rescue the phenotype (ATG MO). 
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Figure 6.4 – In-situ hybridisation of plrn in zebrafish embryos and larvae. 
A, Lateral view of 24 hpf embryos and B, Lateral and ventral views of 5 (dpf) larvae after in-
situ hybridisation using DIG-labelled antisense and sense (control) plrn RNA probes. High 
expression in liver (black arrows) and small intestine (blue arrows) is seen for plrn compared 
with controls.  C and D, Histological transverse sections of 5 dpf larvae processed for plrn 
whole-mount RNA in-situ hybridisation (A, B and C scale bars =200m).  D, Enlarged 
section shown in white rectangle in C reveals a reticular pattern of plrn expression in the 
liver (red arrow heads, scale bar – 20 m) 
Liver 
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Knockdown of plrn in zebrafish embryos by either the ATG or exon 3 MO did not give an 
easily detectable morphological phenotype up to 5 dpf (Figure 6.5).  However, when MO 
injected 4.5 dpf larvae were incubated with the fluorescent compound PED-6 overnight and 
visualised at 5 dpf, a significant dose-dependent reduction in gallbladder size, compared with 
controls, was detected (Figure 6.6).  The quenched PED-6 molecule is fed to the zebrafish 
larvae which they ingest and absorb.  In the liver, the molecule is cleaved by phospho-lipase 
A2 (PLA2), which removes the quench, allowing the green fluorescence of the PED-6 
molecule to be detected in the gall bladder and in the gut [190].  Compared to non-injected 
controls, ATG and Exon 3 MO injected larvae had an observable decrease in gall bladder size.  
Quantification of the gall bladder size revealed a significant decrease to a size less than 31% 
of the non-injected controls (Figure 6.7, 3 separate injections of n=30, p<0.001 by Z-test, raw 
data shown in Appendix 5).  Gall bladder area in one focal plane containing the gall bladder 
was assessed as described in section 2.2.7.3.  This phenotype was not detected in the mis-
match control or mRNA rescued larvae.  The decrease in gallbladder size and fluorescence 
after ingestion of the quenched PED-6, in the plrn MO injected larvae, coupled with the 
normal morphology and size of the liver suggests a defect in biliary secretion and morphology 
[190].  Similar to vps33b knockdown in the zebrafish, plrn knockdown seems to cause defects 
in biliary development and function. 
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Figure 6.5 – Knockdown of plrn in the zebrafish does not cause any morphological 
abnormalities detectable by light microscopy. 
Brightfield images of 5 dpf non-injected, ATG, Exon 3 and Exon 3 mismatch MO injected 
larvae.  No obvious morphological abnormalities and no change in liver size (outlined in red) 
are observed in these larvae.  Orientation of larvae is anterior to the left.  Scale bar = 150 
m. MO injections carried out by A. Zaucker, University of Birmingham, UK. 
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Figure 6.6 – plrn deficiency causes a decreased gall bladder size. 
Brightfield and green fluorescence images of PED-6 treated non-injected and plrn ATG MO-
injected 5-dpf embryos.  Gall bladder size is reduced in plrn ATG MO injected larvae 
compared to non-injected control larvae (white arrows).  Orientation of larvae is anterior to 
the right.  Scale bar = 200 m.  Abbreviations; N – Notochord, SB – Swim Bladder, and  
G - gut.  MO injections carried out by A. Zaucker, University of Birmingham, UK. 
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Figure 6.7 – Quantification of gall bladder size in plrn deficient zebrafish larvae. 
Gallbladder size is significantly reduced in ATG and exon 3 MO-injected larvae compared to non-injected control larvae and to exon 3 
mis-match control larvae.  Injecting plrn mRNA after MO treatment rescued the phenotype.  Value shown is average size relative to non-
injected control.  Errors bars = ± 1 standard deviation (n= 3 experiments with 30 larvae in each group, p<0.001 by Z-test).  MO injections 
carried out by A. Zaucker, University of Birmingham, UK.
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The data presented in chapter 5 identified the role of both Vps33b and Polarin in apical 
junction complex formation in polarised epithelial cells.  In both the cell culture experiments 
and ARC syndrome patient’s liver biopsies, reduced expression of Vps33b or Polarin lead to a 
pronounced defect in e-cadherin expression and its’ reduced presence in the lateral membrane.  
To test this result in the zebrafish with reduced expression of polarin, transverse sections of 5 
dpf liver were taken and immunostained for e-cadherin.  This revealed a significant and 
striking reduction in e-cadherin expression in all the polarin deficient (ATG and exon 3 MO) 
larvae inspected (p=0.02 by two-tailed Fisher’s Exact test, n=6 for each treatment group, 
Figure 6.8). 
 
6.4 – Discussion 
 
The expression pattern of polarin corresponded to that of vps33b (Figures 6.1 and 6.4) [189], 
which is consistent with the synergistic action of the two proteins suggested in both chapters 4 
and 5.  Detailed analysis of the in-situ hybridisation in 5 dpf larvae showed a relatively strong 
reticular pattern of expression of polarin in the zebrafish liver.  This is again consistent with 
the pattern of expression seen with vps33b, and suggests a function of both vps33b and 
polarin in the development of the biliary system in developing zebrafish embryos and larvae. 
 
Morpholino knockdown of the zebrafish POLARIN orthologue led to a reduced gallbladder 
size, as evidenced by decreased PED-6 accumulation (Figure 6.6 and 6.7), thus indicating that 
polarin is active during zebrafish biliary development.  Knockdown of vps33b is also seen to 
effect late stages of biliary development in zebrafish larvae, as reflected in the reduction of 
interconnecting and terminal ducts (Figures 6.2).   
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Figure 6.8 – Immunofluorescence confocal micrographs of e-cadherin in sections of 5 dpf 
larvae livers. 
Staining of e-cadherin in 2 m optical sections of 18 m transverse sections of livers from 
non-injected, plrn exon 3, exon 3 mismatch control and ATG MO injected 5 dpf larvae. Scale 
bar = 10 m.  The same excitation and collection settings were used throughout.  In the 
control livers there is strong e-cadherin expression and correct localisation, in contrast to the 
plrn deficient larvae, which have markedly reduced expression (p=0.02 by two-tailed Fisher’s 
Exact test, n=6 for each treatment group).  MO injections carried out by A. Zaucker, 
University of Birmingham, UK. 
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ARC syndrome is one of several heritable disorders that present with cholestasis in infancy, 
and bile duct paucity in liver biopsies of children with ARC suggests that cholestasis in this 
syndrome may arise from a primary defect of biliary development [192].  The mechanism of 
the biliary tract malformation may be explained by the reduction of bile flow due to the 
mislocalisation of the apical membrane proteins in hepatocytes, such as BSEP in ARC 
syndrome patients [11].  This reduction in bile flow in turn causes a reduction in size and 
apparent number of bile duct radicals, as seen in ARC and some other cholestatic disorders 
[193].   
 
Consistent with the defects with apical junctional complex formation in both cell-culture 
experiments and ARC syndrome patient liver biopsies presented in chapter 5, there was a 
striking reduction of e-cadherin expression in livers from 5 dpf larvae (Figure 6.8).  Thus, 
polarin MO knockdown in the zebrafish mimics a biochemical feature identified in ARC 
syndrome and further confirms the cell line results in chapter 5. 
 
Two other major features of ARC syndrome are neurogenic arthrogryposis and renal tubular 
defect.  Neither vps33b  [189] nor polarin expression could be detected in the any part of the 
nervous system or the kidney.  Furthermore, no easily detectable renal or CNS morphological 
abnormalities were observed in both vps33b and polarin MO injected embryos and larvae 
(Figure 6.5).  However, further characterisation of the kidney function could not be carried 
out due to the lack of suitable markers for functional assays.  A potential explanation for the 
lack of phenotype in these tissues may be due to either an unidentified polarin paralogue, 
which fulfils these functions in the zebrafish, or a non-conserved role for polarin in nervous 
system and kidney development. 
201 
Nevertheless, the results presented in this chapter confirmed the importance of polarin, as 
well as of vps33b orthologues, as proteins active in zebrafish biliary-tract development.  Thus, 
zebrafish models have been created using both vps33b [189] and polarin that mimic some 
ARC syndrome phenotypes and biochemical abnormalities.  Furthermore these models are 
suitable for further investigations of liver and biliary development and studies of cholestatic 
diseases. 
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CHAPTER 7 – DISCUSSION 
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7.1 – VPS33B Interacts with a Novel Protein POLARIN 
 
The mammalian HOPS complex, including VPS33A, was recently found to be involved in a 
Rab5-Rab7 dependent pathway of phagosome biogenesis during apoptosis [79].  The 
CORVET complex can also be formed by class C VPS proteins in yeast [84].  Unlike other 
SM proteins, VPS33 homologues require additional proteins to interact with SNARE 
complexes.  In keeping with this idea a conserved novel protein, POLARIN, was identified.  
It was noted that POLARIN possesses 16% identity to the C-terminal domain of the HOPS 
complex member VPS16.  A POLARIN orthologue has been identified in D. melanogaster, 
which was shown to interact with the Vps33b drosophila orthologue [194].  Although the 
results of experiments presented in this thesis suggest that VPS33B and POLARIN are 
unlikely to form an active part in the conventional HOPS complex function, subunits of this 
complex were shown co-immunoprecipitate with the epitope tagged POLARIN.  Thus a novel 
complex containing POLARIN and VPS33B proteins may interact with VPS11, VPS18, 
VPS39 and VPS41. 
 
Furthermore, neither endogenous VPS33B nor co-overexpressed VPS33B and POLARIN 
clusters significantly co-localised with Rab5, LAMP-1 and CD63, markers of early 
endosomes, late endosomes and lysosomes respectively.  These organelles are the sites of 
action of the conventional HOPS and CORVET complexes [74;84], suggesting another 
function for the newly identified VPS33B-POLARIN complex.  In light of the data presented 
here, it is likely that the VPS33B-POLARIN complex is associated with the Rab4-Rab11 
intracellular trafficking pathway in polarised epithelial cells.  
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Recently, Zhu et al. identified the C. elegans orthologue of human C14orf133, which they 
named hSpe39 and demonstrated that it interacts with Vps33b [195].  Although C. elegans 
Spe-39 mutants were initially identified as having abnormal vesicular biogenesis during 
spermatogenesis, the group also showed that these mutants also have disrupted processing of 
endocytosed proteins in oocytes [195].  In contrast to the data presented in this thesis, they 
suggest that both VPS33A and VPS33B interact with hSpe-39.  Interestingly, MO knockdown 
of Vps33a in C. elegans did not mimic the phenotype of hSp3-39 mutants whereas Vps33b 
did [195].  On the other hand, and consistent with the data presented here, the group also 
showed that Vps33b and hSpe-39 interact with other HOPS complex subunits, and partially 
co-localise with Rab11a [195].   
 
7.2 – Deficiencies of VPS33B or POLARIN in Development and Disease. 
 
Mutations in VPS33B can be identified in around 75% of ARC syndrome patients [1;4].  
However, reduced expression of VPS33B at the RNA and protein level could be detected in 
all ARC syndrome patients with or without detectable VPS33B mutations that could be 
identified by conventional di-deoxy sequencing.  The discovery of pathogenic mutations in 
the gene encoding POLARIN (PLRN) in ARC syndrome patients from different ethnic 
backgrounds provides further insight into the pathophysiology of human diseases.  Reduced 
expression of VPS33B could be detected in patients with PLRN mutations, suggesting that 
POLARIN is required for the stabilisation of VPS33B.  Consistent with the idea that VPS33A 
functions in a different complex and pathway to that of VPS33B and POLARIN, as evidenced 
by the data presented in chapter 4, there was no compensatory up-regulation of VPS33A in 
ARC syndrome patient fibroblasts with reduced expression of VPS33B. 
205 
Mislocalisation of apical membrane proteins previously was demonstrated in kidney and liver 
biopsy specimens from patients with ARC syndrome harbouring VPS33B mutations [1;11]. 
Similar mislocalisation of apical membrane proteins in patients with PLRN mutations have 
now been identified.  Furthermore, mislocalisation of BSEP, a major hepatocyte bile salt 
transporter, was detected in the ARC syndrome patients’ livers.  This is consistent with the 
suggestion that BSEP is trafficked to the apical membrane via a Rab11a pathway, since 
knockdown of either Rab11a or Myosin Vb in WIF-B9 cells, a polarised hepatic cell line, 
caused the mislocalisation of BSEP [180].   
 
Cultured mIMCD-3 cells with decreased expression of Polarin or Vps33b demonstrated 
abnormal formation of the apical membrane and of AJCs.  Interestingly, some apical and 
basolateral membrane proteins are correctly localised in ARC syndrome patient liver biopsies 
and the knockdown cell lines, despite the absence of functional AJCs.  This result goes 
against the central dogma of epithelial cell biology, where TJs are required for the continued 
separation of apical and basolateral plasma membrane domains, by preventing the inter-
mixing of membrane protein pools [88].  However, work by Umeda et al. in 2006 showed that 
reduced expression of either ZO-1 or ZO-2 in an epithelial cell line did not cause the 
dimerisation of Claudins in the membrane, since ZO-1 and -2 are required to catalyse the 
dimerisation of Claudins [103].  Furthermore, and despite the absence of functional TJs, these 
cells retained their separate apical and basolateral membrane domains [103].  Thus these data 
show that the processes of epithelial apical-basolateral polarity formation and maintenance are 
not completely understood.   
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Furthermore, in the Vps33b and Polarin knockdown mIMCD-3 cell lines, there was a 
reduction in overall expression of CEA, an apical membrane marker, suggesting a possibility 
of intracellular CEA degradation.  A similar marked reduction in protein expression was 
observed for E-Cadherin.  Moreover, Polarin- and Vps33b-deficient cell lines failed to 
polarise, as evidenced by reduced TER measurements and by failure of tubule formation in 
culture.  Functional investigations of Vps33b and Polarin suggest that they work 
synergistically in the trafficking of proteins to apical membrane and formation of AJCs.  The 
requirement of Polarin for Vps33b function is supported by the finding that Vps33b 
expression was reduced in patients’ fibroblasts and in cells with Polarin knockdown.  
 
Morpholino knockdown of the zebrafish POLARIN orthologue led to deficient biliary-tract 
formation, indicating that polarin is active during zebrafish development.  Expression of 
polarin corresponded to that of vps33b, which is consistent with the synergistic action of the 
two proteins.  The mechanism of the biliary-tract malformation may be explained by reduced 
bile flow causing reduced size and apparent number of bile duct radicles, as seen in ARC and 
some other cholestatic disorders [193].  Furthermore a reduced expression of E-Cadherin was 
detected in the livers of polarin deficient larvae, similar to that observed in the ARC 
syndrome patient liver biopsies and the cell culture experiments.  Thus zebrafish models have 
been created that are very suitable for further investigations of liver development and disease.   
 
The ultrastructural findings observed in the vps33b ARC syndrome zebrafish model are 
similar to those found in zebrafish with spontaneous mutations of the yeast class C complex 
genes Vps11 and Vps18 [7;196].  This suggests that the bile duct paucity may arise 
autonomously in ARC syndrome patients from a defect in vesicle sorting.  The accumulation 
207 
of intracellular organelles are observed in ARC syndrome patients’ fibroblasts and 
hepatocytes (lipofuscin granules) and in the livers of the vps33b deficient zebrafish 
[148;149;189].  Thus further suggesting a membrane biogenesis defect in the pathophysiology 
of ARC syndrome 
 
Interestingly, mutation of vps18 or vps39 in the zebrafish and vps11 in medaka causes 
cutaneous hypopigmentation, hepatocyte defects and bile duct paucity, but neither motor 
neurone nor kidney defects [172;197-200].   The buff mouse, which has a mutation in Vps33a, 
has hypopigmentation as a cardinal feature, and mutation of VPS33B in humans and 
knockdown in the zebrafish causes hepatocyte defects with bile duct paucity [1;82;189].  The 
partially overlapping phenotypes of vps11-, vps18-, vps33b- and vps39-deficient larvae 
support the idea that in multi-cellular organisms the conventional HOPS complex (VPS33A 
and VPS16) functions alongside the newly identified VPS33B-POLARIN complex which 
utilises proteins form the conventional complex.  Thus if a member of both complexes, such 
as VPS11, VPS18, VPS39 or VPS41 is mutated or the expression reduced, a phenotype 
resulting from he deficiency of both complexes is observed. 
 
Analysis of the developmental expression of VPS33B in human and mouse foetal tissues 
revealed an upregulation in the human kidney between 11 and 16 weeks gestation and strong 
expression at 14.5 days in the mouse.  At this point in kidney development tubules form and 
thus there is a requirement for polarised tissues [150;151].  Interestingly, knockout of Vps33b 
or Polarin in mIMCD-3 cells reduced polarisation and tubule formation.  Furthermore, defects 
in liver development are observed in zebrafish in which vps33b or polarin are knocked down. 
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Taken together, this data demonstrates that VPS33B and POLARIN are critical in the 
formation of tubular structures such as kidney tubules and biliary ducts. 
 
7.3 – VPS33B and POLARIN Function Through a Rab4-Rab11 Pathway 
 
POLARIN contains a Golgin A5 domain which may be crucial for the interaction of the 
VPS33B-POLARIN complex with GTP bound Rab11a, similar to the Golgin domain 
containing SCYL1BP1, which interacts with GTP bound Rab6 [169].  The co-localisation and 
co-immunoprecipitation of VPS33B along with POLARIN and Rab11a at both the over 
expressed and endogenous level, suggests that this maybe the case.  This suggests a common 
mechanism of action for Golgin domain-containing proteins.  Furthermore, mislocalisation of 
Rab11a was seen in Vps33b and Polarin knockdown mIMCD-3 cells.  The VPS33B-
POLARIN complex appears to specifically interact with the GTP bound form of Rab11a, 
suggesting that the newly identified complex may have Rab effector properties, and might 
facilitate specific SNARE-mediated membrane fusion events in the transport of Rab11a-
positive vesicles.   Consistent with this idea, mIMCD-3 cells stably transfected with the GDP 
locked dominant negative Rab11a mimicked some of the phenotype observed in the Vps33b 
and Polarin deficient cell lines (Figure 5.9). 
 
As VPS33B/POLARIN clusters co-localised with Rab11a and also with Rab4, which is 
present on endosomes which become Rab11a-positive, one could speculate that the VPS33B-
POLARIN complex may function in the maturation or Rab4 early endosomes to Rab11a 
recycling endosomes, similar to the conventional HOPS complex function of Rab5 to Rab7 
conversion on early to late endosomes [74].  However, further experiments are needed to be 
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carried out to test this hypothesis and which were not possible within the time limits of this 
project. 
 
In concordance with VPS33B and POLARIN functioning through a Rab11a pathway, there is 
mislocalisation of apical membrane proteins known to require Rab11a for their correct 
trafficking to the apical membrane.  This is observed in both the ARC syndrome patients’ 
kidney and liver biopsies and the cell culture experiments presented in chapter 5.  BSEP is 
mislocalised in ARC syndrome patients’ liver biopsies, whereas a homologue, MRP2, is 
correctly localised to the apical membrane.  It is known that BSEP is stored in Rab11a 
positive endosomes until required on the canalicular membrane, whereas MRP2 is trafficked 
to the apical membrane through a transcytotic route [179].  Consistent with the data presented 
in chapter 5, Desclozeaux et al. observed that functioning Rab11a is required for the correct 
localisation of E-Cadherin to the lateral membrane and the subsequent cyst formation of 
MDCK cells [175], a process analogous to tubule formation in mIMCD-3 cells.   
 
The Rab11a pathway and its’ interacting protein Myosin Vb has recently been shown to be 
important in such diverse cellular functions as brain postsynaptic plasticity and small 
intestinal absorption [201;202].  Inactivation of human CDH1 (encoding E-Cadherin) is 
strongly associated with epithelial to mesenchymal transformation (EMT), tumourigenesis, 
and increased cancer invasiveness [185;203;204].  Interestingly, there is a clear lack of 
polarisation of the Vps33b and Polarin deficient mIMCD-3 cells, coupled with an increase in 
proliferation, suggesting that an EMT might be taking place. 
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7.4 – Conclusions 
 
The gene encoding a novel protein, POLARIN (PLRN) that interacts with VPS33B is mutated 
in a subset of around 25% of ARC syndrome patients.  There is no obvious difference in 
phenotype between ARC syndrome patients with VPS33B or PLRN mutations, suggesting a 
synergistic action of both proteins.  Reduced expression of VPS33B can be detected in all 
ARC syndrome patients irrespective of the gene that is mutated. 
 
The newly identified VPS33B-POLARIN complex is essential for apical junction complex 
formation and the correct trafficking of some apical membrane proteins.  Furthermore, the 
developmental expression pattern of VPS33B coupled with the phenotype of the Vps33b and 
Polarin deficient mIMCD-3 cell lines suggests a role of both proteins in the generation and 
maintenance of polarisation in epithelial cells. 
 
The findings presented in this thesis advance the knowledge of the molecular pathways 
determining cell polarity and provide new evidence on the role of intracellular trafficking 
proteins in formation of functional AJCs and in epithelial polarisation.  Furthermore, the 
fundamental defects in growth and differentiation of epithelial tissues observed in ARC and in 
knockdown cell lines emphasise the importance of the VPS33B-POLARIN pathway for organ 
development and function.   
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7.5 – Future Experiments 
 
7.5.1 – Molecular and Cellular Experiments 
 
There is a reduced expression of VPS33B in all ARC syndrome patients’ fibroblasts 
irrespective of the gene that is mutated.  However, it is not known whether there is a 
concordant reduction in POLARIN expression.  There is currently no commercially available 
antibody against POLARIN, but the level of RNA expression could be assessed by qRT-PCR.  
This could not be assessed in the panel of fibroblasts used in chapter 3 since these cells were 
lost, and a panel of newly referred ARC syndrome patients’ fibroblasts are currently being 
collected.  
 
If there is no reduction in POLARIN expression in ARC syndrome patients with VPS33B 
mutations, then the finding that POLARIN completely co-localises and strongly co-
immunoprecipitates with VPS18 needs to be further investigated (see chapter 4).  The 
functional effect of POLARIN binding to VPS18 and the proteins in which VPS18 interacts 
with in the presence and absence of POLARIN should be assessed. 
 
Although the newly identified VPS33B-POLARIN complex interacts with GTP bound 
Rab11a, the conditions in which the interaction occurs remains unknown.  Since there is only 
a partial co-localisation and a weak interaction between the proteins, it is likely that other 
proteins or protein complexes are required for the interaction to occur.  Consistent with this 
idea, Rab11a was not identified on the yeast-2-hybird screen, where only VPS33B is being 
expressed.  Fast two-colour live cell imaging could be used to further asses the interaction. 
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This will identify if the interaction is always partial or if the two proteins come together, 
interact then move away from each other   
 
The partial co-localisation of the VPS33B-POLARIN clusters with both Rab4 and Rab11a, 
and that Rab4 is believed to be a precursor for Rab11a positive endosomes suggests that 
VPS33B and POLARIN might be required for the maturation to occur.  The conventional 
HOPS complex and the CORVET complex in yeast facilitates the conversion of Rab5 
positive early endosomes to and from Rab7 positive late endosomes respectively [74;84].  
Therefore, whether the newly identified VPS33B-POLARIN complex can function in a 
similar manner on Rab4 and Rab11a endosomes could be addressed. 
 
There are numerous pieces of evidence presented in this thesis that imply that VPS33B and 
POLARIN function synergistically.  Therefore, to address these issues of what proteins bind 
to protein complexes, a Tandem Affinity Purification (TAP) assay could be performed 
expressing all the proteins of interest together followed by mass spectrometry to identify the 
interacting proteins of the complex.  For example, VPS33B together with POLARIN and 
POLARIN together with VPS18. 
 
The exact localisation of the VPS33B-POLARIN clusters is still unknown.  The data from the 
TAP assay coupled with further characterisation of the clusters using VPS33B immunogold 
transmission electron microscopy, will give further biochemical and structural information.   
Additionally, further characterisation of the atypical granules with lamellar membranes and 
vesicular aggregates, could also give an insight into how mutations in VPS33B or PLRN 
causes the generation of such structures.   
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Another novel protein, C1orf149, was identified using the yeast-2-hybrid screen which has 
been characterised as a likely interacting protein of VPS33B.  Analysis of the amino acid 
sequence using in-silico database searches revealed a likely histone acetyl transferase 
function.  An IMAGE clone and a commercially available antibody are available so the 
interaction between the two proteins could be either confirmed or ruled out, and further 
assessed if necessary. 
 
7.5.2 – Animal Models 
 
The experiments suggested above deal primarily with the biochemical interaction of VPS33B 
and POLARIN at the molecular and cellular level.  However, VPS33B and PLRN are mutated 
in a human condition, so the effect of reduced expression of either protein in a mammalian 
animal model would give further information about the pathophysiology of ARC syndrome.  
The mammalian animal model, usually mice could also be used to assess the role of VPS33B 
and POLARIN in development.  Since ARC syndrome patients have indistinguishable 
phenotypes irrespective of the gene mutated only one gene needs to be targeted.  This can be 
done using the gene trap method, where a known sequence of DNA is inserted into the 
genome of Embryonic Stem (ES) cells so that translation of the required transcript is 
prematurely terminated.  Another method is the conditional knockout mouse, which results in 
tissue-specific inactivation of the gene of interest.  This is achieved by breeding mice with 
recombinase sites introduced into the gene of interest with mice expressing the recombinase 
enzyme under a tissue specific promoter.  The tissue-specific expression of the recombinase 
allows the inactivation of the gene of interest only in the tissue where the recombinase is 
expressed.  The former method is cheaper than the conditional knockout method, but carries 
214 
the risk that knocking out the gene completely can lead to embryonic lethality, and very little 
information will be obtained.  Nevertheless, the mouse model can give a lot of information 
about the pathophysiology of a human condition, which might not always be obtainable from 
human samples.  Furthermore potential therapeutic agents can be trialled on these mice before 
clinical trials begin. 
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Appendix 1 
 
 
VPS33B Primer Sequences 
 
 
Exon Forward primer Reverse primer 
Product 
Size 
1 CCTTCTCAGAACGAAGGGC GGAAGAAATGTGCATCCAATG 215 
2 CTGCGGAAGCTCATGTGAC TTGTTCATCAAAAGAAAAACTGC 196 
3 TCTTCGTGTCACACTTTGTGC AGATGAAAGGCAGACGTGC 202 
4 GAGACCTGTAGGGCAAATGG AGGGTCCTTATGGCCAAGG 237 
5 GCAGCTTCCCTGTTTCTAGC CCGGTCCTCAGTCCTGTTC 190 
6 TTGTCTTTCACTGGGTTCGG CCAGGAAAAGAAGGAGCTGG 276 
7 TTCCCTCTTAACGTGGAGC TGGTATTTCTAGCCCTCTGC 254 
8 CTAGGGCTAGCCACTTTCC CAGGGAAAACAGCGTCTGC 225 
9 GGAAGTATCACGTGGAAAGG TAGGGCTGAAAGATGACAGG 228 
10 AAGCTGCCCTTGGACATGC GTCCATCTTGCCAAGATGC 189 
11 GTAGGAGAAGTCCTCATTGG CCCACAGCCTGGTATAAGC 187 
12 GAACACCTGAGTACCCTTCC CTGAGGCAACAAAACAGAGG 217 
13 TGGTTTCTCGTGTCTGAGG GGAGTAATGGTCCTCTGGA 540 
14 AGAACCAGGAGTATGTCAGC TAGAAGCGTGGGCAGTAGC 156 
15-16 CCTGTTAGCATAGATGGCAGC TCACTTCTTCTGTCCCTAAGGC 378 
17 GTTCGTTGCTGGTTGATCTG TGCCCAATAACTGCCCTC 187 
18 TGACAGTACTAGATGCTCTTTGGAC ATGCTGCGTGTTGAGAGAAG 256 
19 CTGTCGTGTCCTGAATGGTG CTCCACAATGGAATGAACCC 212 
20 TTTAAAGGGTTAGGGAGCTGAG AAACATTGAGACACGCCAGG 239 
21 TGCTGTGCCCTTCCTTTCC AGGATCAGACCAGATTCAGC 246 
22 CCCTTCCTTTCCTAAGCCTG GCCCAGCTGACACTTTGTTAC 427 
23 TGGAGAGGCTCTATGGGTTG TGCATCTCACTGAGGAATGTG 211 
 
 
qRT-PCR Primer Sequences 
 
 
Species Gene Direction Sequence Product 
Size 
Human  ACTB F CGATTTCCCGCTCGGC 482 bp 
R GGGGACGAGGCCCAGA 
Human VPS33A F CCACAGGACTGCAGAAGAAA 283 bp 
R TGGGGTTTTACTTCCTTTCA 
Human VPS33B F GGTGGTGTTCTTGGGTGGTTGTACATTCTC 249 bp 
R GGTAGTTGGTGGACACTTGGTTATAGCAGC 
Mouse Actb F AGGTGACAGCATTGCTTCTG 188 bp 
R GCTGCCTCAACACCTCAAC 
Mouse Polarin F CAGAAGAACTGGCGCTATCC 201 bp 
R CAGTCTGCCCTGAAGACTCC 
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Cloning Primer Sequences 
 
 
Gene Direction Primer Seq 
PLRN 
(human) 
F CTTGAATTCCAATGAATCGGACAAAGGGTGA 
R CTTGGTACCTTAATTCTTCCATCGAATTT 
plrn 
(zebrafish) 
F CTTGGATCCATGACACGAGCCAAACCTGA 
R CTTGAATTCTCAGTTTTTCCATCTGATTT 
VPS11 F CTTGAATTCAAATGGCGGCCTACCTGCAGTG 
R CTTGTCGACGCTTAAGTGCCCCTCCTGGAG 
VPS16 F CTTGAATTCCCATGGACTGCTACACGGCGAAC 
R CTTGTCGACCCTCACTTCTTCTGGGCTTGTG 
VPS18 F CTTGAATTCCCATGGCGTCCATCCTGGATGAG 
R CTTGGTAACCTACAGCCAACTGAGCTGCTT 
VPS33A F CTTGTCGACGATGGCGGCTCATCTGTCCTAC 
R CTTGCGGCCGCCTAGAAAGGTTTTTCCATCA 
VPS39 F CTTGTCGACCATGCACGACGCTTTCGAGCC 
R CTTGCGGCCGCTCAAGTGTCTGCTGGGTTTA 
VPS41 F CTTGTCGACCATGGCGGAAGCAGAGGAGCAG 
R CTTGCGGCCGCCTATTTTTTCATCTCCAAAA 
 
 
Plasmid Sequencing Primer Sequences 
 
 
Plasmid Direction Sequence 
pCMV F GTAAAACGACGGCCAGT 
R CAGGAAACAGCTATGAC 
pGFP/YFP F CATGGTCCTGCTGGAGTTCGTGACCGC 
R ATAAGCTGCAATAAACAAGTTAACAAC 
pCS2+ F (Sp6) CCCAAGCTTGATTTAGGTGAC 
R (T7) AATACGACTCACTATAG 
pSM2 F TGTGGAAAGGACGAAACACC 
pGIPz R GCATTAAAGCAGCGTATC 
 
 
shRNA Sequences 
 
 
Gene Hairpin Sequence 
Vps33b - CCCTGGCCAGTGCTGAAGTATT 
Polarin E CCCAGCCTTTGAGCACATGTAT 
F ACCTCGGAAAGGGATATCAGTA 
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Morpholino Oligonucleotide Sequences 
 
 
Morpholino Sequence (5’ - 3’) 
ATG GTTTGGCTCGTGTCATCTTCGGAAT 
Exon 3 CCAGACAAAGGACTGCGTACTTCCC 
Exon 3 Mismatch CCACACAAACGACTGCCTAGTTGCC 
Exon 10 AACAGTGAACTCACTTCAGTAACTC 
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Appendix 2 
 
Antibodies and Dilutions Used for Western Blotting 
 
Antibody Clone Supplier Primary 
Dilution 
Secondary 
Dilution 
Rb  VPS33B - Protein Tech 1/1000 1/1000 
m -actin AC15 Sigma 1/15000 1/20000 
m  myc 9E10 Sigma 1/5000 1/20000 
m  HA HA-7 Sigma 1/1000 1/2000 
m  Rab11a 47/Rab11 BD Biosciences 1/2000 1/2000 
Rb  GFP - Santa Cruz 1/2000 1/2000 
Rb  CEA - Dako 1/1000 1/2000 
Rb  ZO-1 - Invitrogen (Zymed) 1/1000 1/1000 
Rb Claudin-1 - Invitrogen (Zymed) 1/1000 1/1000 
m  E-Cadherin 4A2C7 Invitrogen (Zymed) 1/2000 1/2000 
Rb -Catenin - Abcam 1/4000 1/5000 
 
Antibodies and Dilutions Used for Immunofluorescence Microscopy 
 
Antibody Clone Supplier Primary 
Dilution 
Secondary 
Dilution 
Rb GM130 - BD Biosciences 1/100 1/100 
Rt  LAMP-1 - Hybridoma Bank 1/100 1/100 
m  Rab11a 47/Rab11 BD Biosciences 1/200 1/200 
Rb  VPS33B - Protein Tech 1/100 1/100 
m  myc 9E10 Sigma 1/200 1/200 
Rb  CEA - Dako 1/100 1/100 
m  Na+K+ ATPase C464.6 Millipore 1/100 1/100 
Rb  ZO-1 - Invitrogen (Zymed) 1/100 1/100 
Rb Claudin-1 - Invitrogen (Zymed) 1/400 1/500 
m  E-Cadherin 4A2C7 Invitrogen (Zymed) 1/200 1/200 
Rb  E-Cadherin - Gift from C.P. Heisenberg 1/400 1.250 
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Appendix 3 
 
 
POLARIN Nucleotide and Amino Acid Sequences 
 
 
1    ATGAATCGGACAAAGGGTGATGAGGAGGAGTATTGGAACAGCTCCAAGTTCAAGGCTTTTACCTTTGAC 
1    -M--N--R--T--K--G--D--E--E--E--Y--W--N--S--S--K--F--K--A--F--T--F--D- 
70   GATGAAGACGATGAGCTTTCACAGTTAAAGGAGTCCAAGCGGGCGGTGAACAGCCTCCGAGACTTCGTG 
24   -D--E--D--D--E--L--S--Q--L--K--E--S--K--R--A--V--N--S--L--R--D--F--V- 
139  GATGATGATGACGATGATGACCTGGAGCGAGTCAGCTGGAGTGGGGAACCTGTGGGAAGTATCTCATGG 
47   -D--D--D--D--D--D--D--L--E--R--V--S--W--S--G--E--P--V--G--S--I--S--W- 
208  TCCATCAGAGAGACTGCTGGTAATAGCGGCTCAACCCACGAGGGGCGTGAACAGCTAAAGAGCCGAAAC 
70   -S--I--R--E--T--A--G--N--S--G--S--T--H--E--G--R--E--Q--L--K--S--R--N- 
277  AGCTTCTCCTCCTATGCACAACTACCCAAGCCTACTTCTACCTACTCCCTGAGCAGCTTTTTTAGAGGT 
93   -S--F--S--S--Y--A--Q--L--P--K--P--T--S--T--Y--S--L--S--S--F--F--R--G- 
346  AGAACTAGACCTGGAAGTTTCCAGTCCCTTTCTGATGCTCTGTCAGACACACCTGCCAAAAGCTATGCT 
116  -R--T--R--P--G--S--F--Q--S--L--S--D--A--L--S--D--T--P--A--K--S--Y--A- 
415  CCAGAGCTGGGGAGACCCAAAGGGGAGTATAGGGATTACAGCAATGACTGGAGCCCCAGTGATACAGTG 
139  -P--E--L--G--R--P--K--G--E--Y--R--D--Y--S--N--D--W--S--P--S--D--T--V- 
484  CGACGTCTCCGGAAGGGCAAGGTTTGCTCACTAGAGAGATTCCGCTCCTTACAGGACAAACTACAACTC 
162  -R--R--L--R--K--G--K--V--C--S--L--E--R--F--R--S--L--Q--D--K--L--Q--L- 
533  CTAGAAGAGGCAGTAAGCATGCATGATGGAAACGTCATTACTGCAGTTCTGATTTTCCTGAAGAGGACA 
185  -L--E--E--A--V--S--M--H--D--G--N--V--I--T--A--V--L--I--F--L--K--R--T- 
622  CTGAGCAAAGAGATCCTCTTCCGAGAGCTGGAGGTGCGACAGGTTGCCCTGAGACATCTTATTCACTTC 
208  -L--S--K--E--I--L--F--R--E--L--E--V--R--Q--V--A--L--R--H--L--I--H--F- 
691  CTTAAGGAAATAGGGGATCAAAAGTTGCTTTTAGACCTCTTCAGGTTCCTAGATAGAACAGAAGAGCTT 
231  -L--K--E--I--G--D--Q--K--L--L--L--D--L--F--R--F--L--D--R--T--E--E--L- 
760  GCGCTATCTCATTATCGAGAGCATTTGAACATTCAGGACCCTGACAAACGAAAAGAATTTCTTAAAACC 
254  -A--L--S--H--Y--R--E--H--L--N--I--Q--D--P--D--K--R--K--E--F--L--K--T- 
829  TGTGTTGGTTTGCCATTTTCAGCAGAAGATTCCGCACACATACAGGACCATTACACGCTCCTGGAACGT 
277  -C--V--G--L--P--F--S--A--E--D--S--A--H--I--Q--D--H--Y--T--L--L--E--R- 
898  CAGATCATTATTGAGGCAAATGATCGCCATCTAGAATCAGCAGGACAGACTGAGATCTTCCGAAAGCAC 
300  -Q--I--I--I--E--A--N--D--R--H--L--E--S--A--G--Q--T--E--I--F--R--K--H- 
967  CCCCGCAAAGCCTCCATCCTCAACATGCCACTAGTGACAACACTTTTCTACTCCTGCTTCTATCACTAC 
323  -P--R--K--A--S--I--L--N--M--P--L--V--T--T--L--F--Y--S--C--F--Y--H--Y- 
1036 ACAGAGGCTGAGGGGACATTCAGCAGTCCCGTCAACCTGAAGAAGACATTTAAGATCCCAGATAAACAG 
346  -T--E--A--E--G--T--F--S--S--P--V--N--L--K--K--T--F--K--I--P--D--K--Q- 
1105 TATGTGCTGACAGCCCTGGCTGCTCGTGCCAAGCTTCGAGCCTGGAATGATGTAGATGCCCTATTCACC 
369  -Y--V--L--T--A--L--A--A--R--A--K--L--R--A--W--N--D--V--D--A--L--F--T- 
1174 ACAAAGAACTGGCTGGGCTATACCAAGAAGAGAGCACCCATTGGCTTCCATCGGGTTGTCGAAATTTTG 
392  -T--K--N--W--L--G--Y--T--K--K--R--A--P--I--G--F--H--R--V--V--E--I--L- 
1243 CACAAGAACAATGCCCCTGTGCAGATATTACAGGAGTATGTCAATCTGGTGGAAGATGTGGACACGAAG 
415  -H--K--N--N--A--P--V--Q--I--L--Q--E--Y--V--N--L--V--E--D--V--D--T--K- 
1312 TTGAACTTAGCCACTAAGTTCAAGTGCCATGATGTCGTCATTGATACCTACCGGGACCTGAAGGATCGT 
438  -L--N--L--A--T--K--F--K--C--H--D--V--V--I--D--T--Y--R--D--L--K--D--R- 
1381 CAACAGTTGCTAGCATACAGGAGTAAGGTAGATAAAGGATCAGCAGAGGAGGAGAAGATTGATGCTCTT 
461  -Q--Q--L--L--A--Y--R--S--K--V--D--K--G--S--A--E--E--E--K--I--D--A--L- 
1450 CTCAGCAGCTCGCAAATTCGATGGAAGAATTAA 
484  -L--S--S--S--Q--I--R--W--K--N--*- 
 
 
[www.ensembl.org] 
 
 
 
221 
POLARIN Amino Acid Analysis 
 
 
A - 22 (6.5%) C - 4 (1.2%) D – 22 (6.5%) E - 24 (7.1%) F - 16 (4.8% 
G - 9 (2.7%) H  - 13 (3.9%) I - 19 (5.7%) K - 29 (8.6%) L - 46 (13.7% 
M - 2 (0.6%) N - 12 (3.6%) P - 8 (2.4%) Q - 14 (4.2%) R - 25 (7.4%) 
S - 18 (5.4%) T - 19 (5.7%) V – 21( 6.2%) W - 3 (0.9%) Y - 10 (3.0%) 
 
KR - 54 (16.1%) ED - 46 (13.7%) AGP - 39 (11.6%) 
KRED - 100 (29.8%) KR-ED - 8 (2.4%) FIKMNY - 88 (26.2%) 
LVIFM - 104 (31.0%) ST - 37 (11.0%)  
 
 
[www.ebi.ac.uk/Tools/saps] 
 
 
POLARIN Fold Index 
 
 
 
 
 
[www.bioportal.weizmann.ac.il/fldbin/findex] 
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POLARIN Disorder Index 
 
 
 
 
 
[www.strubi.ox.ac.uk/RONN] 
 
 
POLARIN Coiled Coil Prediction 
 
 
 
 
[www.ch.embnet.org/software/COILS_form] 
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10        20        30        40        50        60        70 
|         |         |         |         |         |         | 
MNRTKGDEEEYWNSSKFKAFTFDDEDDELSQLKESKRAVNSLRDFVDDDDDDDLERVSWSGEPVGSISWS 
cccccccchhhhcccccceeecccchhhhhhhhhhhhhhhccccccccccccceeeeeccccccceeeee 
IRETAGNSGSTHEGREQLKSRNSFSSYAQLPKPTSTYSLSSFFRGRTRPGSFQSLSDALSDTPAKSYAPE 
eecccccccccccchhhhhccccccccccccccccceeeceeecccccccccchhhhhcccccccccccc 
LGRPKGEYRDYSNDWSPSDTVRRLRKGKVCSLERFRSLQDKLQLLEEAVSMHDGNVITAVLIFLKRTLSK 
cccccceeeeeeccccccceeeeecccccccccchhhhhhhhhhhhhhhhhccccchhhhhhhhhhhhhh 
EILFRELEVRQVALRHLIHFLKEIGDQKLLLDLFRFLDRTEELALSHYREHLNIQDPDKRKEFLKTCVGL 
hhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhccccccchhhhhcccccc 
PFSAEDSAHIQDHYTLLERQIIIEANDRHLESAGQTEIFRKHPRKASILNMPLVTTLFYSCFYHYTEAEG 
cccccchhhhhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhccchhhhhccceeeeeeecceeccccccc 
TFSSPVNLKKTFKIPDKQYVLTALAARAKLRAWNDVDALFTTKNWLGYTKKRAPIGFHRVVEILHKNNAP 
ccccccccccccccccchhhhhhhhhhhhhhhhcchhhhhhhhhhhcccccccccccceeeeeeeccccc 
VQILQEYVNLVEDVDTKLNLATKFKCHDVVIDTYRDLKDRQQLLAYRSKVDKGSAEEEKIDALLSSSQIR 
hhhhhhhhcccccchhhhhhhccccccceeeeechhhhhhhhhhhhhhhccccchhhhhhhhhhhhhhhc 
WKN 
eec 
 
 
 
c = random coil, e = extended strand and h = alpha helix, 
 
 
[www.npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_gor4] 
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Appendix 4 
 
 Control ARC Patient 
BSEP 
  
   
CD13 
  
   
CEA 
  
   
MRP2 
  
Immunohistochemical analysis of membrane transporter protein localisation in an ARC 
patient with a PLRN mutation. 
Control and ARC patient liver tissue stained for BSEP (Bile Salt Export Protein), CD13 (N-
aminopeptidase), CEA (Carcino Embryonic Antigen), and MRP2 (Multidrug Resistance 
Protein 2).  In the ARC syndrome patient, BSEP, CEA and CD13 staining loses its specific 
localisation in the apical (canalicular) membrane, and these markers can also be seen in the 
basolateral surface.  MRP2 retains its’ apical membrane localisation in the ARC syndrome 
patient.  A 200x original magnification was used for each, and the specimens were 
counterstained with haematoxylin.  (Images provided by AS Knisely, King's College Hospital, 
London, UK.) 
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Appendix 5 
 
 
Experiment 1 
 
 
 Gall Bladder Area (m2) 
 Non Injected Exon 3 Mismatch Exon 3 Exon 3 Rescue ATG ATG Rescue 
 59684.4 44855.0 24429.1 66589.3 34655.8 72845.7 
 60990.2 72007.2 27690.6 52307.1 25150.2 72355.2 
 63464.2 68818.5 24250.3 72291.3 25356.4 70807.2 
 54075.0 73700.5 31032.9 75550.8 26371.1 71765.2 
 70054.0 71042.7 27463.2 64810.1 28895.7 73141.8 
 72855.4 68915.5 18049.7 63768.9 39182.8 76779.2 
 61134.9 76330.0 16980.3 60663.3 29153.5 69826.6 
 54088.5 72123.4 18497.7 76684.0 52025.5 59500.2 
 57130.5 78414.2 31491.9 54349.9 38864.5 72409.3 
 67339.4 74485.7 26040.9 69930.2 27583.8 62329.1 
 59262.4 64049.2 31835.5 74120.0 14468.2 67294.7 
 68423.9 71470.8 28004.8 82085.2 39168.0 55962.4 
 68215.9 54886.1 19982.9 69581.9 24633.6 63807.1 
 64392.4 79729.2 26135.5 82590.5 27564.9 53320.3 
 69192.3 62435.4 29104.3 83850.4 23858.0 59814.3 
 74765.0 72563.2 28896.9 69525.0 37414.2 69642.9 
 86489.3 70819.6 30291.9 64724.6 17401.5 81850.1 
 82307.1 69908.6 27021.2 75534.8 15453.8 63232.9 
 72291.3 74089.5 21543.3 50734.5 26452.8 70788.2 
 75550.8 78705.5 22957.1 76709.5 22566.7 72717.1 
 64810.1 73597.4 31517.1 76254.3 35153.5 78595.4 
 83768.9 64027.9 18026.9 82318.4 25079.9 57941.9 
 90663.3 66158.8 31435.4 80759.2 14710.5 61026.9 
 86684.0 61237.6 18617.6 81720.5 25789.9 80445.2 
 84349.9 64724.6 30574.6 75589.7 63684.7 59019.5 
 79930.2 75534.8 22428.1 60698.8 24186.0 71149.5 
 74120.0 87435.5 18117.8 75060.8 58011.1 57561.4 
 82035.2 82318.4 29050.9 65387.9 13826.5 60467.8 
 89581.9 75589.7 30621.7 65001.8 26891.6 62090.7 
 82595.5 75060.8 22562.0 54285.1 23581.4 58074.7 
       
n= 30 30 30 30 30 30 
Mean 72008.2 70834.5 25488.4 70115.9 29571.2 66885.4 
SD 10892.9 8298.5 4969.8 9598.6 12018.5 7784.4 
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Experiment 2 
 
 
 Gall Bladder Area (m2) 
 Non Injected Exon 3 Mismatch Exon 3 Exon 3 Rescue ATG ATG Rescue 
 92675.0 81347.1 19789.2 52321.4 20040.5 81039.0 
 62315.1 72174.7 14316.2 89169.0 18934.7 82534.1 
 71197.1 66512.4 18708.5 69160.6 21015.6 65531.7 
 91018.2 81148.9 19745.2 61143.7 16446.5 62518.5 
 74175.8 98453.7 15205.3 63122.1 17276.8 67729.2 
 86794.9 71341.6 18972.4 71451.6 21415.7 91550.7 
 77961.1 69789.2 14310.3 80388.9 15709.6 64913.1 
 59273.0 59479.1 21735.7 73456.6 14275.2 74740.1 
 77630.6 71926.1 14778.1 70508.3 18164.7 51456.6 
 74580.1 69630.2 23929.3 92242.5 13357.7 75347.8 
 92349.4 86663.0 20423.8 85230.4 18765.0 78518.7 
 74968.5 82781.6 15861.1 64170.2 24995.7 62283.6 
 92258.4 74562.9 21364.2 72621.3 20759.6 71517.1 
 93140.9 99161.1 24538.8 71388.7 28105.0 61696.1 
 63634.5 84604.5 17168.4 61216.9 21567.7 71982.5 
 66099.6 51589.7 23215.5 51535.9 17011.7 61707.0 
 82168.8 91887.8 28858.9 86354.5 14762.5 62546.9 
 69661.2 81398.7 30781.9 60533.5 16776.1 61337.3 
 67156.2 92657.8 17278.8 76939.3 14322.5 82170.6 
 62828.7 79794.9 19257.2 81780.4 24127.4 61548.7 
 80350.1 52648.1 16738.7 89188.6 13395.7 82551.3 
 61648.5 65758.2 18864.9 71982.5 17282.8 60194.0 
 61237.5 53885.6 31879.5 70734.5 17397.6 89779.3 
 73655.2 51657.7 19425.6 82473.7 20313.4 76866.2 
 92588.4 89158.7 17367.0 81164.7 16838.5 73910.9 
 76398.1 53141.3 24721.2 71247.3 24912.8 74310.2 
 74646.1 62389.4 18859.3 69139.4 19775.1 72146.0 
 78397.2 91151.1 22383.8 61069.2 18013.9 70744.2 
 82327.7 62750.7 14749.5 77084.7 18585.6 82377.2 
 93505.4 62766.4 26625.3 61342.7 19704.7 56848.5 
       
n= 30 30 30 30 30 30 
Mean 76888.0 73740.4 20395.1 72338.8 18801.7 71079.9 
SD 11116.2 14426.5 4746.7 10757.9 3567.7 9989.2 
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Experiment 3 
 
 
 Gall Bladder Area (m2) 
 Non Injected Exon 3 Mismatch Exon 3 Exon 3 Rescue ATG ATG Rescue 
 72199.9 71699.8 16022.1 65579.2 20103.4 51126.7 
 64428.8 74943.1 18714.8 58417.1 18928.4 69548.9 
 82424.9 59440.7 13713.1 64190.3 32053.9 64643.2 
 92201.1 97204.1 23713.1 73104.4 21887.8 81771.4 
 82424.9 51535.4 22832.1 52918.4 36663.0 73793.9 
 79907.9 66342.6 19660.4 70216.1 19918.0 42994.5 
 83857.0 71944.8 13854.2 61861.1 28923.0 64517.8 
 52729.6 80272.4 22440.7 85500.3 21176.8 62320.6 
 81159.8 59106.2 19678.9 42127.4 17398.0 65841.4 
 62540.2 84979.6 13561.7 57320.8 21416.5 57543.3 
 79576.2 64505.3 20099.8 72391.0 17414.2 72624.3 
 59987.8 71670.3 20131.6 63662.7 15343.5 54838.8 
 67282.3 84960.1 22936.8 82149.1 14152.9 79399.5 
 89222.3 62879.5 15817.9 72561.6 19500.2 67171.2 
 68747.5 72187.4 17090.4 64535.4 19949.1 61944.8 
 53890.1 86166.2 23326.3 82967.1 20781.9 51701.8 
 81889.8 59410.0 19141.3 59850.5 18796.4 72760.8 
 77371.2 74593.1 16179.2 62789.7 16116.4 81341.5 
 94843.1 63476.6 20941.8 51151.9 31194.6 41426.2 
 69130.0 62978.6 14298.8 52317.8 13961.4 73467.4 
 69905.6 62637.6 22141.5 62276.3 17916.8 49740.4 
 74789.1 82978.3 19789.2 49342.5 20401.8 41340.3 
 64824.4 77004.3 17570.9 64181.5 18430.1 54291.1 
 63089.7 70093.6 21347.3 50212.7 16597.3 49395.8 
 75479.7 89101.0 21488.5 68302.6 18918.8 53576.5 
 92131.7 62010.4 20216.1 52053.6 16672.7 58085.5 
 69621.5 91660.6 16336.0 37963.9 22016.6 50706.5 
 70266.2 61807.5 19565.7 40677.3 19537.8 42655.2 
 88126.2 91785.7 19220.8 42727.4 29236.3 61794.9 
 74018.2 74205.7 18138.1 71325.4 21875.2 62012.9 
       
n= 30 30 30 30 30 30 
Mean 74602.2 72786.0 18999.0 61155.8 20909.4 60479.2 
SD 11105.4 11715.6 2999.1 12423.4 5440.2 11851.0 
 
 
Summary 
 
 
 Gall Bladder Area (m2) 
 Non Injected Exon 3 Mismatch Exon 3 Exon 3 Rescue ATG ATG Rescue 
Experiment 1 72008.2 70834.5 25488.4 70115.9 29571.2 66885.4 
Experiment 2 76888.0 73740.4 20395.1 72338.8 18801.7 71079.9 
Experiment 3 74602.2 72786.0 18999.0 61155.8 20909.4 60479.2 
Mean 100.00% 97.28% 29.13% 91.14% 31.18% 88.80% 
SD 14.66% 15.47% 7.30% 16.01% 12.91% 14.34% 
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